

L117	49	L114 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L118	87	L112 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L119	247	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L120	38	L119 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L121	141	L119 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L122	182	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L123	39	L122 NOT L119	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 09:57
L124	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/08/22 09:57
L125	687	L112 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/08/22 09:57
L126	127	L114 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/08/22 09:57
L129	57	((("MANTELLE") near3 ("Juan"))).INV.	US-PGPUB; USPAT; USOCR	OR	OFF	2016/08/22 10:03
L130	2	12/216811	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/08/22 10:09
L131	1	(12/216811).APP.	USPAT; USOCR	OR	OFF	2016/08/22 10:09
L133	15907	A61K31/565.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/08/22 10:15
L134	4711	A61K9/70.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/08/22 10:15
L135	33	L133 L134	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/08/22 10:15
L136	8	L135 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/08/22 10:16

8/ 22/ 2016 10:22:21 AM

C:\Users\mjavier\Documents\EAST\Workspaces\13553972.wsp

PTO/SB/08 (modified)

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	13/553972
		<b>Filing Date</b>	7/20/2012
Date Submitted: August 2, 2016		<b>First Named Inventor</b>	Juan Mantelle
		<b>Art Unit</b>	1611
(use as many sheets as necessary)		<b>Examiner Name</b>	Melissa L. Javier
		<b>Attorney Docket Number</b>	041457-0992
Sheet	1	of	1


U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)				

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document		Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	MANTELLA, "DOT Matrix® Technology," Modified-Release Drug Delivery Technology, Rathbone et al., eds., Chapter 30, pp. 405-415, May 28, 2008.	
	A2	Office Action issued on 05/05/2016 in application number 14/024,985 (US 2014-0200530)	
	A3	Notice of Allowance issued on 10/02/2015 in application number 14/024,985 (US 2014-0200530)	
	A4	Office Action issue on 04/29/2016 in application number 14/738,255 (US 2015-0272905)	
	A5	Office Action issue on 10/26/2015 in application number 14/738,255 (US 2015-0272905)	


Examiner Signature	/MELISSA L JAVIER/	Date Considered	08/22/2016
-----------------------	--------------------	--------------------	------------

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN	
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611	

CPC						
Symbol					Type	Version
A61K		9		7069	F	2013-01-01
A61K		9		7061	I	2013-01-01
A61K		31		565	I	2013-01-01
A61K		47		10	I	2013-01-01
A61K		47		32	I	2013-01-01
A61K		9		0014	I	2013-01-01


CPC Combination Sets				
Symbol	Type	Set	Ranking	Version

(Assistant Examiner) _____ (Date) _____		<b>Total Claims Allowed:</b> 21	
/MELISSA JAVIER/ Examiner.Art Unit 1611		O.G. Print Claim(s) 1	O.G. Print Figure None
(Primary Examiner) _____ (Date) _____			

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

US ORIGINAL CLASSIFICATION						INTERNATIONAL CLASSIFICATION																	
CLASS			SUBCLASS			CLAIMED					NON-CLAIMED												
						A	6	1	K	31 / 565 (2006.01.01)													
CROSS REFERENCE(S)						A	6	1	K	9 / 70 (2006.01.01)													
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)																						

(Assistant Examiner) _____ (Date) _____		<b>Total Claims Allowed:</b> 21	
/MEISSA JAVIER/ Examiner.Art Unit 1611		08/22/2016	08/22/2016
(Primary Examiner) _____ (Date) _____		1	None

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

<input type="checkbox"/> Claims renumbered in the same order as presented by applicant		<input type="checkbox"/> CPA		<input checked="" type="checkbox"/> T.D.		<input type="checkbox"/> R.1.47									
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	16	17	12	33										
	2		18	13	34										
	3		19	14	35										
	4		20	17	36										
	5	2	21	18	37										
	6	3	22	19	38										
	7	4	23	20	39										
	8	5	24	21	40										
	9	6	25												
	10	7	26												
	11		27												
	12	8	28												
	13	9	29												
1	14		30												
	15	10	31												
15	16	11	32												

		<b>Total Claims Allowed:</b>	
		21	
(Assistant Examiner)	(Date)	O.G. Print Claim(s)	O.G. Print Figure
/MELISSA JAVIER/ Examiner.Art Unit 1611	08/22/2016	1	None
(Primary Examiner)	(Date)		

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Appl. No.: 13/553972  
Appl. Filing Date: 7/20/2012  
Examiner: Melissa L. Javier  
Art Unit: 1611  
Confirmation Number: 3635

**REQUEST FOR CONTINUED EXAMINATION (RCE)**  
**TRANSMITTAL**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. This RCE and the enclosed items listed below are being filed prior to the earliest of: (1) payment of the issue fee (unless a petition under 37 C.F.R. § 1.313 is granted); (2) abandonment of the application; or (3) the filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. §141, or the commencement of a civil action under 35 U.S.C. §145 or §146 (unless the appeal or civil action is terminated).

Submission required under 37 C.F.R. §1.114:

- [ X ] Information Disclosure Statement.
- [ X ] Form PTO/SB/08 with copies of 9 listed reference(s).

The filing fee is calculated below at the large entity rate:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Fee Totals
RCE Fee 1.17(e):				\$1,700.00	= \$1,700.00
				0	
Total Claims:	13	-	26 = 0	x \$80.00	= \$0.00
Independents	3	-	5 = 0	x \$420.00	= \$0.00
First presentation of any Multiple Dependent Claims:				+ \$780.00	= \$0.00
RCE and CLAIMS FEE TOTAL:					= \$1,700.00

The above-identified fees of \$1700.00 are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date Nov 28, 2016

By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288



***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device  
and Delivery  
Application No.: 13/553,972  
Filing Date: 7/20/2012  
Examiner: Melissa L. Javier  
Art Unit: 1611  
Confirmation No.: 3635

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

Applicant submits herewith documents for the Examiner's consideration in accordance with 37 CFR §§1.56, 1.97 and 1.98.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The submission of any document herewith is not an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document submitted herewith.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing of a first Office action after the filing of a RCE.

Although Applicant believes that no fee is required, the Commissioner is hereby authorized to charge any additional fees which may be due for this application to Deposit Account Number 19-0741.

Respectfully submitted,

Date November 28, 2016

By /Courtenay C. Brinckerhoff/

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	13/553972
				<b>Filing Date</b>	7/20/2012
Date Submitted: November 28, 2016				<b>First Named Inventor</b>	Juan Mantelle
				<b>Art Unit</b>	1611
(use as many sheets as necessary)				<b>Examiner Name</b>	Melissa L. Javier
				<b>Attorney Docket Number</b>	041457-0992
Sheet	1	of	2		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	TOOLE ET AL., "Evaluation of irritation and sensitisation of two 50 µg/day oestrogen patches," Maturitas, Vol. 43, pp. 257-263, December 2002.	
	A2	MARTY, "New trends in transdermal technologies: Development of the skin patch, Menorest@," International Journal of Gynecology & Obstetrics, Vol. 52, Suppl. 1, pp. S17-S20, March 1996.	
	A3	NOVARTIS, "Estraderm@," Prescribing information, June 2004.	
	A4	NOVARTIS, "Vivelle@," Prescribing information, June 2004.	
	A5	NOVARTIS, "Vivelle-Dot@," Prescribing information, June 2004.	
	A6	BAYER HEALTHCARE, "Climara@," Prescribing information, 2007	
	A7	3M PHARMACEUTICALS, "Menostar™," Prescribing information, June 2004.	
	A8	WATSON PHARMA, INC., "Alora@," Prescribing information, May 2005.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	13/553972
		<b>Filing Date</b>	7/20/2012
Date Submitted: November 28, 2016		<b>First Named Inventor</b>	Juan Mantelle
		<b>Art Unit</b>	1611
(use as many sheets as necessary)		<b>Examiner Name</b>	Melissa L. Javier
		<b>Attorney Docket Number</b>	041457-0992
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A9	SERONO LABORATORIES, INC., "Esclim®," Prescribing information, August 1998.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

## Electronic Patent Application Fee Transmittal

<b>Application Number:</b>	13553972			
<b>Filing Date:</b>	20-Jul-2012			
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY			
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle			
<b>Filer:</b>	Courtenay C. Brinckerhoff			
<b>Attorney Docket Number:</b>	041457-0992			
Filed as Large Entity				
<b>Filing Fees for Utility under 35 USC 111(a)</b>				
<b>Description</b>	<b>Fee Code</b>	<b>Quantity</b>	<b>Amount</b>	<b>Sub-Total in USD(\$)</b>
<b>Basic Filing:</b>				
<b>Pages:</b>				
<b>Claims:</b>				
<b>Miscellaneous-Filing:</b>				
<b>Petition:</b>				
<b>Patent-Appeals-and-Interference:</b>				
<b>Post-Allowance-and-Post-Issuance:</b>				
<b>Extension-of-Time:</b>				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
<b>Miscellaneous:</b>				
RCE- 2ND AND SUBSEQUENT REQUEST	1820	1	1700	1700
<b>Total in USD (\$)</b>				<b>1700</b>

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	27619812
<b>Application Number:</b>	13553972
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3635
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle
<b>Customer Number:</b>	22428
<b>Filer:</b>	Courtenay C. Brinckerhoff/Christine Arthur
<b>Filer Authorized By:</b>	Courtenay C. Brinckerhoff
<b>Attorney Docket Number:</b>	041457-0992
<b>Receipt Date:</b>	28-NOV-2016
<b>Filing Date:</b>	20-JUL-2012
<b>Time Stamp:</b>	14:02:26
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$1700
RAM confirmation Number	112916INTEFSW14032600
Deposit Account	190741
Authorized User	Christine Arthur

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.17 (Patent application and reexamination processing fees)

37 CFR 1.21 (Miscellaneous fees and charges)

<b>File Listing:</b>					
<b>Document Number</b>	<b>Document Description</b>	<b>File Name</b>	<b>File Size(Bytes)/ Message Digest</b>	<b>Multi Part /.zip</b>	<b>Pages (if appl.)</b>
1		rceids.pdf	245161 a6b73ea014c20b5b86f6327612b3fe1cd192e9eb	yes	7
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Request for Continued Examination (RCE)		1		3
	Transmittal Letter		4		5
	Information Disclosure Statement (IDS) Form (SB08)		6		7
<b>Warnings:</b>					
<b>Information:</b>					
2	Non Patent Literature	toole2002.pdf	77843 c70337f8aec67eb6cdf1f41477645405053c0c21	no	7
<b>Warnings:</b>					
<b>Information:</b>					
3	Non Patent Literature	Marty1996.pdf	7295311 050613821102d409c0ad0da289a45d6fe931183e	no	4
<b>Warnings:</b>					
<b>Information:</b>					
4	Non Patent Literature	estradermjune2004.pdf	327689 1d97460ef7b258eaf4b26e416aef8d93dd1edcac	no	22
<b>Warnings:</b>					
<b>Information:</b>					
5	Non Patent Literature	vivelle2004.pdf	522915 bed5c72638aff66d5b0122934eb17e6a87d1a437	no	28



<b>Warnings:</b>					
<b>Information:</b>					
6	Non Patent Literature	vivelledot2004.pdf	391153 e91f07c4d292c518223c7e77c6e7f5a77b8fcd58	no	28
<b>Warnings:</b>					
<b>Information:</b>					
7	Non Patent Literature	climara2007.pdf	275161 2ba61920dd4d73a49f6fb4d41bcbfe2630142296	no	23
<b>Warnings:</b>					
<b>Information:</b>					
8	Non Patent Literature	menostar2004.pdf	322583 818aaf0be23f41cea4bd2d53eaa23d4da1f91b4a	no	28
<b>Warnings:</b>					
<b>Information:</b>					
9	Non Patent Literature	alora2005.pdf	1333321 3150b28ac9894d475dc8d1b1cef0578a7baa05af	no	29
<b>Warnings:</b>					
<b>Information:</b>					
10	Non Patent Literature	esclim98.pdf	934392 6ae80f7cc7ce83f0531c33289500eeff0b71e423	no	19
<b>Warnings:</b>					
<b>Information:</b>					
11	Fee Worksheet (SB06)	fee-info.pdf	30373 62c13ec7b0cc5c97fa0bf42d451c06e96e8d5e71	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>				11755902	

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**



NOTICE OF ALLOWANCE AND FEE(S) DUE

22428 7590 12/09/2016
Foley & Lardner LLP
3000 K STREET N.W.
SUITE 600
WASHINGTON, DC 20007-5109

Table with 2 columns: EXAMINER (JAVIER, MELISSA L), ART UNIT (1611), PAPER NUMBER

DATE MAILED: 12/09/2016

Table with 5 columns: APPLICATION NO. (13/553,972), FILING DATE (07/20/2012), FIRST NAMED INVENTOR (Juan Mantelle), ATTORNEY DOCKET NO. (041457-0992), CONFIRMATION NO. (3635)

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

Table with 7 columns: APPLN. TYPE (nonprovisional), ENTITY STATUS (UNDISCOUNTED), ISSUE FEE DUE (\$960), PUBLICATION FEE DUE (\$0), PREV. PAID ISSUE FEE (\$0), TOTAL FEE(S) DUE (\$960), DATE DUE (03/09/2017)

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

**PART B - FEE(S) TRANSMITTAL**

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 or Fax (571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

22428                      7590                      12/09/2016  
**Foley & Lardner LLP**  
 3000 K STREET N.W.  
 SUITE 600  
 WASHINGTON, DC 20007-5109

**Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/553,972	07/20/2012	Juan Mantelle	041457-0992	3635

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	03/09/2017

EXAMINER	ART UNIT	CLASS-SUBCLASS
JAVIER, MELISSA L	1611	424-487000

<p>1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).</p> <p><input type="checkbox"/> Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.</p> <p><input type="checkbox"/> "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. <b>Use of a Customer Number is required.</b></p>	<p>2. For printing on the patent front page, list</p> <p>(1) The names of up to 3 registered patent attorneys or agents OR, alternatively, _____ 1</p> <p>(2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. _____ 2</p> <p>_____ 3</p>
---	---

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE \_\_\_\_\_ (B) RESIDENCE: (CITY and STATE OR COUNTRY) \_\_\_\_\_

Please check the appropriate assignee category or categories (will not be printed on the patent) :  Individual  Corporation or other private group entity  Government

<p>4a. The following fee(s) are submitted:</p> <p><input type="checkbox"/> Issue Fee</p> <p><input type="checkbox"/> Publication Fee (No small entity discount permitted)</p> <p><input type="checkbox"/> Advance Order - # of Copies _____</p>	<p>4b. Payment of Fee(s): (<b>Please first reapply any previously paid issue fee shown above</b>)</p> <p><input type="checkbox"/> A check is enclosed.</p> <p><input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.</p> <p><input type="checkbox"/> The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).</p>
---	--

5. **Change in Entity Status** (from status indicated above)

Applicant certifying micro entity status. See 37 CFR 1.29

Applicant asserting small entity status. See 37 CFR 1.27

Applicant changing to regular undiscounted fee status.

**NOTE:** Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

**NOTE:** If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

**NOTE:** Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

**NOTE:** This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature \_\_\_\_\_ Date \_\_\_\_\_

Typed or printed name \_\_\_\_\_ Registration No. \_\_\_\_\_



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 5 columns: APPLICATION NO., FILING DATE, FIRST NAMED INVENTOR, ATTORNEY DOCKET NO., CONFIRMATION NO.
13/553,972 07/20/2012 Juan Mantelle 041457-0992 3635

22428 7590 12/09/2016
Foley & Lardner LLP
3000 K STREET N.W.
SUITE 600
WASHINGTON, DC 20007-5109

EXAMINER

JAVIER, MELISSA L

ART UNIT PAPER NUMBER

1611

DATE MAILED: 12/09/2016

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

## OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

### Privacy Act Statement

**The Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

<b>Notice of Allowability</b>	<b>Application No.</b> 13/553,972	<b>Applicant(s)</b> MANTELLE, JUAN	
	<b>Examiner</b> Melissa Javier	<b>Art Unit</b> 1611	<b>AIA (First Inventor to File) Status</b> No

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 11/28/2016.  
 A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on \_\_\_\_\_.
2.  An election was made by the applicant in response to a restriction requirement set forth during the interview on \_\_\_\_\_; the restriction requirement and election have been incorporated into this action.
3.  The allowed claim(s) is/are 14,16,17,21-26,28,29 and 31-40. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see [http://www.uspto.gov/patents/init\\_events/pph/index.jsp](http://www.uspto.gov/patents/init_events/pph/index.jsp) or send an inquiry to [PPHfeedback@uspto.gov](mailto:PPHfeedback@uspto.gov).
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

**Certified copies:**

- a)  All    b)  Some    \*c)  None of the:
1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  
 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.  
**Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |  |   |
|--|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892)   | 5. <input checked="" type="checkbox"/> Examiner's Amendment/Comment       |
| 2. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO/SB/08),<br>Paper No./Mail Date _____ | 6. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| 3. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material         | 7. <input type="checkbox"/> Other _____.                                  |
| 4. <input type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date _____.                             |   |

/Melissa Javier/  
Examiner, Art Unit 1611

### **DETAILED ACTION**

The present application is being examined under the pre-AIA first to invent provisions.

#### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 11/28/2016 has been entered.

#### ***Information Disclosure Statement***

The Information Disclosure Statement (IDS) filed 11/28//2016 has been considered by the examiner.

#### ***Conclusion***

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."




Art Unit: 1611

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melissa Javier whose telephone number is (571)270-7430. The examiner can normally be reached on Monday-Thursday, 8am-6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


/Melissa Javier/  
Examiner, Art Unit 1611

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN	
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611	

CPC						
Symbol					Type	Version
A61K		9		7069	F	2013-01-01
A61K		9		7061	I	2013-01-01
A61K		31		565	I	2013-01-01
A61K		47		10	I	2013-01-01
A61K		47		32	I	2013-01-01
A61K		9		0014	I	2013-01-01


CPC Combination Sets					
Symbol		Type	Set	Ranking	Version

(Assistant Examiner) _____ (Date) _____		<b>Total Claims Allowed:</b> 21	
/MELISSA JAVIER/ Examiner.Art Unit 1611		12/2/2016	O.G. Print Claim(s) 1
(Primary Examiner) _____ (Date) _____		O.G. Print Figure None	

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

US ORIGINAL CLASSIFICATION					INTERNATIONAL CLASSIFICATION									
CLASS		SUBCLASS			CLAIMED					NON-CLAIMED				
					A	6	1	K	31 / 565 (2006.01.01)					
					A	6	1	K	9 / 70 (2006.0)					
<b>CROSS REFERENCE(S)</b>														
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)													

		<b>Total Claims Allowed:</b>	
		21	
(Assistant Examiner) /MELISSA JAVIER/ Examiner.Art Unit 1611	(Date) 12/2/2016	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	None

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

<input type="checkbox"/> Claims renumbered in the same order as presented by applicant		<input type="checkbox"/> CPA		<input checked="" type="checkbox"/> T.D.		<input type="checkbox"/> R.1.47									
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	16	17	12	33										
	2		18	13	34										
	3		19	14	35										
	4		20	17	36										
	5	2	21	18	37										
	6	3	22	19	38										
	7	4	23	20	39										
	8	5	24	21	40										
	9	6	25												
	10	7	26												
	11		27												
	12	8	28												
	13	9	29												
1	14		30												
	15	10	31												
15	16	11	32												

		<b>Total Claims Allowed:</b>	
		21	
(Assistant Examiner)	(Date)	O.G. Print Claim(s)	O.G. Print Figure
/MELISSA JAVIER/ Examiner.Art Unit 1611	12/2/2016	1	None
(Primary Examiner)	(Date)		

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	13/553972
		<b>Filing Date</b>	7/20/2012
Date Submitted: November 28, 2016 <i>(use as many sheets as necessary)</i>		<b>First Named Inventor</b>	Juan Mantelle
		<b>Art Unit</b>	1611
Sheet 1 of 2		<b>Examiner Name</b>	Melissa L. Javier
		<b>Attorney Docket Number</b>	041457-0992

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	TOOLE ET AL., "Evaluation of irritation and sensitisation of two 50 µg/day oestrogen patches," Maturitas, Vol. 43, pp. 257-263, December 2002.	
	A2	MARTY, "New trends in transdermal technologies: Development of the skin patch, Menorest@," International Journal of Gynecology & Obstetrics, Vol. 52, Suppl. 1, pp. S17-S20, March 1996.	
	A3	NOVARTIS, "Estraderm@," Prescribing information, June 2004.	
	A4	NOVARTIS, "Vivelle@," Prescribing information, June 2004.	
	A5	NOVARTIS, "Vivelle-Dot@," Prescribing information, June 2004.	
	A6	BAYER HEALTHCARE, "Climara@," Prescribing information, 2007	
	A7	3M PHARMACEUTICALS, "Menostar™," Prescribing information, June 2004.	
	A8	WATSON PHARMA, INC., "Alora@," Prescribing information, May 2005.	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				<b>Application Number</b>	13/553972
				<b>Filing Date</b>	7/20/2012
Date Submitted: November 28, 2016				<b>First Named Inventor</b>	Juan Mantelle
				<b>Art Unit</b>	1611
(use as many sheets as necessary)				<b>Examiner Name</b>	Melissa L. Javier
				<b>Attorney Docket Number</b>	041457-0992
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A9	SERONO LABORATORIES, INC., "Esclim®," Prescribing information, August 1998.	

Examiner Signature	/MELISSA L JAVIER/	Date Considered	12/02/2016
-----------------------	--------------------	--------------------	------------

## EAST Search History

## EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L2	5333	L1 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L3	886	L2 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L4	34	L3 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L5	260	L3 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L6	50	L3 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L7	88	L1 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L8	257	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L9	42	L8 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L10	149	L8 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L11	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L12	39	L11 NOT L8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L13	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L14	699	L1 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L15	129	L3 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L16	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L17	5333	L16 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2016/12/02 16:37

			JPO; DERWENT			
L18	886	L17 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L19	34	L18 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L20	260	L18 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L21	50	L18 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L22	88	L16 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L23	257	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L24	42	L23 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L25	149	L23 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L26	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L27	39	L26 NOT L23	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L28	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L29	699	L16 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L30	129	L18 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L31	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L32	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L33	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L34	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L35	5333	L34 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L36	886	L35 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L37	34	L36 and estradiol.ab.	US-PGPUB; USPAT;	OR	OFF	2016/12/02



			USOCR; FPRS; EPO; JPO; DERWENT			16:37
L38	260	L36 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L39	50	L36 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L40	88	L34 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L41	257	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L42	42	L41 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L43	149	L41 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L44	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L45	39	L44 NOT L41	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L46	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L47	699	L34 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L48	129	L36 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L49	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L50	5333	L49 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L51	886	L50 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L52	34	L51 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L53	260	L51 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L54	50	L51 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L55	88	L49 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L56	257	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37

L57	42	L56 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L58	149	L56 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L59	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L60	39	L59 NOT L56	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L61	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L62	699	L49 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L63	129	L51 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L64	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L65	5333	L64 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L66	886	L65 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L67	34	L66 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L68	260	L66 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L69	50	L66 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L70	88	L64 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L71	257	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L72	42	L71 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L73	149	L71 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L74	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L75	39	L74 NOT L71	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L76	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37

L77	699	L64 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L78	129	L66 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L79	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L80	5333	L79 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L81	886	L80 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L82	34	L81 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L83	260	L81 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L84	50	L81 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L85	88	L79 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L86	257	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L87	42	L86 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L88	149	L86 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L89	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L90	39	L89 NOT L86	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L91	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L92	699	L79 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L93	129	L81 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L94	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L95	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L96	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L97	15404	estradiol and transdermal	US-PGPUB; USPAT;	OR	OFF	2016/12/02

			USOCR; FPRS; EPO; JPO; DERWENT			16:37
L98	5333	L97 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L99	886	L98 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L100	34	L99 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L101	260	L99 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L102	50	L99 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L103	88	L97 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L104	257	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L105	42	L104 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L106	149	L104 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L107	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L108	39	L107 NOT L104	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L109	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L110	699	L97 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L111	129	L99 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L112	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L113	5333	L112 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L114	886	L113 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L115	34	L114 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L116	260	L114 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37

L117	50	L114 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L118	88	L112 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L119	257	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L120	42	L119 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L121	149	L119 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L122	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L123	39	L122 NOT L119	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L124	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L125	699	L112 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L126	129	L114 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L129	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L130	5333	L129 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L131	886	L130 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L132	34	L131 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L133	260	L131 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L134	50	L131 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L135	88	L129 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L136	257	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L137	42	L136 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L138	149	L136 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37

L139	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L140	39	L139 NOT L136	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L141	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L142	699	L129 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L143	129	L131 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L144	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L145	5333	L144 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L146	886	L145 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L147	34	L146 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L148	260	L146 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L149	50	L146 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L150	88	L144 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L151	257	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L152	42	L151 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L153	149	L151 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L154	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L155	39	L154 NOT L151	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L156	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L157	699	L144 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L158	129	L146 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L159	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2016/12/02 16:37

			JPO; DERWENT			
L160	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L161	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L162	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L163	5333	L162 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L164	886	L163 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L165	34	L164 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L166	260	L164 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L167	50	L164 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L168	88	L162 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L169	257	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L170	42	L169 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L171	149	L169 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L172	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L173	39	L172 NOT L169	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L174	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L175	699	L162 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L176	129	L164 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L177	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L178	5333	L177 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L179	886	L178 and acrylic and	US-PGPUB; USPAT;	OR	OFF	2016/12/02

		silicone and (PVP polyvinyl pyrrolidone)	USOCR; FPRS; EPO; JPO; DERWENT			16:37
L180	34	L179 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L181	260	L179 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L182	50	L179 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L183	88	L177 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L184	257	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L185	42	L184 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L186	149	L184 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L187	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L188	39	L187 NOT L184	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L189	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L190	699	L177 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L191	129	L179 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L192	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L193	5333	L192 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L194	886	L193 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L195	34	L194 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L196	260	L194 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L197	50	L194 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L198	88	L192 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37



L199	257	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L200	42	L199 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L201	149	L199 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L202	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L203	39	L202 NOT L199	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L204	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L205	699	L192 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L206	129	L194 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L207	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L208	5333	L207 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L209	886	L208 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L210	34	L209 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L211	260	L209 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L212	50	L209 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L213	88	L207 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L214	257	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L215	42	L214 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L216	149	L214 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L217	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L218	39	L217 NOT L214	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37

L219	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L220	699	L207 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L221	129	L209 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L222	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L223	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L224	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L225	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L226	5333	L225 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L227	886	L226 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L228	34	L227 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L229	260	L227 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L230	50	L227 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L231	88	L225 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L232	257	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L233	42	L232 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L234	149	L232 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L235	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L236	39	L235 NOT L232	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L237	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L238	699	L225 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L239	129	L227 and ("dipropylene	USPAT; USOCR	OR	OFF	2016/12/02

		glycol" oleyl)				16:37
L240	15404	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L241	5333	L240 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L242	886	L241 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L243	34	L242 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L244	260	L242 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L245	50	L242 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L246	88	L240 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L247	257	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L248	42	L247 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L249	149	L247 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L250	184	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L251	39	L250 NOT L247	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L252	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L253	699	L240 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L254	129	L242 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L255	58	(("MANTELLE") near3 ("Juan")).INV.	US-PGPUB; USPAT; USOCR	OR	OFF	2016/12/02 16:37
L256	2	12/216811	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2016/12/02 16:37
L257	1	(12/216811).APP.	USPAT; USOCR	OR	OFF	2016/12/02 16:37
L258	16305	A61K31/565.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/12/02 16:37
L259	5074	A61K9/70.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/12/02 16:37

L260	33	L258 L259	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/12/02 16:37
L261	8	L260 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2016/12/02 16:37

**12/ 2/ 2016 4:52:22 PM**

**C:\Users\mjavier\Documents\EAST\Workspaces\13553972.wsp**




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3635

<b>SERIAL NUMBER</b> 13/553,972	<b>FILING or 371(c) DATE</b> 07/20/2012 <b>RULE</b>	<b>CLASS</b> 424	<b>GROUP ART UNIT</b> 1611	<b>ATTORNEY DOCKET NO.</b> 041457-0992	
<b>APPLICANTS</b> <b>INVENTORS</b> Juan Mantelle, Miami, FL; <b>** CONTINUING DATA *****</b> This application is a CON of 12/216,811 07/10/2008 PAT 8231906 <b>** FOREIGN APPLICATIONS *****</b> <b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b> 07/31/2012					
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Verified and Acknowledged <u>/MELISSA L JAVIER/</u> Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials _____	<b>STATE OR COUNTRY</b> FL	<b>SHEETS DRAWINGS</b> 1	<b>TOTAL CLAIMS</b> 16	<b>INDEPENDENT CLAIMS</b> 4
<b>ADDRESS</b> Foley & Lardner LLP 3000 K STREET N.W. SUITE 600 WASHINGTON, DC 20007-5109 UNITED STATES					
<b>TITLE</b> TRANSDERMAL ESTROGEN DEVICE AND DELIVERY					
<b>FILING FEE RECEIVED</b> 2540	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		

<b>Search Notes</b>  	<b>Application/Control No.</b>  13553972	<b>Applicant(s)/Patent Under Reexamination</b>  MANTELLE, JUAN
	<b>Examiner</b>  MELISSA JAVIER	<b>Art Unit</b>  1611

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
EAST search (see attached history)	8/25/2013	MJ
Inventor search in EAST	8/25/2013	MJ
Google Scholar search (keywords used: transdermal monolithic estradiol)	8/25/2013	MJ
Updated EAST search	2/21/2014	MJ
Updated Google Scholar search	2/21/2014	MJ
Updated EAST search	4/29/2015	MJ
Updated Google Scholar search	4/29/2015	MJ
Updated EAST search	9/28/2015	MJ
Updated Google Scholar search	9/28/2015	MJ
Updated EAST search	4/22/2016	MJ
Updated Google Scholar search	4/22/2016	MJ
Updated EAST search	8/22/2016	MJ
Updated Google Scholar search	8/22/2016	MJ
(A61K31/565 A61K9/70).cpc. and estradiol	8/22/2016	MJ
Updated EAST search	12/2/2016	MJ
Updated Google Scholar search	12/2/2016	MJ
(A61K31/565 A61K9/70).cpc. and estradiol	12/2/2016	MJ

/M.J./ Examiner.Art Unit 1611	
----------------------------------	--

### INTERFERENCE SEARCH

US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
	(monolith\$2 estradiol transdermal adhesive coat weight flux).clm.	9/28/2015	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	8/22/2016	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	12/2/2016	MJ

/M.J./  
Examiner.Art Unit 1611



ZFW/RCE  
\$

Atty. Dkt. No. 041457-0992

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Appl. No.: 13/553,972  
Appl. Filing Date: 7/20/2012  
Examiner: Melissa L. Javier  
Art Unit: 1611  
Confirmation Number: 3635

**REQUEST FOR CONTINUED EXAMINATION (RCE)**  
**TRANSMITTAL**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. This RCE and the enclosed items listed below are being filed prior to the earliest of: (1) payment of the issue fee (unless a petition under 37 C.F.R. § 1.313 is granted); (2) abandonment of the application; or (3) the filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. §141, or the commencement of a civil action under 35 U.S.C. §145 or §146 (unless the appeal or civil action is terminated).

03/09/2017 SHOHANNE 00000002 13553972  
01 FC:1820 1700.00 OP



Submission required under 37 C.F.R. §1.114:

[ X ] Information Disclosure Statement.

[ X ] Form PTO/SB/08 with copies of 3 listed reference(s).

The filing fee is calculated below at the large entity rate:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Fee Totals
RCE Fee 1.17(e):				\$1,700.00	= \$1,700.00
				0	
Total Claims:	13	-	26 = 0	x \$80.00	= \$0.00
Independents	3	-	5 = 0	x \$420.00	= \$0.00
First presentation of any Multiple Dependent Claims:				+ \$780.00	= \$0.00
RCE and CLAIMS FEE TOTAL:					= \$1,700.00

The above-identified fees of \$1700.00 are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date March 8, 2017

By C. Brinckerhoff

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288



***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device  
and Delivery  
Application No.: 13/553972  
Filing Date: 7/20/2012  
Examiner: Melissa L. Javier  
Art Unit: 1611  
Confirmation No.: 3635

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

Applicant submits herewith documents for the Examiner's consideration in accordance with 37 CFR §§1.56, 1.97 and 1.98.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The submission of any document herewith is not an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document submitted herewith.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing of a first Office action after the filing of a RCE.

**RELEVANCE OF LISTED DOCUMENTS**

Documents A1 and A2 are Office Actions which were issued in the child applications.

Document A3 is a Decision issued in an Opposition of a corresponding European patent. Although the patent was revoked because certain claim language not present in the pending claims was found to constitute an impermissible generalization of the original disclosure, the EPO Opposition Division rejected the Opponent's prior art and enablement-type arguments.

Although Applicant believes that no fee is required, the Commissioner is hereby authorized to charge any additional fees which may be due to Deposit Account Number 19-0741.


Respectfully submitted,

Date March 8, 2011

By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288



Substitute for form 1449/PTO  
**INFORMATION DISCLOSURE  
 STATEMENT BY APPLICANT**

Date Submitted: March 8, 2017

(use as many sheets as necessary)

**Complete if Known**

Application Number	13/553972
Filing Date	7/20/2012
First Named Inventor	Juan Mantelle
Art Unit	1611
Examiner Name	Melissa L. Javier
Attorney Docket Number	041457-0992

Sheet 1 of 1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	Notice of Allowance issued on 01/10/2017 in application number 14/024,985 (US 2014-0200530)	
	A2	Office Action issued on 09/07/2016 in application number 14/870,574 (US 2016-0015655)	
	A3	European Office Action issued on 02/14/2017 in application number EP 09790211.8	

Examiner  
SignatureDate  
Considered



NOTICE OF ALLOWANCE AND FEE(S) DUE

22428 7590 03/23/2017
Foley & Lardner LLP
3000 K STREET N.W.
SUITE 600
WASHINGTON, DC 20007-5109

EXAMINER

FISHER, MELISSA L

ART UNIT PAPER NUMBER

1611

DATE MAILED: 03/23/2017

Table with 5 columns: APPLICATION NO., FILING DATE, FIRST NAMED INVENTOR, ATTORNEY DOCKET NO., CONFIRMATION NO.

13/553,972 07/20/2012 Juan Mantelle 041457-0992 3635

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

Table with 7 columns: APPLN. TYPE, ENTITY STATUS, ISSUE FEE DUE, PUBLICATION FEE DUE, PREV. PAID ISSUE FEE, TOTAL FEE(S) DUE, DATE DUE

nonprovisional UNDISCOUNTED \$960 \$0 \$0 \$960 06/23/2017

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies.

If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.

If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)".

For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

**PART B - FEE(S) TRANSMITTAL**

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 or Fax (571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

22428 7590 03/23/2017  
**Foley & Lardner LLP**  
 3000 K STREET N.W.  
 SUITE 600  
 WASHINGTON, DC 20007-5109

**Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/553,972	07/20/2012	Juan Mantelle	041457-0992	3635

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	06/23/2017

EXAMINER	ART UNIT	CLASS-SUBCLASS
FISHER, MELISSA L	1611	424-487000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). <input type="checkbox"/> Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. <input type="checkbox"/> "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. <b>Use of a Customer Number is required.</b>	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, _____ 1 (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. _____ 2 _____ 3
--	--

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE \_\_\_\_\_ (B) RESIDENCE: (CITY and STATE OR COUNTRY) \_\_\_\_\_

Please check the appropriate assignee category or categories (will not be printed on the patent) :  Individual  Corporation or other private group entity  Government

4a. The following fee(s) are submitted: <input type="checkbox"/> Issue Fee <input type="checkbox"/> Publication Fee (No small entity discount permitted) <input type="checkbox"/> Advance Order - # of Copies _____	4b. Payment of Fee(s): ( <b>Please first reapply any previously paid issue fee shown above</b> ) <input type="checkbox"/> A check is enclosed. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <input type="checkbox"/> The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).
--	---

5. **Change in Entity Status** (from status indicated above)

Applicant certifying micro entity status. See 37 CFR 1.29

Applicant asserting small entity status. See 37 CFR 1.27

Applicant changing to regular undiscounted fee status.

**NOTE:** Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

**NOTE:** If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

**NOTE:** Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

**NOTE:** This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature \_\_\_\_\_ Date \_\_\_\_\_

Typed or printed name \_\_\_\_\_ Registration No. \_\_\_\_\_



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 5 columns: APPLICATION NO., FILING DATE, FIRST NAMED INVENTOR, ATTORNEY DOCKET NO., CONFIRMATION NO.
13/553,972 07/20/2012 Juan Mantelle 041457-0992 3635

22428 7590 03/23/2017
Foley & Lardner LLP
3000 K STREET N.W.
SUITE 600
WASHINGTON, DC 20007-5109

EXAMINER

FISHER, MELISSA L

ART UNIT PAPER NUMBER

1611

DATE MAILED: 03/23/2017

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.



## OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

### Privacy Act Statement

**The Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

<b>Notice of Allowability</b>	<b>Application No.</b> 13/553,972	<b>Applicant(s)</b> MANTELLE, JUAN	
	<b>Examiner</b> Melissa Javier	<b>Art Unit</b> 1611	<b>AIA (First Inventor to File) Status</b> No

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 3/8/2017.  
 A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on \_\_\_\_\_.
2.  An election was made by the applicant in response to a restriction requirement set forth during the interview on \_\_\_\_\_; the restriction requirement and election have been incorporated into this action.
3.  The allowed claim(s) is/are 14,16,17,21-26,28,29 and 31-40. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see [http://www.uspto.gov/patents/init\\_events/pph/index.jsp](http://www.uspto.gov/patents/init_events/pph/index.jsp) or send an inquiry to [PPHfeedback@uspto.gov](mailto:PPHfeedback@uspto.gov).
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

**Certified copies:**

- a)  All    b)  Some    \*c)  None of the:
1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  
 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.  
**Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |  |   |
|--|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892)   | 5. <input checked="" type="checkbox"/> Examiner's Amendment/Comment       |
| 2. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO/SB/08),<br>Paper No./Mail Date _____ | 6. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| 3. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material         | 7. <input type="checkbox"/> Other _____.                                  |
| 4. <input type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date _____.                             |   |

/Melissa Javier/  
Primary Examiner, Art Unit 1611

### **DETAILED ACTION**

The present application is being examined under the pre-AIA first to invent provisions.

#### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 3/8/2017 has been entered.

#### ***Information Disclosure Statement***

The Information Disclosure Statement (IDS) filed 3/8/2017 has been considered by the examiner.

#### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melissa Javier whose telephone number is (571)270-7430. The examiner can normally be reached on Monday-Friday, 8am-5pm.


Art Unit: 1611

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.


/Melissa Javier/  
Primary Examiner, Art Unit 1611

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN	
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611	

CPC						
Symbol					Type	Version
A61K		9		7069	F	2013-01-01
A61K		9		7061	I	2013-01-01
A61K		31		565	I	2013-01-01
A61K		47		10	I	2013-01-01
A61K		47		32	I	2013-01-01
A61K		9		0014	I	2013-01-01


CPC Combination Sets					
Symbol		Type	Set	Ranking	Version

(Assistant Examiner) _____ (Date) _____		<b>Total Claims Allowed:</b> 21	
/MELISSA JAVIER/ Primary Examiner.Art Unit 1611 (Primary Examiner) _____ (Date) _____		O.G. Print Claim(s) 1	O.G. Print Figure None

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

US ORIGINAL CLASSIFICATION					INTERNATIONAL CLASSIFICATION									
CLASS		SUBCLASS			CLAIMED					NON-CLAIMED				
					A	6	1	K	31 / 565 (2006.01.01)					
					A	6	1	K	9 / 70 (2006.01.01)					
<b>CROSS REFERENCE(S)</b>														
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)													

		<b>Total Claims Allowed:</b>	
		21	
(Assistant Examiner) /MELISSA JAVIER/ Primary Examiner.Art Unit 1611	(Date) 03/18/2017	O.G. Print Claim(s)	O.G. Print Figure
(Primary Examiner)	(Date)	1	None

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

<input type="checkbox"/> Claims renumbered in the same order as presented by applicant		<input type="checkbox"/> CPA		<input checked="" type="checkbox"/> T.D.		<input type="checkbox"/> R.1.47									
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	16	17	12	33										
	2		18	13	34										
	3		19	14	35										
	4		20	17	36										
	5	2	21	18	37										
	6	3	22	19	38										
	7	4	23	20	39										
	8	5	24	21	40										
	9	6	25												
	10	7	26												
	11		27												
	12	8	28												
	13	9	29												
1	14		30												
	15	10	31												
15	16	11	32												

		<b>Total Claims Allowed:</b>	
		21	
(Assistant Examiner)	(Date)	O.G. Print Claim(s)	O.G. Print Figure
/MELISSA JAVIER/ Primary Examiner.Art Unit 1611	03/18/2017	1	None
(Primary Examiner)	(Date)		

## EAST Search History

## EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L2	5455	L1 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L3	916	L2 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L4	35	L3 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L5	262	L3 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L6	51	L3 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L7	90	L1 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L8	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L9	42	L8 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L10	151	L8 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L11	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L12	40	L11 NOT L8	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L13	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L14	714	L1 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L15	132	L3 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L16	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L17	5455	L16 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2017/03/18 12:01



			JPO; DERWENT			
L18	916	L17 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L19	35	L18 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L20	262	L18 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L21	51	L18 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L22	90	L16 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L23	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L24	42	L23 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L25	151	L23 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L26	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L27	40	L26 NOT L23	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L28	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L29	714	L16 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L30	132	L18 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L31	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L32	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L33	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L34	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L35	5455	L34 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L36	916	L35 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L37	35	L36 and estradiol.ab.	US-PGPUB; USPAT;	OR	OFF	2017/03/18

			USOCR; FPRS; EPO; JPO; DERWENT			12:01
L38	262	L36 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L39	51	L36 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L40	90	L34 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L41	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L42	42	L41 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L43	151	L41 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L44	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L45	40	L44 NOT L41	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L46	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L47	714	L34 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L48	132	L36 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:01
L49	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L50	5455	L49 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L51	916	L50 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L52	35	L51 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L53	262	L51 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L54	51	L51 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L55	90	L49 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L56	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01

L57	42	L56 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:01
L58	151	L56 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L59	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L60	40	L59 NOT L56	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L61	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L62	714	L49 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L63	132	L51 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L64	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L65	5455	L64 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L66	916	L65 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L67	35	L66 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L68	262	L66 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L69	51	L66 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L70	90	L64 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L71	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L72	42	L71 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L73	151	L71 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L74	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L75	40	L74 NOT L71	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L76	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02

L77	714	L64 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L78	132	L66 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L79	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L80	5455	L79 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L81	916	L80 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L82	35	L81 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L83	262	L81 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L84	51	L81 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L85	90	L79 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L86	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L87	42	L86 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L88	151	L86 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L89	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L90	40	L89 NOT L86	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L91	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L92	714	L79 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L93	132	L81 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L94	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L95	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L96	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L97	15742	estradiol and transdermal	US-PGPUB; USPAT;	OR	OFF	2017/03/18

			USOCR; FPRS; EPO; JPO; DERWENT			12:02
L98	5455	L97 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L99	916	L98 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L100	35	L99 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L101	262	L99 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L102	51	L99 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L103	90	L97 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L104	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L105	42	L104 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L106	151	L104 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L107	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L108	40	L107 NOT L104	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L109	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L110	714	L97 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L111	132	L99 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L112	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L113	5455	L112 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L114	916	L113 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L115	35	L114 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L116	262	L114 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L117	51	L114 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L118	90	L112 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L119	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L120	42	L119 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L121	151	L119 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L122	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L123	40	L122 NOT L119	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L124	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L125	714	L112 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L126	132	L114 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L129	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L130	5455	L129 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L131	916	L130 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L132	35	L131 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L133	262	L131 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L134	51	L131 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L135	90	L129 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L136	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L137	42	L136 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L138	151	L136 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L139	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L140	40	L139 NOT L136	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L141	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L142	714	L129 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L143	132	L131 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L144	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L145	5455	L144 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L146	916	L145 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L147	35	L146 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L148	262	L146 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L149	51	L146 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L150	90	L144 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L151	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L152	42	L151 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L153	151	L151 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L154	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L155	40	L154 NOT L151	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L156	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L157	714	L144 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L158	132	L146 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L159	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2017/03/18 12:02

			JPO; DERWENT			
L160	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L161	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L162	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L163	5455	L162 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L164	916	L163 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L165	35	L164 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L166	262	L164 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L167	51	L164 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L168	90	L162 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L169	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L170	42	L169 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L171	151	L169 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L172	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L173	40	L172 NOT L169	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L174	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L175	714	L162 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L176	132	L164 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L177	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L178	5455	L177 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L179	916	L178 and acrylic and	US-PGPUB; USPAT;	OR	OFF	2017/03/18



		silicone and (PVP polyvinyl pyrrolidone)	USOCR; FPRS; EPO; JPO; DERWENT			12:02
L180	35	L179 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L181	262	L179 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L182	51	L179 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L183	90	L177 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L184	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L185	42	L184 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L186	151	L184 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L187	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L188	40	L187 NOT L184	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L189	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L190	714	L177 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L191	132	L179 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L192	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L193	5455	L192 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L194	916	L193 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L195	35	L194 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L196	262	L194 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L197	51	L194 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L198	90	L192 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L199	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L200	42	L199 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L201	151	L199 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L202	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L203	40	L202 NOT L199	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L204	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L205	714	L192 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L206	132	L194 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L207	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L208	5455	L207 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L209	916	L208 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L210	35	L209 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L211	262	L209 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L212	51	L209 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L213	90	L207 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L214	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L215	42	L214 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L216	151	L214 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L217	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L218	40	L217 NOT L214	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L219	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L220	714	L207 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L221	132	L209 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L222	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L223	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L224	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L225	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L226	5455	L225 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L227	916	L226 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L228	35	L227 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L229	262	L227 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L230	51	L227 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L231	90	L225 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L232	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L233	42	L232 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L234	151	L232 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L235	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L236	40	L235 NOT L232	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L237	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L238	714	L225 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L239	132	L227 and ("dipropylene	USPAT; USOCR	OR	OFF	2017/03/18

		glycol" oleyl)				12:02
L240	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L241	5455	L240 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L242	916	L241 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L243	35	L242 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L244	262	L242 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L245	51	L242 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L246	90	L240 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L247	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L248	42	L247 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L249	151	L247 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L250	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L251	40	L250 NOT L247	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L252	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L253	714	L240 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L254	132	L242 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L255	58	(("MANTELLE") near3 ("Juan")).INV.	US-PGPUB; USPAT; USOCR	OR	OFF	2017/03/18 12:02
L256	2	12/216811	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L257	1	(12/216811).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L258	16747	A61K31/565.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02
L259	5310	A61K9/70.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02

L260	33	L258 L259	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02
L261	8	L260 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02
L265	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L266	5455	L265 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L267	916	L266 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L268	35	L267 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L269	262	L267 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L270	51	L267 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L271	90	L265 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L272	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L273	42	L272 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L274	151	L272 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L275	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L276	40	L275 NOT L272	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L277	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L278	714	L265 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L279	132	L267 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L280	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L281	5455	L280 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L282	916	L281 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L283	35	L282 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L284	262	L282 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L285	51	L282 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L286	90	L280 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L287	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L288	42	L287 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L289	151	L287 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L290	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L291	40	L290 NOT L287	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L292	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L293	714	L280 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L294	132	L282 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L295	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L296	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L297	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L298	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L299	5455	L298 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L300	916	L299 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L301	35	L300 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L302	262	L300 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L303	51	L300 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L304	90	L298 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L305	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L306	42	L305 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L307	151	L305 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L308	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L309	40	L308 NOT L305	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L310	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L311	714	L298 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L312	132	L300 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L313	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L314	5455	L313 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L315	916	L314 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L316	35	L315 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L317	262	L315 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L318	51	L315 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L319	90	L313 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L320	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L321	42	L320 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L322	151	L320 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2017/03/18 12:02

			JPO; DERWENT			
L323	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L324	40	L323 NOT L320	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L325	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L326	714	L313 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L327	132	L315 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L328	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L329	5455	L328 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L330	916	L329 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L331	35	L330 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L332	262	L330 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L333	51	L330 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L334	90	L328 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L335	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L336	42	L335 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L337	151	L335 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L338	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L339	40	L338 NOT L335	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L340	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L341	714	L328 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L342	132	L330 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L343	15742	estradiol and transdermal	US-PGPUB; USPAT;	OR	OFF	2017/03/18



			USOCR; FPRS; EPO; JPO; DERWENT			12:02
L344	5455	L343 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L345	916	L344 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L346	35	L345 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L347	262	L345 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L348	51	L345 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L349	90	L343 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L350	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L351	42	L350 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L352	151	L350 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L353	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L354	40	L353 NOT L350	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L355	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L356	714	L343 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L357	132	L345 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L358	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L359	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L360	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L361	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L362	5455	L361 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L363	916	L362 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L364	35	L363 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L365	262	L363 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L366	51	L363 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L367	90	L361 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L368	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L369	42	L368 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L370	151	L368 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L371	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L372	40	L371 NOT L368	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L373	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L374	714	L361 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L375	132	L363 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L376	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L377	5455	L376 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L378	916	L377 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L379	35	L378 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L380	262	L378 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L381	51	L378 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L382	90	L376 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L383	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L384	42	L383 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L385	151	L383 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L386	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L387	40	L386 NOT L383	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L388	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L389	714	L376 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L390	132	L378 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L391	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L392	5455	L391 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L393	916	L392 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L394	35	L393 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L395	262	L393 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L396	51	L393 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L397	90	L391 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L398	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L399	42	L398 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L400	151	L398 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L401	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L402	40	L401 NOT L398	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L403	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L404	714	L391 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L405	132	L393 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L406	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L407	5455	L406 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L408	916	L407 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L409	35	L408 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L410	262	L408 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L411	51	L408 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L412	90	L406 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L413	259	MANTELLA.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L414	42	L413 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L415	151	L413 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L416	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L417	40	L416 NOT L413	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L418	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L419	714	L406 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L420	132	L408 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L421	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L422	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L423	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO;	OR	OFF	2017/03/18 12:02

			JPO; DERWENT			
L424	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L425	5455	L424 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L426	916	L425 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L427	35	L426 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L428	262	L426 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L429	51	L426 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L430	90	L424 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L431	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L432	42	L431 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L433	151	L431 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L434	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L435	40	L434 NOT L431	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L436	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L437	714	L424 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L438	132	L426 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L439	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L440	5455	L439 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L441	916	L440 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L442	35	L441 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L443	262	L441 and transdermal.ab.	US-PGPUB; USPAT;	OR	OFF	2017/03/18

			USOCR; FPRS; EPO; JPO; DERWENT			12:02
L444	51	L441 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L445	90	L439 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L446	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L447	42	L446 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L448	151	L446 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L449	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L450	40	L449 NOT L446	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L451	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L452	714	L439 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L453	132	L441 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L454	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L455	5455	L454 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L456	916	L455 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L457	35	L456 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L458	262	L456 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L459	51	L456 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L460	90	L454 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L461	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L462	42	L461 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02

L463	151	L461 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L464	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L465	40	L464 NOT L461	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L466	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L467	714	L454 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L468	132	L456 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L469	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L470	5455	L469 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L471	916	L470 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L472	35	L471 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L473	262	L471 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L474	51	L471 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L475	90	L469 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L476	259	MANTEILLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L477	42	L476 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L478	151	L476 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L479	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L480	40	L479 NOT L476	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L481	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L482	714	L469 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L483	132	L471 and ("dipropylene	USPAT; USOCR	OR	OFF	2017/03/18

		glycol" oleyl)				12:02
L484	2	"6638528".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L485	4	"4624665".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L486	3	"20090041831".pn.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L487	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L488	5455	L487 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L489	916	L488 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L490	35	L489 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L491	262	L489 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L492	51	L489 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L493	90	L487 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L494	259	MANTELE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L495	42	L494 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L496	151	L494 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L497	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L498	40	L497 NOT L494	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L499	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L500	714	L487 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L501	132	L489 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L502	15742	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L503	5455	L502 and ("surface area"	US-PGPUB; USPAT;	OR	OFF	2017/03/18



		flux)	USOCR; FPRS; EPO; JPO; DERWENT			2017/03/18 12:02
L504	916	L503 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L505	35	L504 and estradiol.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L506	262	L504 and transdermal.ab.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L507	51	L504 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L508	90	L502 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L509	259	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L510	42	L509 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L511	151	L509 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L512	186	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L513	40	L512 NOT L509	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L514	0	(11/245097).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L515	714	L502 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L516	132	L504 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L517	58	((("MANTELLE") near3 ("Juan")).INV.	US-PGPUB; USPAT; USOCR	OR	OFF	2017/03/18 12:02
L518	2	12/216811	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/03/18 12:02
L519	1	(12/216811).APP.	USPAT; USOCR	OR	OFF	2017/03/18 12:02
L520	16747	A61K31/565.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02
L521	5310	A61K9/70.cpc.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02
L522	33	L520 L521	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	AND	OFF	2017/03/18 12:02
L523	8	L522 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO;	AND	OFF	2017/03/18 12:02

			JPO; DERWENT			
--	--	--	--------------	--	--	--

**3/ 18/ 2017 12:11:11 PM**

**C:\Users\mjavier\Documents\EAST\Workspaces\13553972.wsp**



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3635

<b>SERIAL NUMBER</b> 13/553,972	<b>FILING or 371(c) DATE</b> 07/20/2012 <b>RULE</b>	<b>CLASS</b> 424	<b>GROUP ART UNIT</b> 1611	<b>ATTORNEY DOCKET NO.</b> 041457-0992	
<b>APPLICANTS</b> <b>INVENTORS</b> Juan Mantelle, Miami, FL; <b>** CONTINUING DATA *****</b> This application is a CON of 12/216,811 07/10/2008 PAT 8231906 <b>** FOREIGN APPLICATIONS *****</b> <b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b> 07/31/2012					
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Verified and Acknowledged <u>/MELISSA L JAVIER/</u> Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials _____	<b>STATE OR COUNTRY</b> FL	<b>SHEETS DRAWINGS</b> 1	<b>TOTAL CLAIMS</b> 16	<b>INDEPENDENT CLAIMS</b> 4
<b>ADDRESS</b> Foley & Lardner LLP 3000 K STREET N.W. SUITE 600 WASHINGTON, DC 20007-5109 UNITED STATES					
<b>TITLE</b> TRANSDERMAL ESTROGEN DEVICE AND DELIVERY					
<b>FILING FEE RECEIVED</b> 2540	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		



Atty. Dkt. No. 041457-0992

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
 Title: Transdermal Estrogen Device  
 and Delivery  
 Application No.: 13/553972  
 Filing Date: 7/20/2012  
 Examiner: Melissa L. Javier  
 Art Unit: 1611  
 Confirmation No.: 3635

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Commissioner:

Applicant submits herewith documents for the Examiner's consideration in accordance with 37 CFR §§1.56, 1.97 and 1.98.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The submission of any document herewith is not an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document submitted herewith.

Atty. Dkt. No. 041457-0992

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing of a first Office action after the filing of a RCE.

**RELEVANCE OF LISTED DOCUMENTS**

Documents A1 and A2 are Office Actions which were issued in the child applications.

Document A3 is a Decision issued in an Opposition of a corresponding European patent. Although the patent was revoked because certain claim language not present in the pending claims was found to constitute an impermissible generalization of the original disclosure, the EPO Opposition Division rejected the Opponent's prior art and enablement-type arguments.

Although Applicant believes that no fee is required, the Commissioner is hereby authorized to charge any additional fees which may be due to Deposit Account Number 19-0741.

Respectfully submitted,

Date March 8, 2011


By Courtenay C. Brinckerhoff

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288

PTO/SB/08 (modified)

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	13/553972
		Filing Date	7/20/2012
Date Submitted: March 8, 2017		First Named Inventor	Juan Mantelle
		Art Unit	1611
(use as many sheets as necessary)		Examiner Name	Melissa L. Javier
		Attorney Docket Number	041457-0992
Sheet	1	of	1




U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	Notice of Allowance issued on 01/10/2017 in application number 14/024,985 (US 2014-0200530)	
	A2	Office Action issued on 09/07/2016 in application number 14/870,574 (US 2016-0015655)	
	A3	European Office Action issued on 02/14/2017 in application number EP 09790211.8	

Examiner Signature	/MELISSA L. JAVIER/	Date Considered	03/18/2017
--------------------	---------------------	-----------------	------------

<b>Search Notes</b>  	<b>Application/Control No.</b>  13553972	<b>Applicant(s)/Patent Under Reexamination</b>  MANTELLE, JUAN
	<b>Examiner</b>  MELISSA JAVIER	<b>Art Unit</b>  1611

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
EAST search (see attached history)	8/25/2013	MJ
Inventor search in EAST	8/25/2013	MJ
Google Scholar search (keywords used: transdermal monolithic estradiol)	8/25/2013	MJ
Updated EAST search	2/21/2014	MJ
Updated Google Scholar search	2/21/2014	MJ
Updated EAST search	4/29/2015	MJ
Updated Google Scholar search	4/29/2015	MJ
Updated EAST search	9/28/2015	MJ
Updated Google Scholar search	9/28/2015	MJ
Updated EAST search	4/22/2016	MJ
Updated Google Scholar search	4/22/2016	MJ
Updated EAST search	8/22/2016	MJ
Updated Google Scholar search	8/22/2016	MJ
(A61K31/565 A61K9/70).cpc. and estradiol	8/22/2016	MJ
Updated EAST search	12/2/2016	MJ
Updated Google Scholar search	12/2/2016	MJ
(A61K31/565 A61K9/70).cpc. and estradiol	12/2/2016	MJ
Updated EAST search	3/18/2017	MJ
Updated Google Scholar search	3/18/2017	MJ

	/M.J./ Primary Examiner.Art Unit 1611
--	--

### INTERFERENCE SEARCH

US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
	(monolith\$2 estradiol transdermal adhesive coat weight flux).clm.	9/28/2015	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	8/22/2016	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	12/2/2016	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	3/18/2017	MJ

	/M.J./ Primary Examiner.Art Unit 1611
--	--



***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Appl. No.: 13/553,972  
Appl. Filing Date: 7/20/2012  
Examiner: Melissa L. Fisher  
Art Unit: 1611  
Confirmation Number: 3635

**REQUEST FOR CONTINUED EXAMINATION (RCE)**  
**TRANSMITTAL**

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application. This RCE and the enclosed items listed below are being filed prior to the earliest of: (1) payment of the issue fee (unless a petition under 37 C.F.R. § 1.313 is granted); (2) abandonment of the application; or (3) the filing of a notice of appeal to the U.S. Court of Appeals for the Federal Circuit under 35 U.S.C. §141, or the commencement of a civil action under 35 U.S.C. §145 or §146 (unless the appeal or civil action is terminated).

Submission **required** under 37 C.F.R. §1.114:

[ X ] Amendment/Reply.

The filing fee is calculated below at the large entity rate:

	Claims as Amended	Previously Paid For	Extra Claims Present	Rate	Fee Totals
RCE Fee 1.17(e):				\$1,700.00	= \$1,700.00
				0	
Total Claims:	23	- 26	= 0	x \$80.00	= \$0.00
Independents	2	- 5	= 0	x \$420.00	= \$0.00
First presentation of any Multiple Dependent Claims:				+ \$780.00	= \$0.00
RCE and CLAIMS FEE TOTAL:					= \$1,700.00

The above-identified fees of \$1,700.00 are being paid by credit card via EFS-Web.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date June 6, 2017

By / Courtenay C. Brinckerhoff/

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Appl. No.: 13/553,972  
Filing Date: 7/20/2012  
Examiner: Melissa L. Javier  
Art Unit: 1611  
Confirmation Number: 3635

AMENDMENT

MAIL STOP: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This paper is filed with a Request for Continued Examination. If any extensions of time are required for timely acceptance, Applicant hereby petitions for such extension of time. The Commissioner is hereby authorized to charge any fees which may be due for this application, including any extension of time fees or excess claim fees not submitted herewith, to Deposit Account No. 19-0741.

Amendments to the claims are set forth in the **Listing of Claims** which begins on page 2.

**Remarks/Arguments** begin on page 6.

**Listing of Claims:**

Claims 1-13 (Cancelled)

14. (Previously Presented) A method for administering estradiol, comprising applying to the skin or mucosa of a subject in need thereof a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer defining an active surface area and comprising an adhesive polymer matrix comprising estradiol as the only drug, wherein the polymer matrix has a coat weight of greater than about 10 mg/cm<sup>2</sup> and includes greater than 0.156 mg/cm<sup>2</sup> estradiol, and the system achieves an estradiol flux of from about 0.0125 to about 0.05 mg/cm<sup>2</sup>/day, based on the active surface area.

15. (Canceled)

16. (Previously Presented) A method of making a monolithic transdermal drug delivery system for administering estradiol consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer and, optionally, (iii) a release liner, comprising forming an adhesive polymer matrix comprising estradiol as the only drug and a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble PVP, and applying the adhesive polymer matrix to a support layer to form a single adhesive polymer matrix layer such that the adhesive polymer matrix layer has a coat weight of greater than about 10 mg/cm<sup>2</sup> and includes greater than 0.156 mg/cm<sup>2</sup> estradiol, wherein the system achieves an estradiol flux of from about 0.0125 to about 0.05 mg/cm<sup>2</sup>/day, based on the active surface area.

17. (Original) The method of claim 16, wherein the system has an active surface area that is about 60% of a size selected from the group consisting of 2.5, 3.75, 5.0, 7.5 and 10.0 cm<sup>2</sup>.

18- 20 (Canceled)

21. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble polyvinylpyrrolidone (PVP).

22. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises about 2-25% by weight acrylic adhesive, about 45-70% by weight silicone adhesive, about 2-25% by weight soluble PVP, about 5-15% penetration enhancer, and about 0.1-10% by weight estradiol, all based on the total dry weight of the adhesive polymer matrix.

23. (Previously Presented) The method of claim 22, wherein the penetration enhancer comprises oleyl alcohol.

24. (Previously Presented) The method of claim 22, wherein the penetration enhancer comprises dipropylene glycol.

25. (Previously Presented) The method of claim 22, wherein the penetration enhancer comprises oleyl alcohol and dipropylene glycol.

26. (Previously Presented) The method of claim 22, wherein the acrylic adhesive and silicone adhesive are present in a ratio of from about 1:2 to about 1:6, based on the total weight of the acrylic and silicone adhesives.

27. (Canceled)

28. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises an amount of estradiol effective to deliver a therapeutically effective amount of estradiol over a period of time selected from the group consisting of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days.

29. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises an amount of estradiol effective to deliver an amount of estradiol selected from the group consisting of about 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day.

30. (Canceled)

31. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0125 mg/cm<sup>2</sup>/day, based on the active surface area.
32. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0133 mg/cm<sup>2</sup>/day, based on the active surface area.
33. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.015 mg/cm<sup>2</sup>/day, based on the active surface area.
34. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0167 mg/cm<sup>2</sup>/day, based on the active surface area.
35. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0175 mg/cm<sup>2</sup>/day, based on the active surface area.
36. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0125 mg/cm<sup>2</sup>/day, based on the active surface area.
37. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0133 mg/cm<sup>2</sup>/day, based on the active surface area.
38. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.015 mg/cm<sup>2</sup>/day, based on the active surface area.
39. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0167 mg/cm<sup>2</sup>/day, based on the active surface area.
40. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0175 mg/cm<sup>2</sup>/day, based on the active surface area.
41. (New) The method of claim 14, wherein the adhesive polymer matrix comprises about 1.6% by weight estradiol, based on the total dry weight of the adhesive polymer matrix.

42. (New) The method of claim 16, wherein the adhesive polymer matrix comprises about 1.6% by weight estradiol, based on the total dry weight of the adhesive polymer matrix.



**REMARKS**

A Notice of Allowance allowing claims 14, 16, 17, 21-26, 28, 29, and 31-40 was mailed March 23, 2017.

Claims 41 and 42 are added to recite specific embodiment described in the specification as filed, including in paragraphs [0011], [0069] and [0082]. No new matter is added.

Upon entry of these amendments claims 14, 16-17, 21-26, and 28-29 and 31-42 will be pending. Applicant believes that these claims are in condition for allowance.

Should there be any questions regarding this submission, or should any issue remain, the Examiner is urged to contact the undersigned by telephone to advance prosecution.

Respectfully submitted,

Date: June 6, 2017

By /Courtenay C. Brinckerhoff/

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288

## Electronic Patent Application Fee Transmittal

<b>Application Number:</b>	13553972			
<b>Filing Date:</b>	20-Jul-2012			
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY			
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle			
<b>Filer:</b>	Courtenay C. Brinckerhoff			
<b>Attorney Docket Number:</b>	041457-0992			
Filed as Large Entity				
<b>Filing Fees for Utility under 35 USC 111(a)</b>				
<b>Description</b>	<b>Fee Code</b>	<b>Quantity</b>	<b>Amount</b>	<b>Sub-Total in USD(\$)</b>
<b>Basic Filing:</b>				
<b>Pages:</b>				
<b>Claims:</b>				
<b>Miscellaneous-Filing:</b>				
<b>Petition:</b>				
<b>Patent-Appeals-and-Interference:</b>				
<b>Post-Allowance-and-Post-Issuance:</b>				
<b>Extension-of-Time:</b>				

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
<b>Miscellaneous:</b>				
RCE- 2ND AND SUBSEQUENT REQUEST	1820	1	1700	1700
<b>Total in USD (\$)</b>				<b>1700</b>

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	29406722
<b>Application Number:</b>	13553972
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3635
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle
<b>Customer Number:</b>	22428
<b>Filer:</b>	Courtenay C. Brinckerhoff/Christine Arthur
<b>Filer Authorized By:</b>	Courtenay C. Brinckerhoff
<b>Attorney Docket Number:</b>	041457-0992
<b>Receipt Date:</b>	06-JUN-2017
<b>Filing Date:</b>	20-JUL-2012
<b>Time Stamp:</b>	12:39:47
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$1700
RAM confirmation Number	060617INTEFSW12400900
Deposit Account	
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

--	--	--	--	--	--

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE.pdf	102546	no	3
			ad5731ba910b235b2e92279226e9734a57443a31		

**Warnings:**

This is not a USPTO supplied RCE SB30 form.

**Information:**

2	Amendment Submitted/Entered with Filing of CPA/RCE	amendment.pdf	104738	no	6
			795ff5b7be0cd2a5135e87b03f0fdda1dce06931		

**Warnings:**

**Information:**

3	Fee Worksheet (SB06)	fee-info.pdf	30373	no	2
			7afa426d28fac95b6a98b120e36ac4ae36d4abec		

**Warnings:**

**Information:**

<b>Total Files Size (in bytes):</b>	237657
-------------------------------------	--------

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>PATENT APPLICATION FEE DETERMINATION RECORD</b> Substitute for Form PTO-875	Application or Docket Number <b>13/553,972</b>	Filing Date <b>07/20/2012</b>	<input checked="" type="checkbox"/> To be Mailed
---	---	----------------------------------	--

ENTITY:  LARGE  SMALL  MICRO

**APPLICATION AS FILED – PART I**

FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)
<input type="checkbox"/> BASIC FEE (37 CFR 1.16(a), (b), or (c))	N/A	N/A	N/A	
<input type="checkbox"/> SEARCH FEE (37 CFR 1.16(k), (l), or (m))	N/A	N/A	N/A	
<input type="checkbox"/> EXAMINATION FEE (37 CFR 1.16(o), (p), or (q))	N/A	N/A	N/A	
TOTAL CLAIMS (37 CFR 1.16(i))	minus 20 =	*	X \$ =	
INDEPENDENT CLAIMS (37 CFR 1.16(h))	minus 3 =	*	X \$ =	
<input type="checkbox"/> APPLICATION SIZE FEE (37 CFR 1.16(s))	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENT (37 CFR 1.16(j))				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

**APPLICATION AS AMENDED – PART II**

	(Column 1)	(Column 2)	(Column 3)	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)
<b>AMENDMENT</b>	<b>06/06/2017</b>	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		
		*	Minus	**	=	
	Total (37 CFR 1.16(i))	23		26	= 0	X \$80 = 0
	Independent (37 CFR 1.16(h))	2	Minus	5	= 0	X \$420 = 0
	<input type="checkbox"/> Application Size Fee (37 CFR 1.16(s))					
	<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
					TOTAL ADD'L FEE	<b>0</b>

	(Column 1)	(Column 2)	(Column 3)	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)
<b>AMENDMENT</b>		CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		
		*	Minus	**	=	
	Total (37 CFR 1.16(i))	*	Minus	***	=	X \$ =
	Independent (37 CFR 1.16(h))	*	Minus	***	=	X \$ =
	<input type="checkbox"/> Application Size Fee (37 CFR 1.16(s))					
	<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM (37 CFR 1.16(j))					
					TOTAL ADD'L FEE	

LIE  
LISA THOMAS

\* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.  
 \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".  
 \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 5 columns: APPLICATION NO., FILING DATE, FIRST NAMED INVENTOR, ATTORNEY DOCKET NO., CONFIRMATION NO.
Row 1: 13/553,972, 07/20/2012, Juan Mantelle, 041457-0992, 3635
Row 2: 22428, 7590, 06/14/2017, (Empty), (Empty)
Row 3: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 4: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 5: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 6: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 7: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 8: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 9: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 10: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 11: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 12: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 13: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 14: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 15: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 16: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 17: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 18: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 19: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 20: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 21: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 22: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 23: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 24: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 25: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 26: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 27: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 28: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 29: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 30: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 31: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 32: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 33: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 34: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 35: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 36: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 37: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 38: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 39: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 40: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 41: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 42: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 43: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 44: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 45: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 46: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 47: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 48: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 49: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 50: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 51: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 52: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 53: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 54: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 55: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 56: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 57: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 58: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 59: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 60: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 61: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 62: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 63: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 64: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 65: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 66: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 67: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 68: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 69: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 70: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 71: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 72: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 73: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 74: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 75: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 76: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 77: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 78: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 79: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 80: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 81: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 82: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 83: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 84: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 85: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 86: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 87: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 88: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 89: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 90: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 91: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 92: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 93: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 94: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 95: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 96: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 97: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 98: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 99: (Empty), (Empty), (Empty), (Empty), (Empty)
Row 100: (Empty), (Empty), (Empty), (Empty), (Empty)

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

ipdocketing@foley.com

<b>Applicant-Initiated Interview Summary</b>	<b>Application No.</b> 13/553,972	<b>Applicant(s)</b> MANTELLE, JUAN	
	<b>Examiner</b> Melissa Fisher	<b>Art Unit</b> 1611	

All participants (applicant, applicant's representative, PTO personnel):

- (1) Melissa Fisher. (3) Richard Guy.  
(2) Courtenay Brinckerhoff. (4) \_\_\_\_\_.

Date of Interview: 08 June 2017.

Type:  Telephonic  Video Conference  
 Personal [copy given to:  applicant  applicant's representative]

Exhibit shown or demonstration conducted:  Yes  No.  
If Yes, brief description: \_\_\_\_\_.

Issues Discussed 101 112 102 103 Others  
(For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: \_\_\_\_\_.

Identification of prior art discussed: None.

**Substance of Interview**

(For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

Discussed the attached agenda.

Specifically, Applicant's representative and Dr. Guy explained how the included data supported the unexpected results that increasing the coat weight of the drug-containing adhesive layer resulted in an increased flux per unit area, and permitted the development of smaller transdermal drug delivery systems that achieve comparable daily dosages..

**Applicant recordation instructions:** The formal written reply to the last Office action must include the substance of the interview. (See MPEP section 713.04). If a reply to the last Office action has already been filed, applicant is given a non-extendable period of the longer of one month or thirty days from this interview date, or the mailing date of this interview summary form, whichever is later, to file a statement of the substance of the interview

**Examiner recordation instructions:** Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

Attachment

/Melissa Fisher/  
Primary Examiner, Art Unit 1611



## Summary of Record of Interview Requirements

### Manual of Patent Examining Procedure (MPEP), Section 713.04, Substance of Interview Must be Made of Record

A complete written statement as to the substance of any face-to-face, video conference, or telephone interview with regard to an application must be made of record in the application whether or not an agreement with the examiner was reached at the interview.

### Title 37 Code of Federal Regulations (CFR) § 1.133 Interviews

Paragraph (b)

In every instance where reconsideration is requested in view of an interview with an examiner, a complete written statement of the reasons presented at the interview as warranting favorable action must be filed by the applicant. An interview does not remove the necessity for reply to Office action as specified in §§ 1.111, 1.135. (35 U.S.C. 132)

37 CFR §1.2 Business to be transacted in writing.

All business with the Patent or Trademark Office should be transacted in writing. The personal attendance of applicants or their attorneys or agents at the Patent and Trademark Office is unnecessary. The action of the Patent and Trademark Office will be based exclusively on the written record in the Office. No attention will be paid to any alleged oral promise, stipulation, or understanding in relation to which there is disagreement or doubt.

The action of the Patent and Trademark Office cannot be based exclusively on the written record in the Office if that record is itself incomplete through the failure to record the substance of interviews.

It is the responsibility of the applicant or the attorney or agent to make the substance of an interview of record in the application file, unless the examiner indicates he or she will do so. It is the examiner's responsibility to see that such a record is made and to correct material inaccuracies which bear directly on the question of patentability.

Examiners must complete an Interview Summary Form for each interview held where a matter of substance has been discussed during the interview by checking the appropriate boxes and filling in the blanks. Discussions regarding only procedural matters, directed solely to restriction requirements for which interview recordation is otherwise provided for in Section 812.01 of the Manual of Patent Examining Procedure, or pointing out typographical errors or unreadable script in Office actions or the like, are excluded from the interview recordation procedures below. Where the substance of an interview is completely recorded in an Examiners Amendment, no separate Interview Summary Record is required.

The Interview Summary Form shall be given an appropriate Paper No., placed in the right hand portion of the file, and listed on the "Contents" section of the file wrapper. In a personal interview, a duplicate of the Form is given to the applicant (or attorney or agent) at the conclusion of the interview. In the case of a telephone or video-conference interview, the copy is mailed to the applicant's correspondence address either with or prior to the next official communication. If additional correspondence from the examiner is not likely before an allowance or if other circumstances dictate, the Form should be mailed promptly after the interview rather than with the next official communication.

The Form provides for recordation of the following information:

- Application Number (Series Code and Serial Number)
- Name of applicant
- Name of examiner
- Date of interview
- Type of interview (telephonic, video-conference, or personal)
- Name of participant(s) (applicant, attorney or agent, examiner, other PTO personnel, etc.)
- An indication whether or not an exhibit was shown or a demonstration conducted
- An identification of the specific prior art discussed
- An indication whether an agreement was reached and if so, a description of the general nature of the agreement (may be by attachment of a copy of amendments or claims agreed as being allowable). Note: Agreement as to allowability is tentative and does not restrict further action by the examiner to the contrary.
- The signature of the examiner who conducted the interview (if Form is not an attachment to a signed Office action)

It is desirable that the examiner orally remind the applicant of his or her obligation to record the substance of the interview of each case. It should be noted, however, that the Interview Summary Form will not normally be considered a complete and proper recordation of the interview unless it includes, or is supplemented by the applicant or the examiner to include, all of the applicable items required below concerning the substance of the interview.

A complete and proper recordation of the substance of any interview should include at least the following applicable items:

- 1) A brief description of the nature of any exhibit shown or any demonstration conducted,
- 2) an identification of the claims discussed,
- 3) an identification of the specific prior art discussed,
- 4) an identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary Form completed by the Examiner,
- 5) a brief identification of the general thrust of the principal arguments presented to the examiner,  
(The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments made to the examiner can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner.)
- 6) a general indication of any other pertinent matters discussed, and
- 7) if appropriate, the general results or outcome of the interview unless already described in the Interview Summary Form completed by the examiner.

Examiners are expected to carefully review the applicant's record of the substance of an interview. If the record is not complete and accurate, the examiner will give the applicant an extendable one month time period to correct the record.

### Examiner to Check for Accuracy

If the claims are allowable for other reasons of record, the examiner should send a letter setting forth the examiner's version of the statement attributed to him or her. If the record is complete and accurate, the examiner should place the indication, "Interview Record OK" on the paper recording the substance of the interview along with the date and the examiner's initials.

Outline for June 8, 2017 Examiner Interview

Summary Of Claimed Subject Matter

The claimed subject matter includes transdermal drug delivery systems estradiol that have a smaller active surface area than the prior art Vivelle-Dot® patches, but achieve daily dosages that are about equal to or greater than the Vivelle-Dot® patches. That is, the subject matter includes transdermal drug delivery systems that achieve daily dosages that are about equal to a Vivelle-Dot® patch, in a smaller size. *See, e.g.*, Specification, at paragraph [0014].

As stated in the specification, “the Applicant surprisingly discovered that increasing the coat weight of the drug-containing adhesive layer resulted in an increased flux per unit area, and thus permitted the development of smaller transdermal drug delivery systems that achieve comparable daily dosages.” Specification, at paragraph [0014].

All claims recite a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer defining an active surface area and comprising an adhesive polymer matrix comprising estradiol as the only drug.<sup>1</sup>

The claims of the '972, '985, and '255 applications recite that the polymer matrix has a coat weight of greater than about 10 mg/cm<sup>2</sup> and includes greater than 0.156 mg/cm<sup>2</sup> estradiol, and that the transdermal drug delivery system achieves an estradiol flux of from about 0.0125 to about 0.05 g/cm<sup>2</sup>/day, based on the active surface area.

The claims of the '574 application recite that the coat weight of the polymer matrix is adjusted such that system includes greater than 0.156 mg/cm<sup>2</sup> estradiol, and that the transdermal drug delivery achieves an estradiol flux of from about 0.0125 to about 0.05 g/cm<sup>2</sup>/day, based on the active surface area.

---

<sup>1</sup> Some claims recite an optional release liner that is removed prior to use.

### Summary Of Issues To Be Discussed

- Understanding in the art regarding passive drug flux from a transdermal drug delivery system (Fick's 1<sup>st</sup> Law of Diffusion)
- Impact of polymer components on drug flux (predicted by Fick's 1<sup>st</sup> Law)
- Additional experimental data demonstrating surprising and unexpected result that increasing coat weight increases estradiol flux (not predicted by Fick's 1<sup>st</sup> Law)


### Introduction of Expert

Dr. Richard Guy, Professor of Pharmaceutical Sciences, University of Bath (UK) (in the Department of Pharmacy & Pharmacology)


- over 30 years' research experience in the field of topical and transdermal drug delivery, including the study of drug absorption into and through the skin
- Bachelor of Arts in chemistry from Oxford University (UK) (1977)
- Master of Arts in chemistry from Oxford University (1980)
- Ph.D. in pharmaceutical chemistry from the University of London (UK) (1980).
- D.Sc. from Oxford University (2016).
- co-author on over 350 peer-reviewed articles and over 70 book chapters.
- experience as a consultant (and scientific advisory board member) to numerous pharmaceutical companies involved in the development of transdermal drug delivery formulations (including patches and other gels)
- engaged by the Applicant (Noven Pharmaceuticals, Inc.) to serve as an expert witness in ANDA litigation involving U.S. Patent No.8,231,906 (the '906 Patent ), in the U.S. District Court for the District of Delaware (C.A. No. 15-249) (the "ANDA litigation).
- engaged by the Applicant to prepare a Declaration for U.S. patent applications 13/553,972, 14/024,985, 14/738,255, and 14/870,574 and attend the Patent Office Interview
- His compensation does not depend in any way on the outcome of the examination of the pending applications or on the outcome of the ANDA litigation.

## TECHNICAL BACKGROUND

The inventions claimed in the pending applications generally relate to transdermal drug delivery systems (*e.g.*, transdermal “patches”) for the delivery of estradiol, methods of administering estradiol to a patient using the claimed transdermal drug delivery systems, and delivering estradiol using them, and methods of making them. The claimed transdermal drug delivery systems are “monolithic” drug-in-adhesive systems that consist of (i) a backing layer; (ii) a drug-in-adhesive polymer matrix layer, and, optionally, (iii) a release liner that is removed prior to use, as illustrated below.



The claims recite that the adhesive polymer matrix layers include a certain amount estradiol per unit area and achieve a certain estradiol flux. The flux of a drug is the rate at which it diffuses through the skin. An *in vitro* flux study may be conducted to assess the flux of a drug from a transdermal drug delivery system. The image below shows a typical Franz diffusion cell set up used to conduct an *in vitro* flux study.



In general, the receptor compartment is filled with a receiver solution that is stirred and held at a constant (typically, physiological) temperature. A transdermal system is placed on a skin sample in the donor compartment, and the contents of the receptor compartment are sampled (withdrawn) periodically and analyzed for drug (for example, estradiol) content. From this information, the cumulative amount of drug delivered over time and the flux of drug across the skin as a function of time is calculated.

An illustration of the type of experimental data collected with this approach is shown below for one particular formulation; the results are presented as the average cumulative amounts of drug delivered, and the average drug flux, as a function of time, with the corresponding standard deviations for 4 replicate Franz diffusion cells.

(hours)	(mcg/cm <sup>2</sup> )	(mcg/cm <sup>2</sup> )	(mcg/cm <sup>2</sup> hr)	(mcg/cm <sup>2</sup> hr)
Average Time	Average Cum.	Cum. Stdev	Average Flux	Flux Stdev
0.00	0.00	0.00	0.00	0.00
9.92	2.55	0.49	0.26	0.05
23.95	12.64	1.99	0.72	0.11
33.65	20.85	2.91	0.85	0.10
48.03	33.45	4.10	0.88	0.08
57.58	41.70	4.81	0.86	0.08
72.20	54.23	5.71	0.86	0.06
81.02	61.43	6.07	0.82	0.04

These results may be plotted graphically as illustrated in the specification and the additional experimental data that will be discussed.

## FICK'S FIRST LAW OF DIFFUSION

As of June 10, 2008, a person of ordinary skill in the art understood that the passive flux of a drug can be quantitatively described and modelled by Fick's 1<sup>st</sup> law. Fick's 1<sup>st</sup> law is often used to describe drug delivery (in units of amount per time, *e.g.*, mg/day or µg/hour) from a transdermal patch across the skin:

$$J = A \times k_p \times \Delta C$$

In this formula:

A is the active surface area of the patch.


$k_p$  is the drug's permeability coefficient across the skin, and can be defined as

$k_p = \{D \times K\}/L$ , where D is the drug's diffusivity through the skin barrier, K is its partition coefficient between the skin barrier and the patch, and L is the path length for diffusion across the skin barrier.

$\Delta C$  is the difference in concentration of the drug between that in the patch ( $C_{\text{patch}}$ ) and that on the "downstream" side of the skin barrier ( $C_{\text{downstream}}$ ). In many examples of transdermal delivery, when depletion of drug from the patch is limited,  $\Delta C$  can be approximated to  $C_{\text{patch}}$ .

The following images illustrate these factors:

**Fick's 1<sup>st</sup> Law**

$$\Delta C = (C_{\text{patch}} - C_{\text{skin}}) \approx C_{\text{patch}}$$


$$J = A \times k_p \times \Delta C$$

$J = \text{flux} = \text{mg/day of drug}$

**A** Active surface area of patch

**k<sub>p</sub>** Drug's permeability coefficient  $k_p = \{D \times K\}/L$

**ΔC** The difference in drug concentration between the patch and the skin

**Fick's 1<sup>st</sup> Law**

$$J = A \times k_p \times \Delta C$$

**k<sub>p</sub>** Drug's permeability coefficient

$$k_p = \{D \times K\}/L$$

- \* D = drug's diffusivity through the skin barrier
- \* K = partition coefficient of drug between skin barrier and patch
- \* L = path length for drug diffusion across skin barrier

Fick's 1<sup>st</sup> law indicates that there are four general ways to increase flux:

- Increase the active surface area of the patch to cause a proportional change in flux.
- Increase the drug concentration in the patch until it reaches its limiting solubility.
- Adjust the formulation to increase K, *e.g.*, cause drug concentration to approach more closely its limiting solubility.
- Introduce a penetration enhancer into the formulation to increase D and/or alter the value of K.

Nothing in Fick's 1<sup>st</sup> law indicates or predicts that increasing the coat weight (thickness) of a polymer matrix would increase flux. This is because no factor in Fick's 1<sup>st</sup> law embodies or includes coat weight.

#### THE UNEXPECTED DISCOVERY OF THE INVENTION

As noted above, "the Applicant surprisingly discovered that increasing the coat weight of the drug-containing adhesive layer resulted in an increased flux per unit area, and thus permitted the development of smaller transdermal drug delivery systems that achieve comparable daily dosages." Specification, at paragraph [0014]. As stated in paragraph [0015] in the specification:

This result was surprising because coat weight is typically selected to control the duration of delivery, but is not generally understood to impact delivery rate. Thus, while it is known in the art to increase coat weight to provide delivery over a longer period of time, it was not known that increasing coat weight could increase delivery rate or flux, and thus permit the development of a smaller system while maintaining daily dosage.

Indeed, as explained above, nothing in Fick's 1<sup>st</sup> law indicates or predicts that increasing the coat weight (thickness) of a polymer matrix would increase flux.

#### THE EXAMPLE IN THE SPECIFICATION


The specification illustrates this surprising and unexpected effect in Example 1, which describes an *in vitro* flux study conducted to assess the flux of estradiol from different systems. Figure 1 reports the flux of drug across the skin for the systems tested in Example 1.

Example 1 sets forth the polymer matrix formulation used to prepare Example 1 and Example 1a. As noted in the prosecution history of the '906 Patent, in the Amendment and Reply filed April 20, 2011, the specification as filed had a clerical error in the formulation listed (see below), but the flux data presented in Figure 1 is correct.



	Example 1	Actual Formulation
Silicone (4502)	56.9	66.9
Acrylic (Gelva 788)	30	10
PVP (Kollidon K-30)	7.5	7.5
DPG	8	8
Oleyl Alcohol	6	6
Estradiol	1.6	1.6


As described in the specification, test systems were prepared by applying the polymer matrix to a release liner at two different coat weights: 12.5 mg/cm<sup>2</sup> (Example 1a, ●) and 15 mg/cm<sup>2</sup> (Example 1, ▲), and estradiol flux was assessed in an *in vitro* flux study. As reported in Figure 1, the system with the higher coat weight exhibited a greater flux.



The only experimental variable different between Example 1a and Example 1 is the coat weight of the polymer matrix. The difference in flux reported in Figure 1 between Example 1a and Example 1 can only be attributed, therefore, to the difference in coat weight, which is a surprising and unexpected result that is not predicted by Fick's 1<sup>st</sup> Law.

Figure 1 also reports results achieved with a Vivelle-Dot® system. As described in the prescribing information, Vivelle-Dot® is a monolithic transdermal drug delivery system for estradiol with a polymer matrix layer that includes estradiol as the only drug, acrylic adhesive, silicone adhesive, oleyl alcohol, povidone, and dipropylene glycol. The specification states that each Vivelle-Dot® patch includes 0.156 mg/cm<sup>2</sup> estradiol and has a polymer matrix coat weight of 10 mg/cm<sup>2</sup>. *See, e.g.*, Specification at paragraph [0013]; [0074]. Although Vivelle-Dot® includes the same polymer matrix components of the Example 1 formulation, I have been informed that the Vivelle-Dot® formulation includes different amounts of some components, including different relative amounts of acrylic adhesive and silicone adhesive, with a greater relative amount of acrylic adhesive. That is, the formulation of Examples 1 and 1a have less acrylic adhesive and more silicone adhesive than the Vivelle-Dot® formulation.

Prior art such as U.S. Patent No. 6,024,976 (the “’976 Patent”) and Mantelle, *et al.*, *Effect of Silicone/Acrylic PSA Blends on Skin Permeation*, 26 *Proc. Internat’l Symp. Controlled Release of Bioactive Materials* 5123, 415-16 (Revised July 1999) (the “Mantelle Article”), and post-filing date publications such as Juan A. Mantelle, “Dot Matrix® Technology,” *in* MODIFIED RELEASE DRUG DELIVERY TECHNOLOGY (2<sup>nd</sup> ed. 2008) 405-14 (the “Mantelle Chapter”) teach that the difference in relative amounts of acrylic adhesive and silicone adhesive between the formulation of Examples 1/1a and the Vivelle-Dot® formulation contributes to the difference in flux seen in Figure 1 between Vivelle-Dot® and Example 1 and between Vivelle-Dot® and Example 1a.



It is not possible to quantify from available data the relative contributions of coat weight and polymer composition to the differences in flux observed between the Vivelle-Dot® system and Examples 1/1a systems. However, based on the difference in flux between the Example 1 and 1a systems (which, as explained above, can only be due to the difference in coat weight), and in view of other experimental data discussed below, it is Dr. Guy's expert opinion that the difference in coat weight is contributing to the difference in flux.

#### EXPERIMENTAL DATA – IMPACT OF POLYMER MAKE-UP ON FLUX


As noted above, it was known in the art that the relative amounts of acrylic adhesive and silicone adhesive used in an estradiol polymer matrix can impact the flux of estradiol. This is described in the '976 Patent, which explains that this is because estradiol's solubility in acrylic adhesives differs from that in silicone adhesives. The potential effect of the relative amounts of acrylic adhesive and silicone adhesive is illustrated in Examples 10-13 and Figure 6 of the '976 patent, and in the Mantelle Article. Thus, it was known in the art that the relative amounts of acrylic adhesive and silicone adhesive in an estradiol polymer matrix can impact estradiol flux, and that

increasing the relative amount of silicone polymer generally increased the flux but may alter the drug delivery profile such that the increased flux is not sustained.

Flux Study 1190 conducted by Noven also illustrates this effect. Flux Study 1190 tested five different formulations at the same target coat weight (15 mg/cm<sup>2</sup>) and used a Vivelle-Dot® system (◆) as an internal control. The five formulations differed in the relative amounts of acrylic adhesive and silicone adhesive.

Component (% by weight)	5% Acrylic	10% Acrylic	12.5% Acrylic	15% Acrylic	17.5% Acrylic
Acrylic Adhesive	5	10	12.5	15	17.5
Silicon Adhesive	71.9	66.9	64.5	61.9	59.4
Dipropylene Glycol	8	8	8	8	8
Oleyl Alcohol	6	6	6	6	6
PVP	7.5	7.5	7.5	7.5	7.5
Estradiol	1.6	1.6	1.6	1.6	1.6


A representative sample of the data from this Flux Study are shown in the figure below. The results show that initial flux increased as the relative amount of acrylic polymer decreased but the initially higher flux from the 5% acrylic composition was not sustained:




## EXPERIMENTAL DATA – IMPACT OF COAT WEIGHT ON FLUX

As noted above, while it was known in the art that the relative amounts of acrylic adhesive and silicone adhesive in an estradiol polymer matrix can impact estradiol flux, it was not known or expected that the coat weight of the polymer matrix would impact flux, but Noven conducted a number of other flux studies that showed this effect with monolithic transdermal drug delivery systems for estradiol as described in the pending applications.

Flux Study 1326 is the flux study reported in Example 1 of the pending applications. As discussed above, the same formulation (1.6 % estradiol, 10% acrylic adhesive, 66.9% silicone adhesive, 6% oleyl alcohol, 7.5% povidone, and 8% dipropylene glycol) was tested at coat weights of 12.5 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup>. Both Vivelle® and Vivelle-Dot® were used as internal controls. As noted above, the results (see below) show that the increase in the coat weight of the polymer matrix from Example 1a to Example 1 resulted in an increased flux of estradiol.







Flux Study 1182 conducted by Noven tested four different formulations at three different target coat weights and used a Vivelle-Dot® system as an internal control. The four formulations differed in the relative amounts of acrylic adhesive and silicone adhesive, as follows:

Component (% by weight)	10% Acrylic	15% Acrylic	17.5% Acrylic	20% Acrylic
Acrylic Adhesive	10	15	17.5	20
Silicon Adhesive	66.9	61.9	59.4*	56.9
Dipropylene Glycol	8	8	8	8
Oleyl Alcohol	6	6	6	6
PVP	7.5	7.5	7.5	7.5
Estradiol	1.6	1.6	1.6	1.6


\*Reported as 59.9%, but likely used 59.4% Silicone Adhesive.

The different target coat weights assessed were 10 mg/cm<sup>2</sup>, 12.5 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup>. The overall results show that increasing coat weight from 10 mg/cm<sup>2</sup> to 15 mg/cm<sup>2</sup> surprisingly and unexpectedly increased flux. For illustration, results for the composition with 15% acrylic polymer at a coat weight of 10 mg/cm<sup>2</sup>, 12.5 mg/cm<sup>2</sup>, and 15 mg/cm<sup>2</sup> (☺) are set forth below (Vivelle-Dot® was used as an internal control).



Collectively, the results from Flux Studies 1190 and 1182 indicate that while the relative amounts of acrylic adhesive and silicone adhesive impact the flux of estradiol—as was known in the art—the coat weight of the polymer matrix also impacts flux—which was not known in the art, and indeed was a surprising and unexpected result not predicted by Fick's 1<sup>st</sup> law of diffusion.

The estimated estradiol fluxes from Flux Studies 1190 and 1182 are shown below:




Flux Studies 1523, 1528, 1562 and 1563 assessed other formulations at different target coat weights, as outlined in the following table.

Flux Study	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> ·h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1523	10	69.4	8	6	5	1.6	15	1.57
	10	69.4	8	6	5	1.6	12.5	1.25
	10	69.4	8	6	5	1.6	10	1.18
	Control (flux): Vivelle-Dot® (1.01 µg/cm <sup>2</sup> ·h)							
1528	10	69.4	8	6	5	1.6	15	0.98
	10	69.4	8	6	5	1.6	12.5	0.89
	10	69.4	8	6	5	1.6	10	0.78
	Control (flux): Vivelle-Dot® (0.54 µg/cm <sup>2</sup> ·h)							
1562 (Form. 1)	10	69.4	8	6	5	1.6	15	1.11
	10	69.4	8	6	5	1.6	12.5	0.96
	10	69.4	8	6	5	1.6	10	0.90



Flux Study	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> ·h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
	Control (flux): Vivelle-Dot® (0.62 µg/cm <sup>2</sup> ·h)							
1563 (Form. 1)	10	69.4	8	6	5	1.6	15	1.22
	10	69.4	8	6	5	1.6	12.5	1.10
	10	69.4	8	6	5	1.6	10	0.82
	Control (flux): Vivelle-Dot® (0.85 µg/cm <sup>2</sup> ·h)							

The estimated estradiol fluxes from Flux Studies 1523, 1528, 1562, and 1563 are illustrated below, and again show the surprising and unexpected impact of polymer matrix coat weight on flux:



Flux Studies 1562 and 1563 were repeated with different formulations at coat weights of 12.5 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup> using both Vivelle and Vivelle-Dot® as internal controls.


Flux Study	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1562 (Form. 1)	10	69.4	8	6	5	1.6	15	1.01
	10	69.4	8	6	5	1.6	12.5	0.85
1562 (Form. 2)	7	72.6	8	6	5	1.4	15	1.12
	7	72.6	8	6	5	1.4	12.5	0.92
1562 (Form. 3)	7	74.6	8	6	3	1.4	15	1.07
	7	74.6	8	6	3	1.4	12.5	0.96
1562 Control (flux): Vivelle-Dot® (0.62 µg/cm <sup>2</sup> •h)								
1563 (Form. 1)	10	69.4	8	6	5	1.6	15	1.12
	10	69.4	8	6	5	1.6	12.5	1.04
1563 (Form. 2)	7	72.6	8	6	5	1.4	15	1.08
	7	72.6	8	6	5	1.4	12.5	1.01
1563 (Form. 3)	7	74.6	8	6	3	1.4	15	1.05
	7	74.6	8	6	3	1.4	12.5	0.81
1563 Control (flux): Vivelle-Dot® (0.85 µg/cm <sup>2</sup> •h)								

Flux Study 1550 assessed other formulations at different target coat weights, as outlined in the following table.

Formulation	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
Form. 1	10	71.6	8	6	3	1.4	15	0.49
	10	71.6	8	6	3	1.4	12.5	0.38

Formulation	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> ·h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
Form. 2	10	69.4	8	6	5	1.6	15	0.43
	10	69.4	8	6	5	1.6	12.5	0.41
Form. 3	7	72.6	8	6	5	1.4	15	0.47
	7	72.6	8	6	5	1.4	12.5	0.51
Form. 4	7	74.6	8	6	3	1.4	15	0.54
	7	74.6	8	6	3	1.4	12.5	0.42
Form. 5	10	73.4	6	6	3	1.6	15	0.41
	10	73.4	6	6	3	1.6	12.5	0.37
Control (flux): Vivelle-Dot® (0.29 µg/cm <sup>2</sup> ·h)								

The estimated estradiol fluxes from 1562 and 1563 (second series) and 1550 are illustrated below, and again show the surprising and unexpected impact of polymer matrix coat weight on flux:




EXPERIMENTAL DATA – IMPACT OF SKIN PERMEABILITY ON FLUX

Since drug flux is a measure of the rate at which drug passes through the skin, the permeability of the skin sample used in a flux study can impact the results. The permeability of human skin varies from person to person and region of skin to region of skin. Noven accounted for this variability by using internal controls, such as Vivelle®-Dot or Vivelle®, since it was very familiar with the flux of these FDA-approved systems which were developed at Noven .

The impact of skin permeability on flux and the usefulness of an internal control in this context is illustrated in Flux Studies 1214, 1233, and 1293, which assessed the flux of formulations having the same components as the Example 1 formulation at target coat weights of 10 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup> (and used Vivelle-Dot® and Vivelle as internal controls).

Study #	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> ·h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1323	10	66.9	8	6	7.5	1.6	15	1.42
	10	66.9	8	6	7.5	1.6	12.5	1.11
Control (flux): Vivelle-Dot® (0.77 µg/cm <sup>2</sup> ·h)								
Control (flux): Vivelle® (0.23 µg/cm <sup>2</sup> ·h)								
1214	10	66.9	8	6	7.5	1.6	15	1.25
	10	66.9	8	6	7.5	1.6	10	1.02
Control (flux): Vivelle-Dot® (0.7 µg/cm <sup>2</sup> ·h)								
1293	10	66.9	8	6	7.5	1.6	15	1.09
	10	66.9	8	6	7.5	1.6	10	1.02
Control (flux): Vivelle-Dot® (0.66 µg/cm <sup>2</sup> ·h)								
Control (flux): Vivelle® (0.22 µg/cm <sup>2</sup> ·h)								
1233	10	66.9	8	6	7.5	1.6	15	1.59
	10	66.9	8	6	7.5	1.6	10	1.50
Control (flux): Vivelle-Dot® (1.01 µg/cm <sup>2</sup> ·h)								

The cumulative flux results are illustrated below:



In these studies, the estradiol flux from Vivelle-Dot® was higher than usual, indicating that the donor skin had a higher permeability than usual. While the product label and the patient information leaflet indicate that the estradiol transdermal flux from the Vivelle®-Dot system is nominally  $0.4 \mu\text{g cm}^{-2} \text{h}^{-1}$ , the values observed in these flux studies were 1.5 to 2.5-fold higher. The high fluxes seen from the test formulations are therefore completely consistent with that from the Vivelle®-Dot control (and reinforce the clear benefit of including this system as an internal check in experiments such as these).

Pending Independent Claims

U.S. Patent Application Nos. 13/553,972 (041457-0992)

14. **(Allowed)** A method for administering estradiol, comprising applying to the skin or mucosa of a subject in need thereof a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer defining an active surface area and comprising an adhesive polymer matrix comprising estradiol as the only drug, wherein the polymer matrix has a coat weight of greater than about  $10 \text{ mg/cm}^2$  and includes greater than  $0.156 \text{ mg/cm}^2$  estradiol, and the system achieves an estradiol flux of from about 0.0125 to about  $0.05 \text{ g/cm}^2/\text{day}$ , based on the active surface area.

16. **(Allowed)** A method of making a monolithic transdermal drug delivery system for administering estradiol consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer and, optionally, (iii) a release liner, comprising forming an adhesive polymer matrix comprising estradiol as the only drug and a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble PVP, and applying the adhesive polymer matrix to a support layer to form a single adhesive polymer matrix layer such that the adhesive polymer matrix layer has a coat weight of greater than about  $10 \text{ mg/cm}^2$  and includes greater than  $0.156 \text{ mg/cm}^2$  estradiol, wherein the system achieves an estradiol flux of from about 0.0125 to about  $0.05 \text{ mg/cm}^2/\text{day}$ , based on the active surface area.

U.S. Patent Application Nos. 14/024,985 (041457-1016)

1. **(Allowed)** A monolithic transdermal drug delivery system for estradiol, consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and, optionally, (iii) a release liner, wherein the single adhesive polymer matrix layer comprises an adhesive polymer matrix comprising estradiol as the only drug, wherein the adhesive polymer matrix layer has a coat weight of greater than about 10 mg/cm<sup>2</sup> and includes greater than 0.156 mg/cm<sup>2</sup> estradiol, and the system achieves an estradiol flux of from about 0.0125 to about 0.05 mg/cm<sup>2</sup>/day, based on the active surface area.

U.S. Patent Application Nos. 14/738,255 (041457-1133)

45. (New) A monolithic transdermal drug delivery system for estradiol, consisting of:  
(i) a backing layer;  
(ii) an adhesive polymer matrix layer comprising an adhesive polymer matrix comprising estradiol as the only drug and defining an active surface area, and  
optionally, (iii) a release liner,  
wherein the adhesive polymer matrix layer includes from about 0.195 to about 0.260 mg/cm<sup>2</sup> estradiol and achieves an estradiol flux of from about 0.0125 to about 0.0167 mg/cm<sup>2</sup>/day, based on the active surface area.

59. (New) A transdermal drug delivery system for estradiol, consisting of:  
(i) a backing layer,  
(ii) an adhesive polymer matrix layer defining an active surface area and,  
optionally, (iii) a release liner,  
wherein the adhesive polymer matrix layer comprises an adhesive polymer matrix comprising about 2-25% by weight acrylic adhesive, about 45-70% by weight silicone adhesive, about 2-25% by weight soluble PVP, about 5-15% penetration enhancer, and about 0.1-10% by weight estradiol as the only drug, and includes from about 0.195 to about 0.260 mg/cm<sup>2</sup> estradiol, achieves an estradiol flux of from about 0.0125 to about 0.0167 mg/cm<sup>2</sup>/day, based on the active

surface area, and comprises an amount of estradiol effective to deliver a therapeutically effective amount of estradiol over a period of time of at least 1 day.

U.S. Patent Application Nos. 14/870,575 (041457-1160)

21. (New) A monolithic transdermal drug delivery system for estradiol, consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and, optionally, (iii) a release liner,

wherein the single adhesive polymer matrix layer comprises 2-25% by weight acrylic adhesive, 45-70% by weight silicone adhesive, 2-25% by weight soluble PVP, 5-15% by weight penetration enhancer, and 0.1-10% by weight estradiol as the only drug, and

wherein the coat weight of the adhesive polymer matrix layer is adjusted such that the system includes greater than  $0.156 \text{ mg/cm}^2$  estradiol and achieves an estradiol flux of from about  $0.0125$  to about  $0.05 \text{ mg/cm}^2/\text{day}$ , based on the active surface area.

35. (New) A method of making a transdermal drug delivery system according to claim 21, comprising forming an adhesive polymer matrix comprising 2-25% by weight acrylic adhesive, 45-70% by weight silicone adhesive, 2-25% by weight soluble PVP, 5-15% by weight penetration enhancer, and 0.1-10% by weight estradiol as the only drug, and applying the adhesive polymer matrix to support layer to form a single adhesive polymer matrix layer,

wherein the coat weight of the adhesive polymer matrix is adjusted such that the system includes greater than  $0.156 \text{ mg/cm}^2$  estradiol and achieves an estradiol flux of from about  $0.0125$  to about  $0.05 \text{ mg/cm}^2/\text{day}$ , based on the active surface area.



***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Appl. No.: 13/553,972  
Filing Date: 7/20/2012  
Examiner: Melissa L. Javier  
Art Unit: 1611  
Confirmation Number: 3635

**SUPPLEMENTAL RESPONSE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

This paper is filed subsequent to the Request for Continued Examination filed June 6, 2017. If any extensions of time are required for timely acceptance, Applicant hereby petitions for such extension of time. The Commissioner is hereby authorized to charge any fees which may be due for this application, including any extension of time fees or excess claim fees not submitted herewith, to Deposit Account No. 19-0741.

A **Listing of Claims** begins on page 2.

**Remarks** begin on page 6.

**Listing of Claims:**

Claims 1-13 (Cancelled)

14. (Previously Presented) A method for administering estradiol, comprising applying to the skin or mucosa of a subject in need thereof a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer defining an active surface area and comprising an adhesive polymer matrix comprising estradiol as the only drug, wherein the polymer matrix has a coat weight of greater than about 10 mg/cm<sup>2</sup> and includes greater than 0.156 mg/cm<sup>2</sup> estradiol, and the system achieves an estradiol flux of from about 0.0125 to about 0.05 mg/cm<sup>2</sup>/day, based on the active surface area.

15. (Canceled)

16. (Previously Presented) A method of making a monolithic transdermal drug delivery system for administering estradiol consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer and, optionally, (iii) a release liner, comprising forming an adhesive polymer matrix comprising estradiol as the only drug and a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble PVP, and applying the adhesive polymer matrix to a support layer to form a single adhesive polymer matrix layer such that the adhesive polymer matrix layer has a coat weight of greater than about 10 mg/cm<sup>2</sup> and includes greater than 0.156 mg/cm<sup>2</sup> estradiol, wherein the system achieves an estradiol flux of from about 0.0125 to about 0.05 mg/cm<sup>2</sup>/day, based on the active surface area.

17. (Original) The method of claim 16, wherein the system has an active surface area that is about 60% of a size selected from the group consisting of 2.5, 3.75, 5.0, 7.5 and 10.0 cm<sup>2</sup>.

18- 20 (Canceled)

21. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises a polymer blend comprising an acrylic adhesive, a silicone adhesive, and soluble polyvinylpyrrolidone (PVP).

22. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises about 2-25% by weight acrylic adhesive, about 45-70% by weight silicone adhesive, about 2-25% by weight soluble PVP, about 5-15% penetration enhancer, and about 0.1-10% by weight estradiol, all based on the total dry weight of the adhesive polymer matrix.

23. (Previously Presented) The method of claim 22, wherein the penetration enhancer comprises oleyl alcohol.

24. (Previously Presented) The method of claim 22, wherein the penetration enhancer comprises dipropylene glycol.

25. (Previously Presented) The method of claim 22, wherein the penetration enhancer comprises oleyl alcohol and dipropylene glycol.

26. (Previously Presented) The method of claim 22, wherein the acrylic adhesive and silicone adhesive are present in a ratio of from about 1:2 to about 1:6, based on the total weight of the acrylic and silicone adhesives.

27. (Canceled)

28. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises an amount of estradiol effective to deliver a therapeutically effective amount of estradiol over a period of time selected from the group consisting of at least 1 day, at least 2 days, at least 3 days, at least 4 days, at least 5 days, at least 6 days and at least 7 days.

29. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises an amount of estradiol effective to deliver an amount of estradiol selected from the group consisting of about 0.025, 0.0375, 0.05, 0.075 and 0.1 mg/day.

30. (Canceled)

31. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0125 mg/cm<sup>2</sup>/day, based on the active surface area.

32. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0133 mg/cm<sup>2</sup>/day, based on the active surface area.

33. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.015 mg/cm<sup>2</sup>/day, based on the active surface area.

34. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0167 mg/cm<sup>2</sup>/day, based on the active surface area.

35. (Previously Presented) The method of claim 14, wherein the system achieves an estradiol flux of about 0.0175 mg/cm<sup>2</sup>/day, based on the active surface area.

36. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0125 mg/cm<sup>2</sup>/day, based on the active surface area.

37. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0133 mg/cm<sup>2</sup>/day, based on the active surface area.

38. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.015 mg/cm<sup>2</sup>/day, based on the active surface area.

39. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0167 mg/cm<sup>2</sup>/day, based on the active surface area.

40. (Previously Presented) The method of claim 16, wherein the system achieves an estradiol flux of about 0.0175 mg/cm<sup>2</sup>/day, based on the active surface area.

41. (Previously Presented) The method of claim 14, wherein the adhesive polymer matrix comprises about 1.6% by weight estradiol, based on the total dry weight of the adhesive polymer matrix.

42. (Previously Presented) The method of claim 16, wherein the adhesive polymer matrix comprises about 1.6% by weight estradiol, based on the total dry weight of the adhesive polymer matrix.

**REMARKS**

A Notice of Allowance allowing claims 14, 16-17, 21-26, and 28-29 and 31-40 was mailed March 9, 2017. Claims 41-42 were added in the response filed June 6, 2017. No claims are amended, added or canceled herein. Thus, claims 14, 16-17, 21-26, and 28-29 and 31-42 are pending and presented for reconsideration.

Applicant thanks Examiner Fisher for the courtesies extended during the Patent Office Interview on June 8, 2017. Applicant's Statement of the Substance of the Interview is provided here, in accordance with MPEP § 713.04. Applicant concurs with the Examiner's summary of the substance of the Applicant-Initiated Interview held June 8, 2017, and confirms that the substance of the agenda attached to the Examiner's summary was discussed.

Applicant submits herewith a Declaration under 37 C.F.R. § 1.132 of Dr. Richard H. Guy that presents the evidence discussed during the interview.

Applicant submits herewith an Information Disclosure Statement that makes of record the Mantelle Article discussed in Dr. Guy's Declaration. The other references discussed in Dr. Guy's Declaration already are of record.

Applicant believes that the application is in condition for allowance. If there are any questions regarding this submission, or if any issue remain, the Examiner is urged to contact the undersigned by telephone in order to advance prosecution.

Respectfully submitted,

Date: June 15, 2017

By /Courtenay C. Brinckerhoff/

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Application No.: 13/553972  
Filing Date: 7/20/2012  
Examiner: Melissa L. Fisher  
Art Unit: 1611  
Confirmation No.: 3635

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Commissioner:

Applicant submits herewith documents for the Examiner's consideration in accordance with 37 CFR §§1.56, 1.97 and 1.98.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The submission of any document herewith is not an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document submitted herewith.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing of a first Office action after the filing of a RCE.

**RELEVANCE OF LISTED DOCUMENT**

Document A1 is discussed in the Rule 132 Declaration of Dr. Richard H. Guy submitted herewith. The other references discussed in the Declaration are already of record.

Documents A2 and A3 are Office Actions which issued in child applications.

Although Applicant believes that no fee is required, the Commissioner is hereby authorized to charge any additional fees which may be due to Deposit Account Number 19-0741.

Respectfully submitted,

Date June 15, 2017

By /Courtenay C. Brinckerhoff/

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 295-4094  
Facsimile: (202) 672-5399

Courtenay C. Brinckerhoff  
Attorney for Applicant  
Registration No. 37,288



Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: June 15, 2017  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	13/553972
		Filing Date	7/20/2012
		First Named Inventor	Juan Mantelle
		Art Unit	1611
		Examiner Name	Melissa L. Javier
		Attorney Docket Number	041457-0992
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A1	MANTELLE ET AL., "Effect of Silicone/Acrylic PSA Blends on Skin Permatation," Procced. Int'l. Symp. Control. Rel. Bioact. Mater., June 20-23, 1999	
	A2	Notice of Allowance issued on 04/26/2017 in application number 14/024,985 (US 2014/0200530)	
	A3	Office Action issued on 06/15/2017 in application number 14/870,574 (US 2016/0015655)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

First Inventor Name: Juan Mantelle  
Title: Transdermal Estrogen Device and Delivery  
Examiner: Javier  
Art Unit: 1611

App. No.	13/553,972	Filing Date: 7/20/2012	Conf. No.: 3635	Atty. Dkt No.041457-0992
App. No.	14/024,985	Filing Date: 9/12/2013	Conf. No.: 7031	Atty. Dkt No.041457-1016
App. No.	14/738,255	Filing Date: 6/12/2015	Conf. No.: 5737	Atty. Dkt No.041457-1133
App. No.	14/870,574	Filing Date: 9/30/2015	Conf. No.: 5148	Atty. Dkt No.041457-1160

**DECLARATION UNDER 37 CFR § 1.132 OF RICHARD H. GUY, PH.D.**

I, Richard H. Guy, Ph.D., hereby declare and say that:

I. QUALIFICATIONS AND EXPERIENCE

1. I have more than 30 years' research experience in the field of topical and transdermal drug delivery, including the study of drug absorption into and through the skin. During that time my research interests have spanned a wide range of subjects including the characterization of skin barrier function, transdermal drug delivery, enhancement of percutaneous absorption, iontophoresis, noninvasive biosensing, and the prediction and assessment of skin penetration and topical bioavailability.

2. I am currently Professor of Pharmaceutical Sciences at the University of Bath (UK) in the Department of Pharmacy & Pharmacology. I have held this position since 2004. From 2006-2008, I also served as Head of the Department of Pharmacy & Pharmacology at the University of Bath. Prior to joining the faculty at the University of Bath in 2004, I was Scientific Director of the Centre interuniversitaire de recherche et d'enseignement (Universities of Geneva (CH) and Lyon (FR)), and Professor of Biopharmaceutics in the Faculty of Sciences at the University of Geneva (CH). I held these positions between 1996 and 2004. Prior to that, I served as an

Assistant (1980-87), Associate (1987-1991) and Full Professor (1991-96) of Biopharmaceutical Sciences and Pharmaceutical Chemistry at the University of California, San Francisco (“UCSF”). During my time at UCSF (1987-1996), I was also Vice-Chair of the Department of Biopharmaceutical Sciences.

3. I obtained my Bachelor of Arts degree in chemistry from Oxford University (UK) in 1977, my Master of Arts degree in chemistry from Oxford University in 1980, and my Ph.D. in pharmaceutical chemistry from the University of London (UK) in 1980. I was awarded a D.Sc. by Oxford University in 2016.

4. I have co-authored more than 350 peer-reviewed articles and over 70 book chapters. Many of my peer-reviewed articles describe my research into understanding the mechanisms of topical and transdermal drug delivery. For example, in early work, I was involved in the development of diffusion and pharmacokinetic models of skin penetration and their application to the feasibility assessment of candidates for transdermal drug delivery. Subsequently, my research centered on a sustained effort to understand the mechanisms of skin penetration enhancement induced by chemical enhancers and other approaches, including (in particular) iontophoresis, and sonophoresis.

5. I have served as the Associate Editor of the Journal of Pharmaceutical Sciences (2002-2007) and currently serve on the editorial advisory boards of the European Journal of Pharmaceutical Sciences, Skin Pharmacology & Physiology, and the European Journal of Pharmaceutics and Biopharmaceutics.

6. Over the course of my career, I have earned numerous professional awards and honors, which are described in my curriculum vitae. For example, I am an elected Fellow of the Royal Society of Chemistry (UK, 1988), the American Association of Pharmaceutical Scientists (US, 1990), the American Association for the Advancement of Science (US, 1992), the Academy of Pharmaceutical Sciences, Great Britain (UK, 2007) and the Controlled Release Society College of Fellows (UK, 2010). More recently, I became a Fellow of the UCL School of Pharmacy,

University College, London, in recognition of my “distinguished contribution to the pharmaceutical sciences.”

7. I am also a co-inventor of 12 issued U.S. patents in the field of transdermal drug delivery and glucose biosensing.

8. In the course of my career, I have served as a consultant (and scientific advisory board member) to numerous pharmaceutical companies, which have been involved in the development of transdermal drug delivery formulations (including both patches and other vehicles, such as gels). My role has involved assisting with the identification and evaluation of potential drug candidates for transdermal delivery and, quite often, with offering advice on formulation and/or enhancement strategies by which the skin absorption of target compounds might be increased to ensure therapeutic activity. I have authored or co-authored more than 30 articles and book chapters on aspects of transdermal delivery (including, most recently, “Transdermal Drug Delivery: 30+ Years of War and Still Fighting! S. Wiedersberg and R.H. Guy. *J. Control. Release* 190: 150-156 (2014)”) and I have co-edited two books on the subject: [1] *Transdermal Delivery Systems: Developmental Issues and Research Initiatives*. Edited by J. Hadgraft and R.H. Guy. New York: Marcel Dekker, 1989; reprinted 1993. A 2<sup>nd</sup> Edition, revised and expanded, was published in 2003. [2] *Mechanisms of Transdermal Drug Delivery*. Edited by R.O. Potts and R.H. Guy. New York: Marcel Dekker, 1997. Several publications and book chapters address the manner in which drug pharmacokinetics can be modified and controlled by transdermal delivery, and describe the different patch designs, which have been used, their performance and benefits. The feasibility of transdermal delivery for certain drugs has been explored as well in this body of work, a subject which has been the focus of multiple interactions with the pharmaceutical industry as a consultant and scientific advisor.

9. A copy of my curriculum vitae, which includes my education background, work and research history, and a list of selected publications and presentations, is attached to this declaration as Exhibit 1.

10. Any opinions expressed herein are based on my education, research, knowledge and experience over the past 30 years in the field of transdermal drug delivery.

11. I was engaged by Noven Pharmaceuticals, Inc. (“Noven”), to serve as an expert witness in ANDA litigation involving U.S. Patent No.8,231,906 (the ’906 Patent ), in the U.S. District Court for the District of Delaware (C.A. No. 15-249) (the “ANDA litigation). I understand that U.S. patent applications 13/553,972, 14/024,985, 14/738,255, and 14/870,574 (the “pending applications”) claim priority to the ’906 Patent, and are assigned to Noven. I was engaged by Noven to prepare this declaration for the pending applications.

12. Noven is compensating me for my time associated with the pending applications at my customary consulting rate of \$400 per hour. My compensation does not depend in any way on the outcome of the examination of the pending applications or on the outcome of the ANDA litigation.


## II. THE PENDING CLAIMS

13. I understand that the claims of the pending applications are directed to monolithic transdermal drug delivery systems for estradiol consisting of (i) a backing layer, (ii) a single adhesive polymer matrix layer defining an active surface area and comprising an adhesive polymer matrix comprising estradiol as the only drug, and, optionally, (iii) a release liner, methods for administering estradiol using such systems, and methods for making such systems. With regard to the adhesive polymer matrix, I understand that the claims of the ’972, ’985, and ’255 applications recite that the adhesive polymer matrix has a coat weight of greater than about  $10 \text{ mg/cm}^2$ , includes greater than  $0.156 \text{ mg/cm}^2$  estradiol, and achieves an estradiol flux of from about  $0.0125$  to about  $0.05 \text{ mg/cm}^2/\text{day}$ , based on the active surface area, with some claims reciting additional features. I understand that the claims of the ’574 application recite that the coat weight of the adhesive polymer matrix layer is adjusted such that the system includes greater than  $0.156 \text{ mg/cm}^2$  estradiol and achieves an estradiol flux of from about  $0.0125$  to about  $0.05 \text{ mg/cm}^2/\text{day}$ , based on the active surface area.

### III. TECHNICAL BACKGROUND

14. I understand that the '906 Patent and the pending applications have a priority date of July 10, 2008. Thus, I discuss below what would have been known to a person of ordinary skill in the field of transdermal drug delivery as of July 10, 2008.

15. The inventions claimed in the pending applications generally relate to transdermal drug delivery systems (*e.g.*, transdermal “patches”) for the delivery of estradiol, methods of administering estradiol to a patient using the claimed transdermal drug delivery systems, and delivering estradiol using them, and methods of making them. The claimed transdermal drug delivery systems are “monolithic” drug-in-adhesive systems that consist of (i) a backing layer; (ii) a drug-in-adhesive polymer matrix layer, and, optionally, (iii) a release liner that is removed prior to use, as illustrated below.



16. The claims recite that the adhesive polymer matrix layers include a certain amount estradiol per unit area and achieve a certain estradiol flux.

17. The flux of a drug is the rate at which it diffuses through the skin. As of June 10, 2008, a person of ordinary skill in the art understood that the passive flux of a drug can be quantitatively described and modelled by Fick’s 1<sup>st</sup> law. Fick’s 1<sup>st</sup> law is often used to describe drug delivery (in units of amount per time, *e.g.*, mg/day or µg/hour) from a transdermal patch across the skin:

$$J = A \times k_p \times \Delta C$$

In this formula:

A is the active surface area of the patch.

$k_p$  is the drug's permeability coefficient across the skin, and can be defined as

$k_p = \{D \times K\}/L$ , where D is the drug's diffusivity through the skin barrier, K is its partition coefficient between the skin barrier and the patch, and L is the path length for diffusion across the skin barrier.

$\Delta C$  is the difference in concentration of the drug between that in the patch ( $C_{patch}$ ) and that on the "downstream" side of the skin barrier ( $C_{downstream}$ ). In many examples of transdermal delivery, when depletion of drug from the patch is limited,  $\Delta C$  can be approximated to  $C_{patch}$ .

The following images illustrate these factors:

**Fick's 1<sup>st</sup> Law**

$$\Delta C = (C_{patch} - C_{skin}) \approx C_{patch}$$

$$J = A \times k_p \times \Delta C$$

J = flux = mg/day of drug

**A** Active surface area of patch

**$k_p$**  Drug's permeability coefficient  $k_p = \{D \times K\}/L$

**$\Delta C$**  The difference in drug concentration between the patch and the skin

**Fick's 1<sup>st</sup> Law**

$$J = A \times k_p \times \Delta C$$

**$k_p$**  Drug's permeability coefficient

$$k_p = \{D \times K\}/L$$

- D = drug's diffusivity through the skin barrier
- K = partition coefficient of drug between skin barrier and patch
- L = path length for drug diffusion across skin barrier

18. Fick's 1<sup>st</sup> law indicates that there are four general ways to increase flux:
- Increase the active surface area of the patch to cause a proportional change in flux.
  - Increase the drug concentration in the patch until it reaches its limiting solubility.
  - Adjust the formulation to increase K, *e.g.*, cause drug concentration to approach more closely its limiting solubility.
  - Introduce a penetration enhancer into the formulation to increase D and/or alter the value of K.

Nothing in Fick's 1<sup>st</sup> law indicates or predicts that increasing the coat weight (thickness) of a polymer matrix would increase flux. This is because no factor in Fick's 1<sup>st</sup> law embodies or includes coat weight.

#### IV. THE INVENTION

19. As set forth in the specification of the pending applications, the subject matter includes transdermal drug delivery systems for the transdermal delivery of estrogen that have a smaller active surface area than the prior art Vivelle-Dot® patches, but achieve daily dosages that are about equal to or greater than the Vivelle-Dot® patches. That is, the subject matter includes transdermal drug delivery systems that achieve daily dosages that are about equal to a Vivelle-Dot® patch, in a smaller size. *See, e.g.*, Specification, at paragraph [0014].

20. As stated in the specification, "the Applicant surprisingly discovered that increasing the coat weight of the drug-containing adhesive layer resulted in an increased flux per unit area, and thus permitted the development of smaller transdermal drug delivery systems that achieve comparable daily dosages." Specification, at paragraph [0014].

21. As stated in paragraph [0015] in the specification:


This result was surprising because coat weight is typically selected to control the duration of delivery, but is not generally understood to impact delivery rate. Thus, while it is known in the art to increase coat weight to provide delivery over a



longer period of time, it was not known that increasing coat weight could increase delivery rate or flux, and thus permit the development of a smaller system while maintaining daily dosage.

I agree with this statement because, as explained above, nothing in Fick's 1<sup>st</sup> law indicates or predicts that increasing the coat weight (thickness) of a polymer matrix would increase flux. That is, in accordance with Fick's 1<sup>st</sup> law, simply increasing the thickness of the patch formulation, *i.e.*, increasing the coat weight, would not increase flux, because coat weight *per se* would not affect any of the parameters/variables that determine flux according to Fick's 1<sup>st</sup> law. Thus, a person of ordinary skill in the art would not have thought of coat weight as a parameter to be adjusted to affect the flux of a drug from a transdermal patch. Indeed, the person of ordinary skill in the art would not have viewed coat weight as having any effect on flux and would not have been motivated to consider adjusting coat weight as a flux enhancement method. Rather, coat weight was understood by persons of ordinary skill in the art to affect only the duration over which a certain flux could be maintained. That is, persons of ordinary skill in the art understood that an increase in coat weight would potentially extend the time period over which the patch would achieve a given flux, and so might be adjusted to modify the wear period of a patch. However, neither Fick's 1<sup>st</sup> law, nor any other principle of transdermal drug delivery known in the art, indicated that increasing the coat weight of the drug-containing polymer matrix would increase flux.

22. The specification illustrates this surprising and unexpected effect in Example 1, which describes an *in vitro* flux study conducted to assess the flux of estradiol from different systems. The image below shows a typical Franz diffusion cell set up used to conduct an *in vitro* flux study.




In general, the receptor compartment is filled with a receiver solution that is stirred and held at a constant (typically, physiological) temperature. A transdermal system is placed on a skin sample in the donor compartment, and the contents of the receptor compartment are sampled (withdrawn) periodically and analyzed for drug (for example, estradiol) content. From this information, the cumulative amount of drug delivered over time and the flux of drug across the skin as a function of time is calculated. An illustration of the type of experimental data collected with this approach is shown below for one particular formulation; the results are presented as the average cumulative amounts of drug delivered, and the average drug flux, as a function of time, with the corresponding standard deviations for 4 replicate Franz diffusion cells.

(hours)	(mcg/cm <sup>2</sup> )	(mcg/cm <sup>2</sup> )	(mcg/cm <sup>2</sup> hr)	(mcg/cm <sup>2</sup> hr)
Average Time	Average Cum.	Cum. Stdev	Average Flux	Flux Stdev
0.00	0.00	0.00	0.00	0.00
9.92	2.55	0.49	0.26	0.05
23.95	12.64	1.99	0.72	0.11
33.65	20.85	2.91	0.85	0.10
48.03	33.45	4.10	0.88	0.08
57.58	41.70	4.81	0.86	0.08
72.20	54.23	5.71	0.86	0.06
81.02	61.43	6.07	0.82	0.04

23. Figure 1 reports the flux of drug across the skin for the systems tested in Example 1. Example 1 sets forth the polymer matrix formulation used to prepare Example 1 and Example 1a. As noted in the prosecution history of the '906 Patent, in the Amendment and Reply filed April 20, 2011, the specification as filed had a clerical error in the formulation listed (see below), but the flux data presented in Figure 1 is correct.

	<u>Example 1</u>	<u>Actual Formulation</u>
Silicone (4502)	56.9	66.9
Acrylic (Gelva 788)	20	10
PVP (Kollidon K-30)	7.5	7.5
DPG	8	8
Oleyl Alcohol	6	6
Estradiol	1.6	1.6

As described in the specification, test systems were prepared by applying the polymer matrix to a release liner at two different coat weights: 12.5 mg/cm<sup>2</sup> (Example 1a, ●) and 15 mg/cm<sup>2</sup> (Example 1, ▲), and estradiol flux was assessed in an *in vitro* flux study. As reported in Figure 1, the system with the higher coat weight exhibited a greater flux.




The only experimental variable different between Example 1a and Example 1 is the coat weight of the polymer matrix. The difference in flux reported in Figure 1 between Example 1a and Example 1 can only be attributed, therefore, to the difference in coat weight, which is a surprising and unexpected result that is not predicted by Fick's 1<sup>st</sup> Law.

24. Figure 1 also reports results achieved with a Vivelle-Dot® system. As described in the prescribing information, Vivelle-Dot® is a monolithic transdermal drug delivery system for estradiol with a polymer matrix layer that includes estradiol as the only drug, acrylic adhesive, silicone adhesive, oleyl alcohol, povidone, and dipropylene glycol. The specification states that each Vivelle-Dot® patch includes 0.156 mg/cm<sup>2</sup> estradiol and has a polymer matrix coat weight of 10 mg/cm<sup>2</sup>. See, e.g., Specification at paragraph [0013]; [0074]. Although Vivelle-Dot® includes the same polymer matrix components of the Example 1 formulation, I have been informed that the Vivelle-Dot® formulation includes different amounts of some components, including different relative amounts of acrylic adhesive and silicone adhesive, with a greater relative amount of acrylic adhesive. That is, the formulation of Examples 1 and 1a have less acrylic adhesive and more silicone adhesive than the Vivelle-Dot® formulation. I have been

informed that the precise formulation of Vivelle-Dot® is confidential, proprietary information of a third party that Noven is contractually obligated to maintain confidential.

25. I understand from prior art such as U.S. Patent No. 6,024,976 (the “’976 Patent”) and Mantelle, *et al.*, *Effect of Silicone/Acrylic PSA Blends on Skin Permeation*, 26 *Proc. Internat’l Symp. Controlled Release of Bioactive Materials* 5123, 415-16 (Revised July 1999) (“Mantelle Article”), and from Juan A. Mantelle, “Dot Matrix® Technology,” in *MODIFIED RELEASE DRUG DELIVERY TECHNOLOGY* (2<sup>nd</sup> ed. 2008) 405-14 (“Mantelle Chapter”), and the experimental data presented below, that the difference in relative amounts of acrylic adhesive and silicone adhesive between the formulation of Examples 1 and 1a and the Vivelle-Dot® formulation contributes to the difference in flux seen in Figure 1 between Vivelle-Dot® and Example 1 and Example 1a.



I cannot quantify the relative contributions of coat weight and polymer composition to the differences in flux observed between the Vivelle-Dot® system and Examples 1 and 1a systems. However, based on the difference in flux between the Example 1 and 1a systems (which, as explained above, can only be due to the difference in coat weight), and in view of other experimental data discussed below, it is my opinion that the difference in coat weight is

contributing to the difference in flux between the Vivelle-Dot® system and the Example 1 and 1a systems.

## V. EXPERIMENTAL DATA – IMPACT OF POLYMER MAKE-UP ON FLUX

26. As noted above, I understand from prior art such as the '976 Patent and the Mantelle Article that the relative amounts of acrylic adhesive and silicone adhesive used in an estradiol polymer matrix can impact the flux of estradiol. As described in the '976 Patent, this is because estradiol's solubility in acrylic adhesives differs from that in silicone adhesives. The potential effect of the relative amounts of acrylic adhesive and silicone adhesive is illustrated in Examples 10-13 and Figure 6 of the '976 patent, which reports:

FIG. 6 shows estradiol flux progressively increased with increased silicone polymer content during the first 22 hours of delivery, but was affected to a much lesser degree during the remainder of the study (22 to 99 hours). Thus, significant adjustment of the estradiol delivery rate during the initial phase of delivery was accomplished, with minor effects on the later delivery phase, by modulating the polysiloxane to polyacrylate polymer ratio. FIG. 6 also illustrates that the delivery characteristics over time can be adjusted by the appropriate choice of polymers and respective weight ratios. For example, the formulation of Example 10 delivers drug at approximately the same rate over time whereas the formulation of Example 13 delivers more quickly in the early phase than the latter.

A similar effect is reported in the Mantelle Article, which states:


As shown, varying the silicone to acrylic psa ratio from 56.9:20 to 61.9:15 to 66.9:10 resulted in an average flux rate increase ... with the additional effect of having altered the initial burst effect and subsequent sustenance of the pseudo-zero-order delivery profile. As can be seen in Figure 2, higher silicone to acrylic psa ratios resulted in a shift of the permeation profile from a pseudo-zero-order to a first order delivery system incapable of sustaining the targeted 84 hour delivery.

Thus, it was known in the art that the relative amounts of acrylic adhesive and silicone adhesive in an estradiol polymer matrix can impact estradiol flux, and that increasing the relative amount of silicone polymer generally increased the flux but may alter the drug delivery profile such that the increased flux is not sustained.

27. This effect is shown by the results for Flux Study 1190 conducted by Noven. Flux Study 1190 tested five different formulations at the same target coat weight (15 mg/cm<sup>2</sup>) and used a Vivelle-Dot® system (◆) as an internal control. The five formulations differed in the relative amounts of acrylic adhesive and silicone adhesive, as follows:

Component (% by weight)	5% Acrylic	10% Acrylic	12.5% Acrylic	15% Acrylic	17.5% Acrylic
Acrylic Adhesive	5	10	12.5	15	17.5
Silicon Adhesive	71.9	66.9	64.5	61.9	59.4
Dipropylene Glycol	8	8	8	8	8
Oleyl Alcohol	6	6	6	6	6
PVP	7.5	7.5	7.5	7.5	7.5
Estradiol	1.6	1.6	1.6	1.6	1.6

A representative sample of the data from this Flux Study are shown in the figure below. The results (reported as the average of 5 replicates) show that initial flux increased as the relative amount of acrylic polymer decreased but the initially higher flux from the 5% acrylic composition was not sustained:




## VI. EXPERIMENTAL DATA – IMPACT OF COAT WEIGHT ON FLUX

28. As noted above, while it was known in the art that the relative amounts of acrylic adhesive and silicone adhesive in an estradiol polymer matrix can impact estradiol flux, it was not known or expected that the coat weight of the polymer matrix would impact flux, but Noven conducted a number of other flux studies that showed this effect with monolithic transdermal drug delivery systems for estradiol as described in the pending applications.

29. Flux Study 1326 is the flux study reported in Example 1 of the pending applications. As discussed above, the same formulation (1.6 % estradiol, 10% acrylic adhesive, 66.9% silicone adhesive, 6% oleyl alcohol, 7.5% povidone, and 8% dipropylene glycol) was tested at coat weights of 12.5  $\text{mg}/\text{cm}^2$  and 15  $\text{mg}/\text{cm}^2$ . Both Vivelle® and Vivelle-Dot® were used as internal controls. As noted above, the results (see below) (reported as the average of 4 replicates) show that the increase in the coat weight of the polymer matrix from Example 1a to Example 1 resulted in an increased flux of estradiol.







30. Flux Study 1182 conducted by Noven tested four different formulations at three different target coat weights and used a Vivelle-Dot® system as an internal control. The four formulations differed in the relative amounts of acrylic adhesive and silicone adhesive, as follows:

Component (% by weight)	10% Acrylic	15% Acrylic	17.5% Acrylic	20% Acrylic
Acrylic Adhesive	10	15	17.5	20
Silicon Adhesive	66.9	61.9	59.4*	56.9
Dipropylene Glycol	8	8	8	8
Oleyl Alcohol	6	6	6	6
PVP	7.5	7.5	7.5	7.5
Estradiol	1.6	1.6	1.6	1.6


\*Reported as 59.9%, but likely used 59.4% Silicone Adhesive.

The different target coat weights assessed were 10 mg/cm<sup>2</sup>, 12.5 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup>. The overall results show that increasing coat weight from 10 mg/cm<sup>2</sup> to 15 mg/cm<sup>2</sup> surprisingly and unexpectedly increased flux. For illustration, results (reported as the average of 4 replicates) for the composition with 15% acrylic polymer at a coat weight of 10 mg/cm<sup>2</sup>, 12.5 mg/cm<sup>2</sup>, and 15 mg/cm<sup>2</sup> are set forth below (Vivelle-Dot® was used as an internal control).





31. The estimated estradiol fluxes from Flux Studies 1190 and 1182 (reported as the average of 5 and 4 replicates, respectively) are shown below (some values are slightly displaced along the x-axis to facilitate visualization of each data point; for example, the estimated flux for 1182 10% at a coat weight of 10 mg/cm<sup>2</sup> is plotted at 9.9 on the x-axis and the estimated flux for 1182 15% at a coat weight of 10 mg/cm<sup>2</sup> is plotted at 10.1 on the x-axis, because they both had an estimated flux of 0.6 µg/cm<sup>2</sup>/hr):




32. Collectively, the results from Flux Study 1190 and Flux Study 1182 indicate that while the relative amounts of acrylic adhesive and silicone adhesive impact the flux of estradiol—as was known in the art—the coat weight of the polymer matrix also impacts flux—which was not known in the art, and indeed was a surprising and unexpected result not predicted by Fick’s 1<sup>st</sup> law of diffusion.

33. Flux Studies 1523, 1528, 1562 and 1563 assessed other formulations at different target coat weights, as outlined in the following table.

Flux Study	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1523	10	69.4	8	6	5	1.6	15	1.57
	10	69.4	8	6	5	1.6	12.5	1.25
	10	69.4	8	6	5	1.6	10	1.18
	Control (flux): Vivelle-Dot® (1.01 µg/cm <sup>2</sup> •h)							

Flux Study	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1528	10	69.4	8	6	5	1.6	15	0.98
	10	69.4	8	6	5	1.6	12.5	0.89
	10	69.4	8	6	5	1.6	10	0.78
	Control (flux): Vivelle-Dot® (0.54 µg/cm <sup>2</sup> •h)							
1562 (Form. 1)	10	69.4	8	6	5	1.6	15	1.11
	10	69.4	8	6	5	1.6	12.5	0.96
	10	69.4	8	6	5	1.6	10	0.90
	Control (flux): Vivelle-Dot® (0.62 µg/cm <sup>2</sup> •h)							
1563 (Form. 1)	10	69.4	8	6	5	1.6	15	1.22
	10	69.4	8	6	5	1.6	12.5	1.10
	10	69.4	8	6	5	1.6	10	0.82
	Control (flux): Vivelle-Dot® (0.85 µg/cm <sup>2</sup> •h)							

34. The estimated estradiol fluxes from Flux Studies 1523, 1528, 1562, and 1563 are illustrated below (reported as the average of 3 or 4 replicates; some values are again slightly displaced along the x-axis to facilitate visualization of the data points), and again show the surprising and unexpected impact of polymer matrix coat weight on flux:



35. Flux Studies 1562 and 1563 were repeated with different formulations at coat weights of 12.5 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup> using both Vivelle and Vivelle-Dot® as internal controls.


Flux Study	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> ·h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1562 (Form. 1)	10	69.4	8	6	5	1.6	15	1.01
	10	69.4	8	6	5	1.6	12.5	0.85
1562 (Form. 2)	7	72.6	8	6	5	1.4	15	1.12
	7	72.6	8	6	5	1.4	12.5	0.92
1562 (Form. 3)	7	74.6	8	6	3	1.4	15	1.07
	7	74.6	8	6	3	1.4	12.5	0.96
1562 Control (flux): Vivelle-Dot® (0.62 µg/cm <sup>2</sup> ·h)								
1563	10	69.4	8	6	5	1.6	15	1.12

Flux Study (Form. 1)	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
	10	69.4	8	6	5	1.6	12.5	1.04
1563 (Form. 2)	7	72.6	8	6	5	1.4	15	1.08
	7	72.6	8	6	5	1.4	12.5	1.01
1563 (Form. 3)	7	74.6	8	6	3	1.4	15	1.05
	7	74.6	8	6	3	1.4	12.5	0.81
1563 Control (flux): Vivelle-Dot® (0.85 µg/cm <sup>2</sup> •h)								

36. Flux Study 1550 assessed other formulations at different target coat weights, as outlined in the following table.

Formulation	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (µg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
Form. 1	10	71.6	8	6	3	1.4	15	0.49
	10	71.6	8	6	3	1.4	12.5	0.38
Form. 2	10	69.4	8	6	5	1.6	15	0.43
	10	69.4	8	6	5	1.6	12.5	0.41
Form. 3	7	72.6	8	6	5	1.4	15	0.47
	7	72.6	8	6	5	1.4	12.5	0.51
Form. 4	7	74.6	8	6	3	1.4	15	0.54
	7	74.6	8	6	3	1.4	12.5	0.42
Form. 5	10	73.4	6	6	3	1.6	15	0.41
	10	73.4	6	6	3	1.6	12.5	0.37
Control (flux): Vivelle-Dot® (0.29 µg/cm <sup>2</sup> •h)								

37. The estimated estradiol fluxes from 1562 and 1563 (second series) (reported as the average of 3 replicates; some values are slightly displaced along the x-axis to facilitate visualization of the data points) and 1550 are illustrated below (reported as the average of 4 replicates), and again show the surprising and unexpected impact of polymer matrix coat weight on flux:





38. Although the results for Flux Study 1550 - Formulation 3 show a higher flux for the lower coat weight, that does not change my opinion that the totality of the data show the surprising and unexpected result that increasing coat weight increases flux. Indeed, Formulation 3 of Flux Study 1550 is the same formulation as Formulation 2 of Flux Study 1562 and Formulation 2 of Flux Study 1563 and, in both of those flux studies, this formulation exhibited a higher flux at the higher coat weight.

39. I also reviewed Flux Study 1333, which assessed the flux of a formulation having the same components as the Example 1 formulation at a target coat weight of 12.5 mg/cm<sup>2</sup> and 15 mg/cm<sup>2</sup> and used a Vivelle® system as an internal control. Although the researcher, who



oversaw this study, prepared the graphs shown below (reporting the average of 4 replicates), which indicate that increasing coat weight increased flux, the experimental data reported by the technician correlate the 12.5 mg/cm<sup>2</sup> sample with the higher flux results. I understand that the researcher, who oversaw this study, believes that the technician switched or mislabeled the samples. However, regardless of whether this set of flux results are reported correctly, they do not change my opinion that the totality of the data, when viewed in its entirety, consistently show the surprising and unexpected result that increasing coat weight increases flux. Indeed, as shown above, several other studies using the same formulations show that the higher coat weight was correlated with greater flux.






#### VII. EXPERIMENTAL DATA – IMPACT OF SKIN PERMEABILITY ON FLUX

40. Since drug flux is a measure of the rate at which drug passes through the skin, the permeability of the skin sample used in a flux study can impact the results. The permeability of human skin varies from person to person and region of skin to region of skin. I understand that Noven accounted for this variability by using internal controls, such as Vivelle®-Dot or Vivelle®, since it was very familiar with the flux of these FDA-approved systems which were developed at Noven .

41. The impact of skin permeability on flux and the usefulness of an internal control in this context is illustrated in Flux Studies 1214, 1233, and 1293, which assessed the flux of formulations having the same components as the Example 1 formulation at target coat weights of 10  $\text{mg}/\text{cm}^2$  and 15  $\text{mg}/\text{cm}^2$  (and used Vivelle-Dot® and Vivelle as internal controls).

Study #	Formulation Components (% by weight)						Coat Wt. (mg/cm <sup>2</sup> )	Drug Flux (μg/cm <sup>2</sup> •h)
	Acrylate	Silicone	DPG	OAlc	PVP	Estradiol		
1323	10	66.9	8	6	7.5	1.6	15	1.42
	10	66.9	8	6	7.5	1.6	12.5	1.11
Control (flux): Vivelle-Dot® (0.77 μg/cm <sup>2</sup> •h)								
Control (flux): Vivelle® (0.23 μg/cm <sup>2</sup> •h)								
1214	10	66.9	8	6	7.5	1.6	15	1.25
	10	66.9	8	6	7.5	1.6	10	1.02
Control (flux): Vivelle-Dot® (0.7 μg/cm <sup>2</sup> •h)								
1293	10	66.9	8	6	7.5	1.6	15	1.09
	10	66.9	8	6	7.5	1.6	10	1.02
Control (flux): Vivelle-Dot® (0.66 μg/cm <sup>2</sup> •h)								
Control (flux): Vivelle® (0.22 μg/cm <sup>2</sup> •h)								
1233	10	66.9	8	6	7.5	1.6	15	1.59
	10	66.9	8	6	7.5	1.6	10	1.50
Control (flux): Vivelle-Dot® (1.01 μg/cm <sup>2</sup> •h)								

The cumulative flux results (reported as the average of 4 or 5 replicates; some values are once more slightly displaced along the x-axis to facilitate visualization of each data point) are illustrated below:



42. In these studies, the estradiol flux from Vivelle-Dot® was higher than usual, indicating that the donor skin had a higher permeability than usual. While the product label and the patient information leaflet indicate that the estradiol transdermal flux from the Vivelle®-Dot system is nominally  $0.4 \mu\text{g cm}^{-2} \text{h}^{-1}$ , the values observed in these flux studies were 1.5 to 2.5-fold higher. The high fluxes seen from the test formulations are therefore completely consistent with that from the Vivelle®-Dot control (and reinforce the clear benefit of including this system as an internal check in experiments such as these).

#### VIII. NO PRIOR ART SUGGESTS THAT COAT WEIGHT WOULD IMPACT FLUX

43. As I noted above, a person of ordinary skill in the art would not have thought of coat weight as a parameter to be adjusted to affect the flux of a drug from a transdermal patch. In this

regard, I confirm that none of the prior art references cited by the Patent Office Examiner during examination of the pending applications suggests that increasing coat weight would increase flux. Rather, to the extent any of the prior art cited by the Patent Office Examiner discusses coat weight, the references simply provide ranges of typical coat weights. Indeed, prior to the teachings of the specification, the coat weight (thickness) of the polymer matrix was understood to be relevant to the patch's ability to sustain desired flux over time. Thus, while the person of ordinary skill in the art would have expected an increase in coat weight to extend the period that the patch could sustain a given flux (*i.e.*, the number of days for which a patch would deliver the target daily dose), he or she would not have expected an increase in coat weight to increase flux (*i.e.*, the daily dose). Rather, the prior art shows that the most predictable way to obtain a greater flux of drug across the skin from a transdermal patch is to increase its size, since there is a direct relationship between flux and active surface area in Fick's 1<sup>st</sup> law of diffusion. This is seen, for example, in the different strengths of Vivelle-Dot®, which differ only in active surface area.


44. .

45. Thus, the prior art does not teach or suggest that coat weight is a parameter to be adjusted to affect the rate of drug flux.

However, the pending applications describe this surprising and unexpected result and demonstrate it in Example 1. Moreover, the additional experimental data discussed above provide further support for the surprising and unexpected effect.

\* \* \*

46. I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.



June 13, 2017

Date

\_\_\_\_\_  
Richard H. Guy

## Richard H. GUY – Curriculum Vitae

Richard Guy received an M.A. in Chemistry from Oxford University, and his Ph.D. in Pharmaceutical Chemistry from the University of London in 1980. He then joined the faculty of the University of California, San Francisco (UCSF), where he was Assistant (1980-87), Associate (1987-1991) and finally Full Professor (1991-1996) of Biopharmaceutical Sciences & Pharmaceutical Chemistry. From 1987 until 1996, Dr. Guy was Vice-Chair of the Department of Biopharmaceutical Sciences at UCSF. During the next 8 years, Dr. Guy was Scientific Director of the *Centre interuniversitaire de recherche et d'enseignement* (Universities of Geneva and Lyon), and Professor of Biopharmacy in the Faculty of Sciences at the University of Geneva. In 2004, he assumed his present position as Professor of Pharmaceutical Sciences at the University of Bath and was Head of the Department of Pharmacy & Pharmacology at Bath from 2006 to 2008. He has also fulfilled the broader role of University Research Advisor. He remains an Adjunct Professor of Bioengineering and Therapeutic Sciences at UCSF.

Dr. Guy's principal achievements have been made in the areas of skin barrier function characterization, transdermal drug delivery, enhancement of percutaneous absorption, iontophoresis, noninvasive biosensing of blood glucose and other analytes, and the prediction and assessment of skin penetration and topical bioavailability. In total, Dr. Guy has published over 350 peer-reviewed articles and over 70 book chapters. He has co-authored one book and co-edited 7 others. He is also co-inventor of 12 patents. His research is presently supported by the U.S. Food & Drug Administration and the pharmaceutical and personal care industries. Current h-index (Scopus) is 67, with over 15,000 citations to Dr. Guy's publications.

Specific ongoing projects include: the development and validation of *in vitro-in vivo* correlations for the assessment of topical drug product bioequivalence; investigation of polymeric film-forming systems as sustained release platforms for topical drugs; determination of the disposition of drug and formulation excipients (including nanoparticles) post-application to the skin and nail using coherent Raman scattering and confocal microscopy; and derivation and evaluation of predictive models of percutaneous penetration for pharmaceutical and cosmetic 'actives', and for potentially toxic chemicals, which contact the skin.

Dr. Guy was an Associate Editor of the Journal of Pharmaceutical Sciences (2002-07) and currently serves on the editorial advisory boards of Diabetes Technology and Therapeutics, the European Journal of Pharmaceutical Sciences, Skin Pharmacology & Physiology, and the European Journal of Pharmaceutics and Biopharmaceutics. He was President of the Controlled Release Society (CRS) in 2000-01, and has served as a member of the Academy of Pharmaceutical Sciences (GB) board. Dr. Guy serves as a consultant and scientific advisor to several companies in the pharmaceutical, cosmetic and biotechnology industries.

Dr. Guy is an elected Fellow of the Royal Society of Chemistry (1988), the American Association of Pharmaceutical Scientists (1990), the American Association for the Advancement of Science (1992), the Academy of Pharmaceutical Sciences, Great Britain (2007) and the Controlled Release Society (CRS) College of Fellows (2010). He was the first recipient of the CRS Young Investigator Award in 1988, when he also won the British Pharmaceutical Conference Science Award. Dr. Guy was awarded, for his work in "reverse iontophoresis" and noninvasive glucose monitoring, the Prix Applications Médicales de l'Electricité, 1997 by the Institut Electricité Santé, Paris, France. In April 2000, Dr. Guy received the APV Research Award for Outstanding Achievements in the Pharmaceutical Sciences and, in 2007, he won the "Prix Pharmapeptides" from the Universities of Geneva and Lyon. In 2010, Dr. Guy became a Fellow of The School of Pharmacy (now the UCL School of Pharmacy), University of London, in recognition of "his distinguished contribution to the pharmaceutical sciences", and he received the CRS Founders Award in 2013. The Maurice-Marie Janot Award from the Association Pharmacie Galénique Industrielle (APGI) followed in 2016 for his "original and innovative papers in the domain of pharmaceutics, biopharmaceutics and pharmaceutical technology", the same year that he was awarded the degree of Doctor of Science from Oxford University.

## Curriculum Vitae - Richard H. Guy

**Date of Birth:** November 27, 1954

**Nationality:** British

### Current Position & Address:

Professor of Pharmaceutical Sciences

*Adjunct Professor*

Department of Pharmacy & Pharmacology

*University of California, San Francisco*

University of Bath

*Department of Bioengineering & Therapeutic Sciences*

Claverton Down, Bath, BA2 7AY, UK

*San Francisco, CA 94143-0446, USA*

Tel. +44.1225.384901; [r.h.guy@bath.ac.uk](mailto:r.h.guy@bath.ac.uk)

### Education (Undergraduate, Graduate, Postgraduate, Fellowships)

1977	B.A., Chemistry (First Class) Oxford University, Oxford, England
1980	M.A., Chemistry Oxford University, Oxford, England
1977-80	Ph.D., Pharmaceutical Chemistry University of London, London, England
2016	D.Sc., Medical Sciences Division Oxford University, Oxford, England

### Specialty; Subspecialty

Chemistry; Physical Pharmaceutical Chemistry

### Academic and Professional Positions Held

1978-80	Teaching Fellow School of Pharmacy, University of London, London, England
1980-87	Assistant Professor Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, California
1982-96	Research Associate Department of Dermatology, School of Medicine University of California, San Francisco, California
1986-2000	Honorary Professor The Welsh School of Pharmacy, Cardiff University, Cardiff, Wales
1987-91	Associate Professor



Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry,  
School of Pharmacy, University of California, San Francisco, California

- 1987-96      Member  
Bioengineering Graduate Group, School of Medicine  
University of California, San Francisco; and  
College of Engineering, University of California - Berkeley, California
- Vice-Chairman  
Department of Biopharmaceutical Sciences, School of Pharmacy  
University of California, San Francisco, California
- 1989          Academic Visitor (sabbatical)  
Department of Chemistry  
Imperial College of Science, Technology & Medicine, University of London  
London, England
- Chercheur (sabbatical)  
Centre International de Recherches Dermatologiques  
Sophia Antipolis, Valbonne, France
- 1991-96      Professor  
Departments of Biopharmaceutical Sciences and Pharmaceutical Chemistry,  
School of Pharmacy, University of California, San Francisco, California
- 1994-95      Visiting Professor (sabbatical)  
Faculté de Pharmacie de Châtenay-Malabry, Université de Paris-Sud, France
- 1995          Visiting Professor (sabbatical)  
Facultad de Farmacia, Departamento de Farmacología, Farmacia y Tecnología  
Farmacéutica, Universidade de Santiago de Compostela, Spain
- 1996-2001    Adjunct Professor [Professeur Associé]  
Faculté des Sciences, Université de Genève, Genève, Switzerland
- 1996 -2001    Directeur Scientifique  
Centre interuniversitaire de recherche et d'enseignement, "Pharmapeptides"  
Universités de Genève et Lyon, Campus Universitaire, Archamps, France
- 1996-          Adjunct Professor  
Department of Bioengineering and Therapeutic Sciences,  
School of Pharmacy, University of California, San Francisco, California
- 1997-98      Professeur Invité  
Faculté de Pharmacie, Université Claude Bernard, Lyon, France
- 2001-03      Directeur  
Ecole romande de pharmacie, Universités de Genève et Lausanne  
Genève, Lausanne, Switzerland

- 2001-04      Professeur  
 Faculté des Sciences, Université de Genève, Genève, Switzerland
- Directeur  
 Centre interuniversitaire de recherche et d'enseignement, "Pharmapeptides"  
 Universités de Genève et Lyon, Campus Universitaire, Archamps, France
- Visiting Professor  
 University of Greenwich, England
- 2004-          Professor of Pharmaceutical Sciences  
 University of Bath, Department of Pharmacy & Pharmacology  
 Bath, England
- 2006-08      Head, Department of Pharmacy & Pharmacology  
 University of Bath, Bath, England
- 2008-10      University Research Adviser  
 University of Bath, Bath, England
- 2015          Academic Visitor (sabbatical)  
 Physical & Theoretical Chemistry Laboratory, Department of Chemistry  
 Oxford University

### Honors and Awards

- 1984          Pennwalt Award for the "Best Pharmaceutical Paper," Controlled Release Society. San Francisco, California
- 1984-87      Special Emphasis Research Career Award, National Institute of Occupational Safety and Health, "Cutaneous Toxicity: Predictive Pathways"
- 1987          Walter F. Enz Lecturer, Department of Pharmaceutical Chemistry, University of Kansas. Lawrence, Kansas
- 4th Annual Minnetonka Lectureship in Pharmaceutics, College of Pharmacy, University of Minnesota. Minneapolis, Minnesota
- 1988          Young Investigator Award (1<sup>st</sup> recipient), Controlled Release Society  
 British Pharmaceutical Conference Science Award  
 Elected Fellow of the Royal Society of Chemistry
- 1990          Elected Fellow of the American Association of Pharmaceutical Scientists  
 Lecturer in the University of Medicine & Dentistry of New Jersey Distinguished Lecture Series in Biomaterials and Biomedical Devices, Rutgers University. Piscataway, New Jersey

- 1992 Elected Fellow of the American Association for the Advancement of Science
- 1993 Visiting Eminent Scholar Series in Drug Delivery, University of Florida, Gainesville, Florida
- 1997 Recipient, *Prix Applications Médicales de l'Electricité, 1997*, Electricité de France, Institut Electricité Santé, Paris, France
- 1999 Lauréat du Concours "Création d'entreprise de technologies innovantes", Ministère de l'Education Nationale, de la Recherche et de la Technologie, France
- 2000 Recipient, APV (International Association for Pharmaceutical Technology) Research Award for Outstanding Achievements in the Pharmaceutical Sciences
- 2005 APGI (Association de Pharmacie Galénique Industrielle) Sanofi-Aventis Young Investigator Award to Anke Sieg, Ph.D., former doctoral student, for her thesis performed under the co-direction of Dr. M.B. Delgado-Charro & Prof. R.H. Guy
- 2006 Research cited in *The Better World Report. "Technology Transfer Stories: 25 Innovations that Changed the World". 2006 edition.* [http://www.autm.net/documents/AUTM\\_BWR.pdf](http://www.autm.net/documents/AUTM_BWR.pdf). 'Tiny monitor gives diabetics frequent, automatic readings', ch. 6, pp. 55-58. The first non-invasive continuous monitoring device, pioneered at the University of California, San Francisco, helps patients better manage diabetes.
- 2007 Elected Fellow of the Academy of Pharmaceutical Sciences, Great Britain (APSGB).  
Prix Pharmapeptides, Universities of Geneva and Lyon.
- 2010 Elected to the College of Fellows of the Controlled Release Society  
Elected Fellow of The School of Pharmacy, University of London (now the UCL School of Pharmacy), in recognition of "*his distinguished contribution to the pharmaceutical sciences*"
- 2013 Founders Award, Controlled Release Society
- 2014 Award from the Royal Pharmaceutical Society of Great Britain to the RPSGB Pharmaceutical Science Expert Advisory Panel (RHG is a member) in recognition of its contribution to promoting the pharmaceutical sciences
- 2016 D.Sc., Medical Sciences Division, Oxford University, Oxford, England  
Maurice-Marie Janot Award from the Association de Pharmacie Galénique Industrielle (APGI) for original and innovative research in pharmaceuticals, biopharmaceuticals and pharmaceutical technology.

### **Description of Current Research Program**

Research focuses on skin barrier function characterization, transdermal drug delivery, enhancement of percutaneous absorption, iontophoresis, noninvasive biosensing, and the prediction and assessment of skin penetration and topical bioavailability. Specific ongoing projects include: measurement of the skin's biomechanical properties at the nanoscale using atomic force microscopy; the potential of polymeric film-forming systems as sustained release platforms for topical drugs; determination of the disposition of drug and formulation excipients (including nanoparticles) post-application to the skin and to

the nail using coherent Raman scattering and confocal microscopy; the impact of laser, microneedle and other poration technologies on drug delivery into and through skin and nail; examination of a graphene-based biosensor for noninvasive, transdermal glucose monitoring; development of *in vitro* – *in vivo* correlations with which to assess the bio(in)equivalence of topical drug products; and derivation and evaluation of predictive models of percutaneous penetration for pharmaceutical and cosmetic 'actives', and for potentially toxic chemicals, which come into contact with skin.

## PUBLICATIONS

### Journal Articles

- (1) The Estimation of Diffusion Coefficients Using the Rotating Diffusion Cell. R.H. Guy and R. Fleming. *Int. J. Pharmaceut.* **3**, 143-149 (1979).
- (2) A Novel Method to Study the Permeability of a Phospholipid Barrier. R.H. Guy and R. Fleming. *J. Chem. Soc., Chem. Commun.*, 729-730 (1979).
- (3) Long-Time Solution of the Equations Describing the Flow of  $^{22}\text{Na}^+$  in a Finite Composite System Containing a Synthetic Phospholipid-Protein Membrane: Calculation of Permeability Coefficient. R.H. Guy and R. Fleming. *Int. J. Pharmaceut.* **4**, 241-248 (1980).
- (4) A Theoretical Description Relating Skin Penetration to the Thickness of the Applied Medicament. R.H. Guy, and J. Hadgraft. *Int. J. Pharmaceut.* **6**, 321-332 (1980).
- (5) Diffusion Coefficient Determination Using a Filter-Paper Diaphragm Cell Technique. A.D. Cadman, R. Fleming, and R.H. Guy. *J. Pharm. Pharmacol.* **33**, 121-123 (1981).
- (6) Capillary Diffusion and Interfacial Kinetics. R.H. Guy and J. Hadgraft. *J. Colloid Interface Sci.* **80**, 386-392 (1981).
- (7) Interfacial Transport of Salicylic Acid. R.H. Guy and J. Hadgraft. *J. Colloid Interface Sci.* **81**, 69-74 (1981).
- (8) Calculations of Drug Release Rates From Cylinders. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **8**, 159-165 (1981).
- (9) Transport Across a Phospholipid Barrier. R.H. Guy and R. Fleming. *J. Colloid Interface Sci.* **83**, 130-137 (1981).
- (10) A Theoretical Comparison of Release Rates of Drugs Into Sink and Non-Sink Conditions. R.H. Guy and J. Hadgraft. *J. Pharm. Sci.* **70**, 1243-1245 (1981).
- (11) Diffusion of Lysozyme Chloride in Water and Aqueous Potassium Chloride Solutions. A.D. Cadman, R. Fleming, and R.H. Guy. *Biophys. J.* **37**, 569-574 (1982).
- (12) Kinetics of Solute Transfer Across Aqueous Phase- Liquid Hydrocarbon Interfaces. R.H. Guy, T.R. Aquino, and D.H. Honda. *J. Phys. Chem.* **86**, 280-283 (1982).
- (13) The Influence of Urea on the Kinetics of Interfacial Transfer. R.H. Guy, D.H. Honda, and T.R. Aquino. *J. Colloid Interface Sci.* **87**, 107-114 (1982).
- (14) Rapid Radial Transport of Methyl Nicotinate in the Dermis. R.H. Guy and H.I. Maibach. *Arch. Dermatol. Res.* **273**, 91-95 (1982).
- (15) A Pharmacokinetic Model for Percutaneous Absorption. R.H. Guy, J. Hadgraft, and H.I. Maibach. *Int. J. Pharmaceut.* **11**, 119-129 (1982).
- (16) Percutaneous Metabolism with Saturable Enzyme Kinetics. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **11**, 187-197 (1982).

- (17) Calculations of Drug Release Rates from Spherical Particles. R.H. Guy, J. Hadgraft, I. W. Kellaway, and M. J. Taylor. *Int. J. Pharmaceut.* **11**, 199-207 (1982).
- (18) Solute Transfer Across Liquid-Liquid Interfaces. Kinetic and Thermodynamic Evaluation. R.H. Guy, T.R. Aquino III, and D.H. Honda. *J. Phys. Chem.* **86**, 2861-2866 (1982).
- (19) Release of Non-Electrolytes from Liposomes. R.H. Guy, J. Hadgraft, M.J. Taylor, and I.W. Kellaway. *J. Pharm. Pharmacol.* **35**, 12-14 (1983).
- (20) Solute Transfer Across Liquid-Liquid Interfaces. R.H. Guy. *Ann. N.Y. Acad. Sci.* **404**, 194-197 (1983).
- (21) Kinetics and Thermodynamics of Interfacial Transfer. R. Fleming, R.H. Guy and J. Hadgraft. *J. Pharm. Sci.* **72**, 142-145 (1982).
- (22) Malathion Percutaneous Absorption Following Repeated Administration To Man. R.C. Wester, H.I. Maibach, D.A.W. Bucks, and R.H. Guy. *Toxicol. Appl. Pharmacol.* **68**, 116-119 (1983).
- (23) Interfacial Transfer Kinetics of  $^{22}\text{Na}^+$  Across a Synthetic Phospholipid-Protein Membrane. R. Fleming, R.H. Guy, and J. Hadgraft. *J. Colloid Interface Sci.* **94**, 54-59 (1983).
- (24) Noninvasive Assessment of Local Nicotinate Pharmacodynamics by Photoplethysmography. E. Tur, R.H. Guy, M. Tur, and H.I. Maibach. *J. Invest. Dermatol.* **80**, 499-503 (1983).
- (25) A Physicochemical Interpretation of the Pharmacokinetics of Percutaneous Absorption. R.H. Guy and J. Hadgraft. *J. Pharmacokin. Biopharm.* **11**, 189-203 (1983).
- (26) Percutaneous Absorption: Transport in the Dermis. W.J. Albery, R.H. Guy, and J. Hadgraft. *Int. J. Pharmaceut.* **15**, 125-148 (1983).
- (27) Noninvasive Assessments of the Percutaneous Absorption of Methyl Nicotinate in Humans. R.H. Guy, R.C. Wester, E. Tur, and H.I. Maibach. *J. Pharm. Sci.* **72**, 1077-1079 (1983).
- (28) Drug Delivery to Local Subcutaneous Structures Following Topical Administration. R.H. Guy and H.I. Maibach. *J. Pharm. Sci.* **72**, 1375-1380 (1983).
- (29) Percutaneous Absorption: Multidose Pharmacokinetics. R.H. Guy, J. Hadgraft, H.I. Maibach. *Int. J. Pharmaceut.* **17**, 23-28 (1983).
- (30) Preliminary Skin Blood Flow Measurements Appear Unsuccessful for Assessing Topical Corticosteroid Effect. M. Amantea, E. Tur, H.I. Maibach, and R.H. Guy. *Arch. Dermatol. Res.* **275**, 419-420 (1983).
- (31) Basal Perfusion of the Cutaneous Microcirculation: Measurements as a Function of Anatomic Position. E. Tur, M. Tur, H.I. Maibach, and R.H. Guy. *J. Invest. Dermatol.* **81**, 441-446 (1983).
- (32) Correction Factors for Determining Body Exposure From Forearm Percutaneous Absorption. R.H. Guy and H.I. Maibach. *J. Appl. Toxicol.* **4**, 26-28 (1984).
- (33) Pharmacodynamic Measurements of Methyl Nicotinate Percutaneous Absorption. R.H. Guy, E. Tur, B. Bugatto, C. Gaebel, L.B. Sheiner, and H.I. Maibach. *Pharmaceut. Res.* **1**, 76-81 (1984).
- (34) A Theoretical Description of the Effects of Volatility and Substantivity on Percutaneous Absorption. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **18**, 139-147 (1984).

- (35) Minoxidil Stimulates Cutaneous Blood Flow in Human Balding Scalps: Pharmacodynamics Measured by Laser Doppler Velocimetry and Photopulse Plethysmography. R.C. Wester, H.I. Maibach, R.H. Guy, and E. Novak. *J. Invest. Dermatol.* **82**, 515-517 (1984).
- (36) Solute Transport Resistance at the Octanol-Water Interface. R.H. Guy and D.H. Honda. *Int. J. Pharmaceut.* **19**, 129-137 (1984).
- (37) Prediction of Drug Disposition Kinetics in Skin and Plasma Following Topical Administration. R.H. Guy and J. Hadgraft. *J. Pharm. Sci.* **73**, 883-887 (1984).
- (38) Quantitative Assessment of UV-Induced Changes in Microcirculatory Flow by Laser Doppler Velocimetry. V. Drouard, H.I. Maibach, D.R. Wilson, and R.H. Guy. *J. Invest. Dermatol.* **83**, 188-192 (1984).
- (39) Percutaneous Absorption Kinetics of Topically Applied Agents Liable To Surface Loss. R.H. Guy and J. Hadgraft. *J. Soc. Cosmet. Chem.* **35**, 103-113 (1984).
- (40) Pharmacokinetics of Percutaneous Absorption with Concurrent Metabolism. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **20**, 43-51 (1984).
- (41) Solute Transport and Perturbation at Liquid-Liquid Interfaces. R.H. Guy, R.S. Hinz, and M. Amantea. *Faraday Discuss. Chem. Soc.* **77**, 127-137 (1984).
- (42) Percutaneous Absorption in Man: A Kinetic Approach. R.H. Guy, J. Hadgraft, and H.I. Maibach. *Toxicol. Appl. Pharmacol.* **78**, 123-129 (1985).
- (43) Optical Techniques for Monitoring Cutaneous Microcirculation: Recent Applications. R.H. Guy, E. Tur, and H.I. Maibach. *Int. J. Dermatol.* **24**, 88-94 (1985).
- (44) Regional Blood Flow and Mycosis Fungoides. H.S. Zackheim, E. Tur, and R.H. Guy. *J. Am. Acad. Dermatol.* **12**, 578-580 (1985).
- (45) Are There Age and Racial Differences to Methyl Nicotinate-Induced Vasodilatation in Human Skin? R.H. Guy, E. Tur, S. Bjerke, and H.I. Maibach. *J. Am. Acad. Dermatol.* **12**, 1001-1006 (1985).
- (46) The Prediction of Plasma Levels of Drugs Following Transdermal Application. R.H. Guy and J. Hadgraft. *J. Control. Rel.* **1**, 177-182 (1985).
- (47) Transdermal Drug Delivery: The Ground Rules are Emerging. R.H. Guy and J. Hadgraft. *Pharm. Int.* **6**, 112-116 (1985).
- (48) *Via* Transdermal? R.H. Guy. *Pharm. Int.* **6**, 125-126 (1985).
- (49) Transdermal Drug Delivery: A Simplified Pharmacokinetic Approach. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **24**, 267-274 (1985).
- (50) Spatial Variability of Vasodilatation in Human Forearm Skin. E. Tur, H.I. Maibach, and R.H. Guy. *Br. J. Dermatol.* **113**, 197-203 (1985).
- (51) Pharmacokinetic Interpretation of the Plasma Levels of Clonidine Following Transdermal Delivery. R.H. Guy and J. Hadgraft. *J. Pharm. Sci.* **74**, 1016-1018 (1985).
- (52) Kinetic Analysis of Transdermal Nitroglycerin Delivery. R.H. Guy and J. Hadgraft. *Pharmaceut. Res.*

- 2, 206-211 (1985).
- (53) The Microbial Degradation of Topically Applied Drugs. S.P. Denyer, R.H. Guy, J. Hadgraft, and W.B. Hugo. *Int. J. Pharmaceut.* **26**, 89-97 (1985).
- (54) Laser Doppler Velocimetry to Quantify UV-B Induced Increase in Human Skin Blood Flow. A.R. Young, R.H. Guy, and H.I. Maibach. *Photochem. Photobiol.* **42**, 385-390 (1985).
- (55) Transdermal Drug Delivery to Neonates. N. Evans, R.H. Guy, J. Hadgraft, G.D. Parr, and N. Rutter. *Int. J. Pharmaceut.* **24**, 259-265 (1985).
- (56) Percutaneous Absorption of Steroids: Effect of Repeated Application. D.A.W. Bucks, H.I. Maibach, and R.H. Guy. *J. Pharm. Sci.* **74**, 1337-1339 (1985).
- (57) Recent Advances in Transdermal Drug Delivery. R.H. Guy. *Ther. Res.* **3**, 69-80 (1985).
- (58) Pharmacodynamic Measurements of Percutaneous Penetration Enhancement *In Vivo*. K.S. Ryatt, J.M. Stevenson, H.I. Maibach, and R.H. Guy. *J. Pharm. Sci.* **75**, 374-377 (1986).
- (59) The Bioavailability of Dermatological and Other Topically Applied Drugs. R.H. Guy, A.H. Guy, H.I. Maibach, and V.P. Shah. *Pharm. Res.* **3**, 253-262 (1986).
- (60) The Influence of Urea on Percutaneous Absorption. J. Beastall, R.H. Guy, J. Hadgraft, and I. Wilding. *Pharm. Res.* **3**, 294-297 (1986).
- (61) Interpretation and Prediction of the Kinetics of Transdermal Drug Delivery: Oestradiol, Hyoscine, and Timolol. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **32**, 159-163 (1986).
- (62) Determination of Vehicle Effects on Percutaneous Absorption by Laser Doppler Velocimetry. R.H. Guy, E. Tur, L.M. Schall, S. Elamir, and H.I. Maibach. *Arch. Dermatol. Res.* **278**, 500-502 (1986).
- (63) Percutaneous Penetration of Nicotines: *In Vivo* and *In Vitro* Measurements. R.H. Guy, E.M. Carlstrom, D.A.W. Bucks, R.S. Hinz, and H.I. Maibach. *J. Pharm. Sci.* **75**, 968-972 (1986).
- (64) Transdermal Drug Delivery and Cutaneous Metabolism. R.H. Guy, J. Hadgraft, and D.A.W. Bucks. *Xenobiotica* **17**, 325-343 (1987).
- (65) Transdermal Drug Delivery: A Perspective. R.H. Guy and J. Hadgraft. *J. Control. Rel.* **4**, 237-251 (1987).
- (66) A Capillary Tube Method for the Measurement of Solute Transport Across Liquid-Liquid Interfaces. R.S. Hinz and R.H. Guy. *J. Phys. Chem.* **91**, 2915-2917 (1987).
- (67) The Effect of Penetration Enhancers on the Kinetics of Percutaneous Absorption. R.H. Guy and J. Hadgraft. *J. Control. Rel.* **5**, 43-51 (1987).
- (68) Blood Flow in Psoriatic Skin Lesions: The Effect of Treatment. A. Khan, L.M. Schall, E. Tur, H.I. Maibach, and R.H. Guy. *Br. J. Dermatol.* **117**, 193-201 (1987).
- (69) Transdermal Drug Delivery: Problems and Possibilities. V.M. Knepp, R.H. Guy, and J. Hadgraft. *CRC Crit. Rev. Ther. Drug Carrier Syst.* **4**, 13-37 (1987).
- (70) FDA and AAPS Report of the Workshop on Principles and Practice of *In Vitro* Percutaneous



- Absorption Studies: Relevance to Bioavailability and Bioequivalence. J.P. Skelly, V.P. Shah, H.I. Maibach, R.H. Guy, R.C. Wester, G. Flynn, and A. Yacobi. *Pharm. Res.* **4**, 265-267 (1987).
- (71) Controlled Drug Release from a Novel Liposomal Delivery System. I. Investigation of Transdermal Potential. V.M. Knepp, R.S. Hinz, F.C. Szoka, and R.H. Guy. *J. Control. Rel.* **5**, 211-221 (1988).
- (72) Membrane Models for Skin Penetration Studies. J. Houk and R.H. Guy. *Chem. Rev.* **88**, 455-471 (1988).
- (73) Mass Balance and Dose Accountability in Percutaneous Absorption Studies: Development of a Non-Occlusive Application System. D.A.W. Bucks, H.I. Maibach, and R.H. Guy. *Pharm. Res.* **5**, 313-315 (1988).
- (74) A New System for *In Vitro* Studies of Iontophoresis. P. Glikfeld, C. Cullander, R.S. Hinz, and R.H. Guy. *Pharm. Res.* **5**, 443-446 (1988).
- (75) Pharmacokinetic Considerations in the Use of Newer Transdermal Formulations. G. Ridout, G. Santus, and R.H. Guy. *Clin. Pharmacokin.* **15**, 114-131 (1988).
- (76) Methodology to Measure the Transient Effect of Occlusion on Skin Penetration and Stratum Corneum Hydration *In Vivo*. K.S. Ryatt, M. Mobayen, J.M. Stevenson, H.I. Maibach, and R.H. Guy. *Brit. J. Dermatol.* **119**, 307-312 (1988).
- (77) Percutaneous Absorption of Hydroquinone in Humans: Effect of 1-Dodecylaza-cycloheptan-2-one (Azone) and the 2-Ethylhexyl Ester of 4-(Dimethylamino)-Benzoic Acid (Escalol 507). D.A.W. Bucks, J.R. McMaster, R.H. Guy, and H.I. Maibach. *J. Tox. Environ. Health* **24**, 279-289 (1988).
- (78) Bioavailability of Topically Administered Steroids: A "Mass Balance" Technique. D.A.W. Bucks, J.R. McMaster, H.I. Maibach, and R.H. Guy. *J. Invest. Dermatol.* **91**, 29-33 (1988).
- (79) The Relationship of pKa and Acute Skin Irritation in Man. B. Berner, D.R. Wilson, R.H. Guy, G.C. Mazzenga, F.H. Clarke, and H.I. Maibach. *Pharm. Res.* **5**, 660-663 (1988).
- (80) Physicochemical Aspects of Percutaneous Absorption and its Enhancement. R.H. Guy and J. Hadgraft. *Pharm. Res.* **5**, 753-758 (1988).
- (81) *In Vitro* and *In Vivo* Enhancement of Skin Penetration with Oleic and Lauric Acids. P.G. Green, R.H. Guy, and J. Hadgraft. *Int. J. Pharm.* **48**, 103-111 (1988).
- (82) Laser Doppler Velocimetric Measurement of Skin Blood Flow: A Reply. A.J. Bircher, K.V. Roskos, H.I. Maibach, and R.H. Guy. *Int. J. Pharm.* **45**, 263-265 (1988).
- (83) *In Vitro* Percutaneous Penetration: Evaluation of the Utility of Hairless Mouse Skin. R.S. Hinz, C.D. Hodson, C.R. Lorence, and R.H. Guy. *J. Invest. Dermatol.* **93**, 87-91 (1989).
- (84) Cutaneous Responses to Topical Methyl Nicotinate in Black, Oriental, and Caucasian Subjects. C. Gean, E. Tur, H.I. Maibach, and R.H. Guy. *Arch. Dermatol. Res.* **281**, 95-98 (1989).
- (85) Noninvasive Sampling of Biological Fluids by Iontophoresis. P. Glikfeld, R.S. Hinz, and R.H. Guy. *Pharm. Res.* **6**, 988-990 (1989).
- (86) Transport of Steroids at Model Biomembrane Surfaces and Across Organic Liquid-Aqueous Phase Interfaces. V.M. Knepp and R.H. Guy. *J. Phys. Chem.* **93**, 6817-6823 (1989).

- (87) Assessment of Skin Barrier Function Using Transepidermal Water Loss: Effect of Age. K.V. Roskos and R.H. Guy. *Pharm. Res.* **6**, 949-953 (1989).
- (88) The Effect of Aging on Percutaneous Absorption in Man. K.V. Roskos, H.I. Maibach, and R.H. Guy. *J. Pharmacokin. Biopharm.* **17**, 617-630 (1989).
- (89) Relationship of pKa and Acute Skin Irritation in Humans. B. Berner, D.R. Wilson, R.H. Guy, G.C. Mazzenga, F.H. Clarke, and H.I. Maibach. *J. Toxicol.-Cut. & Ocular Toxicol.* **8**, 481-492 (1989).
- (90) Percutaneous Penetration and Mass Balance Accountability: Technique and Implications for Dermatology. D.A.W. Bucks, R.H. Guy, and H.I. Maibach. *J. Toxicol.-Cut. & Ocular Toxicol.* **8**, 439-451 (1989).
- (91) Pharmacodynamic Measurements of Methyl Nicotinate Percutaneous Absorption: The Effect of Aging on Microcirculation. K.V. Roskos, A.J. Bircher, H.I. Maibach, R.H. Guy. *Brit. J. Dermatol.* **122**, 165-171 (1990).
- (92) Controlled Drug Release from a Novel Liposomal Delivery System. II. Transdermal Delivery Characteristics. V.M. Knepp, F.C. Szoka, and R.H. Guy. *J. Control. Release* **12**, 25-30 (1990).
- (93) Oleic Acid Concentration and Effect in Human Stratum Corneum: Non-invasive Determination by Attenuated Total Reflectance Infrared Spectroscopy *In Vivo*. V.H.W. Mak, R.O. Potts, R.H. Guy. *J. Control. Release* **12**, 67-75 (1990).
- (94) Mechanism of Percutaneous Penetration Enhancement: Effect of n-Alkanols on the Permeability Barrier of Hairless Mouse Skin. T.Kai, V.H.W. Mak, R.O. Potts, and R.H. Guy. *J. Control. Release* **12**, 103-112 (1990).
- (95) On the Determination of Drug Release Rates from Topical Dosage Forms. R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **60**, R1-R3 (1990).
- (96) Partitioning of Chemicals Into Human Stratum Corneum: Implications for Risk Assessment Following Dermal Exposure. C. Surber, K-P. Wilhelm, H.I. Maibach, L.L. Hall, and R.H. Guy. *Fund. Appl. Toxicol.* **15**, 99-107 (1990).
- (97) Percutaneous Penetration Enhancement *In Vivo* Measured by Attenuated Total Reflectance Infrared Spectroscopy. V.H.W. Mak, R.O. Potts, R.H. Guy. *Pharm. Res.* **7**, 835-841 (1990).
- (98) *In Vivo* Percutaneous Absorption of Chemicals: A Multiple-Dose Study in Rhesus Monkeys. D.A.W. Bucks, R.S. Hinz, R. Sarason, H.I. Maibach, R.H. Guy. *Food Chem. Toxicol.* **28**, 129-132 (1990).
- (99) Examination of Stratum Corneum Barrier Function *In Vivo* by Infrared Spectroscopy. D. Bommannan, R.O. Potts, and R.H. Guy. *J. Invest. Dermatol.* **95**, 403-408 (1990).
- (100) Cutaneous Pharmacodynamics of Transdermally Delivered Isosorbide Dinitrate. M. Hori, S. Ohtsuka, R.H. Guy, and H.I. Maibach. *Pharm. Res.* **7**, 1298-1301 (1990).
- (101) Optimization of Topical Therapy: Partitioning of Drugs Into Stratum Corneum. C. Surber, K-P. Wilhelm, H.I. Maibach, and R.H. Guy. *Pharm. Res.* **7**, 1320-1324 (1990).
- (102) The Relationship Between pKa and Skin Irritation for a Series of Basic Penetrants in Man. B. Berner, D.R. Wilson, R.J. Steffens, G.C. Mazzenga, R.S. Hinz, R.H. Guy, and H.I. Maibach. *Fund. Appl. Toxicol.* **15**, 760-766 (1990).

- (103) The Effects of Zwitterionic Surfactants on Skin Barrier Function. G.R. Ridout, R.S. Hinz, J.J. Hostynek, A.K. Reddy, R.J. Wiersema, C.D. Hodson, C.R. Lorence, and R.H. Guy. *Fund. Appl. Toxicol.* **16**, 41-50 (1991).
- (104) Enhancement of Propranolol Hydrochloride and Diazepam Skin Absorption *In Vitro*: Effect of Enhancer Lipophilicity. M. Hori, S. Satoh, H.I. Maibach, and R.H. Guy. *J. Pharm. Sci.* **80**, 32-35 (1991).
- (105) Barrier Function of Human Keratinocyte Cultures Grown at the Air-Liquid Interface. V.H. W. Mak, M.B. Cumpstone, A.H. Kennedy, C.S. Harmon, R.H. Guy, and R.O. Potts. *J. Invest. Dermatol.* **96**, 323-327 (1991).
- (106) Sites of Iontophoretic Current Flow Into the Skin: Identification and Characterization with the Vibrating Probe Electrode. C. Cullander, and R.H. Guy. *J. Invest. Dermatol.* **97**, 55-64 (1991).
- (107) Mechanism and Enhancement of Solute Transport Across the Stratum Corneum. R.O. Potts, G.M. Golden, M.L. Francoeur, V.H.W. Mak, and R.H. Guy. *J. Control. Release* **15**, 249-260 (1991).
- (108) Strategies to Enhance Permeability *via* Stratum Corneum Lipid Pathways. R.O. Potts, V.H.W. Mak, R.H. Guy, and M.L. Francoeur. *Adv. Lipid Res.* **24**, 175-212 (1991).
- (109) Iontophoretic Delivery of Amino Acids and Amino Acid Derivatives Across the Skin *In Vitro*. P.G. Green, R.S. Hinz, C. Cullander, G. Yamane, and R.H. Guy. *Pharm. Res.* **8**, 1113-1120 (1991).
- (110) Iontophoretic Delivery of a Series of Tripeptides Across the Skin *In Vitro*. P.G. Green, R.S. Hinz, A. Kim, F.C. Szoka, and R.H. Guy. *Pharm. Res.* **8**, 1121-1127 (1991).
- (111) Does Hydration Affect Intercellular Lipid Organization in the Stratum Corneum? V.H.W. Mak, R.O. Potts, and R.H. Guy. *Pharm. Res.* **8**, 1064-1065 (1991).
- (112) Lineweaver-Burk Analysis of Skin Penetration Enhancement. M. Hori, K-C. Moon, H.I. Maibach, and R.H. Guy. *J. Control. Release* **16**, 263-266 (1991).
- (113) Examination of the Effect of Ethanol on Human Stratum Corneum *In Vivo* Using Infrared Spectroscopy. D. Bommannan, R.O. Potts, and R.H. Guy. *J. Control. Release* **16**, 299-304 (1991).
- (114) Percutaneous Penetration of *para*-Substituted Phenols *In Vitro*. R.S. Hinz, C.R. Lorence, C.D. Hodson, C. Hansch, L.L. Hall, and R.H. Guy. *Fund. Appl. Toxicol.* **17**, 575-583 (1991).
- (115) Percutaneous Penetration Kinetics of Nitroglycerin and Its Dinitrate Metabolites Across Hairless Mouse Skin *In Vitro*. T. Kikkoji, M. Gumbleton, N. Higo, R.H. Guy, and L.Z. Benet. *Pharm. Res.* **8**, 1231-1237 (1991).
- (116) Percutaneous Penetration of Methyl Nicotinate at Three Anatomic Sites: Evidence for an Appendageal Contribution to Transport? E. Tur, H.I. Maibach, and R.H. Guy. *Skin Pharmacol.* **4**, 230-234 (1991).
- (117) *In Vivo* Percutaneous Penetration/Absorption, Washington, DC, May 1989. V.P. Shah, G.L. Flynn, R.H. Guy, H.I. Maibach, H. Schaefer, J.P. Skelly, R.C. Wester, and A. Yacobi. *Pharm. Res.* **8**, 1071-1075 (1991); *Int. J. Pharmaceut.* **74**, 1-8 (1991); *Skin Pharmacol.* **4**, 220-228 (1991).
- (118) Enhancement of Propranolol Hydrochloride and Diazepam Skin Absorption *In Vitro* . II: Drug, Vehicle and Enhancer Penetration Kinetics. M. Hori, H.I. Maibach, and R.H. Guy. *J. Pharm. Sci.* **81**, 330-333 (1992).

- (119) Cutaneous Metabolism of Nitroglycerin I: Homogenized *Versus* Intact Skin. N. Higo, R.S. Hinz, D.T.W. Lau, L.Z. Benet, and R.H. Guy. *Pharm. Res.* **9**, 187-190 (1992).
- (120) Cutaneous Metabolism of Nitroglycerin II: Effect of Skin Condition and Penetration Enhancement. N. Higo, R.S. Hinz, D.T.W. Lau, L.Z. Benet, and R.H. Guy. *Pharm. Res.* **9**, 299-302 (1992).
- (121) Sonophoresis I. The Use of High-Frequency Ultrasound to Enhance Transdermal Drug Delivery. D. Bommannan, H. Okuyama, P. Stauffer, and R.H. Guy. *Pharm. Res.* **9**, 559-564 (1992).
- (122) Predicting Skin Permeability. R.O. Potts and R.H. Guy. *Pharm. Res.* **9**, 663-669 (1992).
- (123) Sonophoresis II: Examination of the Mechanism(s) of Ultrasound-Enhanced Transdermal Drug Delivery. D. Bommannan, G.K. Menon, H. Okuyama, P.M. Elias, and R.H. Guy. *Pharm. Res.* **9**, 1047-1051 (1992).
- (124) Transdermal Delivery of Peptides and Proteins. C. Cullander and R.H. Guy. *Adv. Drug Delivery Rev.* **8**, 291-324 (1992).
- (125) Epidermal Lipids and Topical Drug Delivery. J. Hadgraft, K.A. Walters, and R.H. Guy. *Seminars in Dermatology*, **11**, 139-144 (1992).
- (126) Transdermal Iontophoresis of Amino Acids and Peptides *In Vitro*. P.G. Green, R.S. Hinz, A. Kim, C. Cullander, G. Yamane, F.C. Szoka, and R.H. Guy. *J. Control. Release* **21**, 187-190 (1992).
- (127) Cutaneous Blood Flow in Gestational Hypertension. E. Tur, A. Tamir, and R.H. Guy. *J. Invest. Dermatol.* **99**, 310-314 (1992).
- (128) *In Vitro* and *In Vivo* Iontophoresis of a Tripeptide Across Nude Rat Skin. P.G. Green, F. Bernerd, W.R. Pilgrim, B. Shroot, and R.H. Guy. *J. Control. Release* **20**, 209-218 (1992).
- (129) On Structure-Permeability Relationships in Percutaneous Penetration. R.H. Guy and R.O. Potts. *J. Pharm. Sci.* **81**, 603-604 (1992).
- (130) Rate Control in Transdermal Drug Delivery? R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **82**, R1-R6 (1992).
- (131) Iontophoretic Delivery of Piroxicam Across the Skin *In Vitro*. C.L. Gay, P.G. Green, R.H. Guy, and M.L. Francoeur. *J. Control. Release* **22**, 57-68 (1992).
- (132) Routes of Ionic Permeability through Mammalian Skin. R.O. Potts, R.H. Guy, and M.L. Francoeur. *Solid State Ionics* **53-56**, 165-169 (1992).
- (133) Visualization of Iontophoretic Pathways with Confocal Microscopy and the Vibrating Probe Electrode. C. Cullander and R.H. Guy. *Solid State Ionics* **53-56**, 197-206 (1992).
- (134) An Evaluation of Structure-Penetration Relationships in Percutaneous Absorption. G. Ridout, J. Houk, G. Santus, J. Hadgraft, L.L. Hall, and R.H. Guy. *Il Farmaco* **47**, 869-892 (1992).
- (135) Are Water Permeability Measurements Sufficient to Characterize *In Vitro* Cultured Human Skin Surrogates? V.H.W. Mak, A.H. Kennedy, G.M. Golden, M.L. Francoeur, A. Jakowski, R.H. Guy, and C.L. Gay. *J. Toxicol. – Cut. & Ocular Toxicol.* **12**, 139-159 (1993).
- (136) The Influence of Molecular Volume and Hydrogen-Bonding on Peptide Transport Across Epithelial

- Membranes. R.O. Potts and R.H. Guy. *Pharm. Res.* **10**, 635-637 (1993).
- (137) Penetration of Industrial Chemicals Across the Skin. R.H. Guy and R.O. Potts. *Amer. J. Ind. Med.* **23**, 711-719 (1993).
- (138) Uptake of Two Zwitterionic Surfactants into Human Skin *In Vivo*. D.A.W. Bucks, J.J. Hostynek, R.S. Hinz, and R.H. Guy. *Toxicol. Appl. Pharmacol.* **120**, 224-227 (1993).
- (139) Validation of Reflectance Infrared Spectroscopy as a Quantitative Method to Measure Percutaneous Penetration *In Vivo*. N. Higo, A. Naik, D. Bommannan, R.O. Potts, and R.H. Guy. *Pharm. Res.* **10**, 1500-1506 (1993).
- (140) Effect of Current, Ionic Strength and Temperature on the Electrical Properties of Skin. S.Y. Oh, L. Leung, D. Bommannan, R.H. Guy, and R.O. Potts. *J. Control. Release* **27**, 115-125 (1993).
- (141) Convective Solvent Flow Across the Skin During Iontophoresis. A. Kim, P.G. Green, G. Rao, and R.H. Guy. *Pharm. Res.* **10**, 1315-1320 (1993).
- (142) Reverse Iontophoresis: Development of a Noninvasive Approach for Glucose Monitoring. G. Rao, P. Glikfeld and R.H. Guy. *Pharm. Res.* **10**, 1751-1755 (1993).
- (143) Metals and the Skin. J.J. Hostynek, R.S. Hinz, C.R. Lorence, M. Price, and R.H. Guy. *CRC Critical Reviews in Toxicology* **23**, 171-235 (1993).
- (144) Characterization of Low-Temperature (i.e., < 65°C) Lipid Transitions in Human Stratum Corneum. C.L. Gay, R.H. Guy, G.M. Golden, V.H.W. Mak, and M.L. Francoeur. *J. Invest. Dermatol.* **103**, 233-239 (1994).
- (145) The Effect of Oleic Acid and Propylene Glycol on the Electrical Properties of Skin. S.Y. Oh and R.H. Guy. *J. Kor. Pharm. Sci.* **24**, 281-287 (1994).
- (146) What is the Transport-Limiting Barrier in Iontophoresis? P. Singh, R.H. Guy, H.I. Maibach and M.S. Roberts. *Int. J. Pharmaceut.* **101**, R1-R5 (1994).
- (147) Characterization of Convective Solvent Flow During Iontophoresis. M.B. Delgado-Charro and R.H. Guy. *Pharm. Res.* **11**, 929-935 (1994).
- (148) Workshop III Report: Scaleup of Liquid and Semisolid Disperse Systems. G.A. Van Buskirk, V.P. Shah, D. Adair, H.M. Arbit, S.V. Dighe, M. Fawzi, T. Feldman, G.L. Flynn, M.A. González, V.A. Gray, R.H. Guy, *et al.* *Pharm. Res.* **11**, 1216-1220 (1994).
- (149) Effect of Enhancers on the Electrical Properties of Skin: The Effect of Azone and Ethanol. S.Y. Oh and R.H. Guy. *J. Kor. Pharm. Sci.* **24**, S41-S47 (1994).
- (150) Iontophoretic Delivery of Nafarelin Across the Skin. M.B. Delgado-Charro and R.H. Guy. *Int. J. Pharmaceut.*, **117**, 165-172 (1995).
- (151) Iontophoresis of Nicotine *In Vitro*: Pulsatile Drug Delivery Across the Skin? R.M. Brand and R.H. Guy. *J. Control. Release*, **33**, 285-292 (1995).
- (152) Effects of Iontophoresis on the Electrical Properties of Human Skin *In Vivo*. S.Y. Oh and R.H. Guy. *Int. J. Pharmaceut.* **124**: 137-142 (1995).

- (153) Percutaneous Absorption: Physical Chemistry Meets the Skin. R.H. Guy. *Current Probl. Dermatol.* **22**, 132-138 (1995).
- (154) Iontophoresis of Nafarelin: Effects of Current Density and Concentration on Electrotransport *In Vitro*. M.B. Delgado-Charro, A.M. Rodríguez-Bayón and R.H. Guy. *J. Control. Release*, **35**, 35-40 (1995).
- (155) Optimization of *In Vitro* Flux Through Hairless Mouse Skin of Cidofovir, a Potent Nucleotide Analog. E. Aspe, R.H. Guy, W.A. Lee, J.A. Kennedy, G.C. Visor and R.D. Ennis. *J. Pharm. Sci.* **84**, 750-754 (1995).
- (156) Predicting Skin Permeability: II. The Effects of Molecular Size and Hydrogen Bond Activity. R.O. Potts and R.H. Guy. *Pharm. Res.* **12**, 1628-1633 (1995).
- (157) Current Profile Regulates Iontophoretic Delivery of Amino Acids Across the Skin. J. Hirvonen, F. Hueber and R.H. Guy. *J. Control. Release* **37**: 239-249 (1995).
- (158) The Electrical Characteristics of Human Skin *In Vivo*. Y. Kalia and R.H. Guy. *Pharm. Res.* **12**, 1605-1613 (1995).
- (159) A Sweeter Life for Diabetics? R.H. Guy. *Nature Medicine* **1**: 1132-1133 (1995). {News & Views}
- (160) Mechanism of Oleic Acid-Induced Skin Penetration Enhancement *in Vivo* in Humans. A. Naik, L.A.R.M. Pechtold, R.O. Potts and R.H. Guy. *J. Control. Release* **37**, 299-306 (1995).
- (161) Reverse Iontophoresis: Noninvasive Glucose Monitoring *In Vivo* in Humans. G. Rao, R.H. Guy, P. Glikfeld, W.R. LaCourse L. Leung, J. Tamada, R.O. Potts, and N. Azimi. *Pharm. Res.* **12**, 1869-1873 (1995).
- (162) Reverse Iontophoresis - Parameters Determining Electroosmotic Flow: I. pH and Ionic Strength. P. Santi and R.H. Guy. *J. Control. Release* **38**, 159-165 (1996).
- (163) Iontophoresis of Nafarelin Across Human Skin *In Vitro*. A.M. Rodríguez-Bayón and R.H. Guy. *Pharm. Res.* **13**, 798-800, (1996).
- (164) Drug Smuggling - Creative Ways to Cross Biological Barriers. R.H. Guy, Y.N. Kalia, C.S. Lim, L.B. Nonato and N.G. Turner. *Chemistry in Britain* **32**, 42-45 (1996).
- (165) Hypoglycaemia Warning on the Basis of Intracorporal Glucose Monitoring. U. Fischer, I. Bendtson, J. Bolinder, G. Reach and R.H. Guy. *Diabetes, Nutrition & Metabolism* **9**,33-35 (1996).
- (166) Noninvasive Techniques for *In Vivo* Glucose Sensing: Current Prospects. R.H. Guy, R.O. Potts and J.A. Tamada. *Diabetes, Nutrition & Metabolism* **9**, 42-46 (1996).
- (167) Iontophoresis of Bases, Nucleosides and Nucleotides. R. van der Geest, F. Hueber, F.C. Szoka and R.H. Guy. *Pharm. Res.* **13**, 551-556 (1996).
- (168) The Effect of Iontophoresis on Skin Barrier Integrity: Non-invasive Evaluation by Impedance Spectroscopy and Transepidermal Water Loss. Y.N. Kalia, L.B. Nonato and R.H. Guy. *Pharm. Res.* **13**, 958-961, (1996).
- (169) Reverse Iontophoresis - Parameters Determining Electroosmotic Flow: II. Electrode Chamber Formulation. P. Santi and R.H. Guy. *J. Control. Release* **42**, 29-36 (1996).

- (170) Characterization of Human Air-Liquid Epidermal Keratinocyte Cultures. V.H.W. Mak, A.H. Kennedy, A. Jakowski, G.M. Golden, C.L. Gay, R.H. Guy, and M.L. Francoeur. *Pharm. Res.* **13**, 1162-1167 (1996).
- (171) Current Status and Future Prospects of Transdermal Drug Delivery. R.H. Guy. *Pharm. Res.* **13**, 1765-1769 (1996).
- (171a) Controlled Release Technologies: Current Status and Future Prospects. R. Guy, M. Powell, J. Fix and K. Park. *Pharm. Res.* **13**, 1759 (1996).
- (172) Homogeneous Transport in a Heterogeneous Membrane: Water Diffusion Across Human Stratum Corneum *In Vivo*. Y.N. Kalia, F. Pirot and R.H. Guy. *Biophys. J.* **71**, 2692-2700 (1996).
- (173) Imaging Regions of Transport Across Human Stratum Corneum During High-Voltage and Low-Voltage Exposures. M.R. Prausnitz, J.A. Gimm, R.H. Guy, R. Langer, J.C. Weaver and C. Cullander. *J. Pharm. Sci.* **85**, 1363-1370 (1996).
- (174) Transdermal Delivery of Peptides by Iontophoresis. J. Hirvonen, Y.N. Kalia and R.H. Guy. *Nature Biotech.* **14**, 1710-1713 (1996).
- (175) Metabolic Approaches to Enhance Transdermal Drug Delivery. I. Effect of Lipid Synthesis Inhibitors. J-C. Tsai, R.H. Guy, C.R. Thornfeldt, K.R. Feingold and P.M. Elias. *J. Pharm. Sci.*, **85**, 643-648 (1996).
- (175a) Methods for Assessing Percutaneous Absorption. D. Howes, R. Guy, J. Hadgraft, J. Heylings, F. Kemper, H. Maibach, J.-P. Marty, H. Merk, J. Parra, D. Rekkas, I. Rondelli, H. Schaefer, U. Täuber, N. Verbiese. *ATLA* **24**: 81-106 (1996).
- (176) Characterization of the Permeability Barrier of Human Skin *In Vivo*. F. Pirot, Y.N. Kalia, A.L. Stinchcomb, G. Keating, A.L. Bunge and R.H. Guy. *Proc. Natl. Acad. Sci., USA* **94**, 1562-1567 (1997).
- (177) Interaction between Penetration Enhancers and Iontophoresis: Effect on Human Skin Impedance *In Vivo*. Y.N. Kalia and R.H. Guy. *J. Control. Release* **44**, 33-42 (1997).
- (178) Acute Effects of Iontophoresis on Human Skin *In Vivo*. R.M. Brand, P. Singh, E. Aspe-Carranza, H.I. Maibach and R.H. Guy. *Eur. J. Pharm. Biopharm.* **43**, 133-138 (1997).
- (179) Delivery of a Hydrophilic Solute Through the Skin from Novel Microemulsion Systems. M.B. Delgado-Charro, G. Iglesias-Vilas, J. Blanco-Méndez, M.A. López-Quintela, J-P. Marty and R.H. Guy. *Eur. J. Pharm. Biopharm.* **43**, 37-42 (1997).
- (180) Iontophoretic Delivery Across the Skin: Electroosmosis and its Modulation by Drug Substances. J. Hirvonen and R.H. Guy. *Pharm. Res.*, **14**, 1258-1263 (1997).
- (181) Iontophoretic Transport Pathways: Dependence on Penetrant Physicochemical Properties. N.G. Turner and R.H. Guy. *J. Pharm. Sci.*, **86**, 1385-1389 (1997).
- (182) Iontophoresis of Poly-L-Lysines: the Role of Molecular Weight? N.G. Turner, L. Ferry, M. Price, C. Cullander and R.H. Guy. *Pharm. Res.*, **14**, 1322-1331 (1997).
- (183) The Effect of Current on Skin Barrier Function *in vivo*: Recovery Kinetics Post-Iontophoresis. N.G. Turner, Y.N. Kalia and R.H. Guy. *Pharm. Res.*, **14**, 1252-1257 (1997).
- (184) Transdermal Therapy and Diagnosis by Iontophoresis. V. Merino, Y.N. Kalia, R.H. Guy. *Trends in*

- Biotechnology* **15**: 288-290 (1997).
- (185) Transdermal and Skin-Targeted Drug Delivery V. Merino, I. Alberti, Y.N. Kalia, R.H. Guy. *Journal of Cutaneous Medicine & Surgery* **2**: 108-119 (1997).
- (185a) Transdermal Iontophoresis: Modulation of Electroosmosis by Polypeptides. J. Hirvonen and R.H. Guy. *J. Control. Release*, **50**: 283-289 (1998).
- (186) Iontophoresis of Monomeric Insulin Analogues *in vitro*: Effects of Insulin Charge and Skin Pretreatment. L. Langkjær, J. Brange, G.M. Grodsky and R.H. Guy. *J. Control. Release*, **51**: 47-56 (1998).
- (187) Transdermal Drug Delivery: Clinical Aspects. Y.N. Kalia, V. Merino, R.H. Guy. *Dermatologic Clinics* **16**: 289-299 (1998).
- (188) Stratum Corneum Thickness and Apparent Water Diffusivity: Facile and Noninvasive Quantitation In Vivo. F. Pirot, E. Berardesca, Y.N. Kalia, M. Singh, H.I. Maibach and R.H. Guy. *Pharm. Res.*, **15**, 490-492 (1998).
- (189) Iontophoresis - Recent Developments. R.H. Guy. *J. Pharm. Pharmacol.* **50**: 371-374 (1998).
- (190) Iontophoretic Permselectivity of Mammalian Skin: Characterization of Hairless Mouse and Porcine Membrane Models. A. Luzardo-Alvarez, M. Rodríguez-Fernández, J. Blanco-Méndez, R.H. Guy and M.B. Delgado-Charro. *Pharm. Res.*, **15**: 984-987 (1998).
- (191) Development of Skin Barrier Function in Premature Infants. Y.N. Kalia, L.B. Nonato, C.H. Lund and R.H. Guy. *J. Invest. Dermatol.* **111**: 320-326 (1998).
- (192) Visualization and Quantitation of Iontophoretic Pathways Using Confocal Microscopy. N.G. Turner and R.H. Guy. *J. Invest. Dermatol. Symp. Proc.* **3**: 136-142 (1998).
- (193) Determination of the pH Gradient Across the Stratum Corneum. N.G. Turner, C. Cullander and R.H. Guy. *J. Invest. Dermatol. Symp. Proc.* **3**: 110-113 (1998).
- (194) Ion Mobility Across Human Stratum Corneum In Vivo. Y.N. Kalia, F. Pirot, R.O. Potts and R.H. Guy. *J. Pharm. Sci.* **87**: 1508-1511 (1998).
- (195) Percutaneous Penetration and Transdermal Drug Delivery. M.B. Delgado-Charro and R.H. Guy. *Progress in Dermatology* **32**: 1-12 (1998).
- (196) Blockage of Skin Invasion by Schistosome Cercariae by Serine Protease Inhibitors. K.C. Lim, E. Sun, M. Bahgat, D. Bucks, R. Guy, R.S. Hinz, C. Cullander and J.H. McKerrow. *Am. J. Trop. Med. Hyg.* **60**: 487-492 (1999).
- (197) Electrorepulsion versus Electroosmosis: Effect of pH on the Iontophoretic Flux of 5-Fluorouracil. V. Merino, A. López, Y.N. Kalia and R.H. Guy. *Pharm. Res.* **16**: 758-761 (1999).
- (198) The Determination of a Diffusion Pathlength through the Stratum Corneum. A.L. Bunge, R.H. Guy and J. Hadgraft. *Int. J. Pharmaceut.* **188**: 121-124 (1999).
- (199) Noninvasive Sampling of Phenylalanine by Reverse Iontophoresis. V. Merino, A. López, D. Hochstrasser and R.H. Guy. *J. Control. Release* **61**: 65-69 (1999).



- (200) Chemical Uptake into Human Stratum Corneum *In Vivo* from Volatile and Non-volatile Solvents. A.L. Stinchcomb, F. Pirot, G.D. Touraille, A.L. Bunge and R.H. Guy. *Pharm. Res.* **16**: 1288-1293 (1999).
- (201) Iontophoresis: Electrorepulsion and Electroosmosis. R.H. Guy, Y.N. Kalia, M.B. Delgado-Charro, V. Merino, A. Lopéz and D. Marro. *J. Control. Release*, **64**: 129-132 (2000).
- (202) Transepidermal water loss in 24 and 25 weeks gestational age infants. L.B. Nonato, C.H. Lund, Y.N. Kalia, R.H. Guy. *Acta Paediatr.*, **89**: 747-748 (2000).
- (203) Recovery of Human Skin Impedance *In Vivo* After Iontophoresis: Effect of Metal Ions. C. Curdy, Y.N. Kalia, F. Falson-Rieg, R.H. Guy. *AAPS Pharmsci* 2000; **2 (3)** article 23 (<http://www.pharmsci.org/>)
- (204) Transdermal Drug Delivery: Overcoming the Skin's Barrier Function. A. Naik, Y.N. Kalia and R.H. Guy. *Pharm.Sci. Tech. Today*, **3**: 318-326 (2000).
- (205) Normalization of Stratum Corneum Barrier Function and Transepidermal Water Loss *In Vivo*. Y.N. Kalia, I. Alberti, N. Sekkat, C. Curdy, A. Naik and R.H. Guy. *Pharm. Res.* **17**: 1148-1150 (2000).
- (206) Does Epidermal Turnover Reduce Percutaneous Penetration? M.B. Reddy, R.H. Guy and A.L. Bunge. *Pharm. Res.* **17**: 1414-1419 (2000).
- (207) Permeation Enhancement of a Highly Lipophilic Drug Using Supersaturated Systems. K. Moser, K. Kriwet, C. Froehlich, A. Naik, Y.N. Kalia and R.H. Guy. *J. Pharm. Sci.*, **90**: 607-616 (2001).
- (208) Characterization of the Iontophoretic Permselectivity Properties of Human and Pig Skin. D. Marro, R.H. Guy and M.B. Delgado-Charro. *J. Control. Release*, **70**: 213-217 (2001).
- (209) Iontophoretic Delivery of 5-Aminolevulinic Acid (ALA): Effect of pH. R.F.V. Lopez, M.V.L.B. Bentley, M.B. Delgado-Charro and R.H. Guy. *Pharm. Res.*, **18**: 311-315 (2001).
- (210) Noninvasive Assessment of the Effects of Iontophoresis on Human Skin *In Vivo*. C. Curdy, Y.N. Kalia and R.H. Guy. *J. Pharm. Pharmacol.*, **53**: 769-777 (2001).
- (211) *In Vivo* Assessment of the Enhanced Topical Delivery of Terbinafine to Human Stratum Corneum. I. Alberti, Y.N. Kalia, A. Naik, J.-D. Bonny and R.H. Guy. *J. Control. Release*, **71**: 319-327 (2001).
- (212) Effect of Ethanol and Isopropyl Myristate on the Bioavailability of Topical Terbinafine to Human Stratum Corneum *in Vivo*. I. Alberti, Y.N. Kalia, A. Naik, J.-D. Bonny and R.H. Guy. *Int. J. Pharm.*, **219**: 11-19 (2001).
- (213) Supersaturation: Enhancement of Skin Penetration and Permeation of a Lipophilic Drug. K. Moser, K. Kriwet, C. Froehlich, Y.N. Kalia and R.H. Guy. *Pharm. Res.*, **18**: 1006-1011 (2001).
- (214) Modeling Transdermal Release. Y.N. Kalia and R.H. Guy. *Adv. Drug Delivery Rev.*, **48**: 159-172 (2001).
- (215) Enhanced Skin Permeation of a Lipophilic Drug Using Supersaturated Formulations. K. Moser, K. Kriwet, Y.N. Kalia and R.H. Guy. *J. Control. Release*, **73**: 245-253 (2001).
- (216) Assessment and Prediction of the Cutaneous Bioavailability of Topical Terbinafine *in vivo*, in Man. I. Alberti, Y.N. Kalia, A. Naik, J.-D. Bonny and R.H. Guy. *Pharm. Res.*, **18**: 1472-1475 (2001).
- (217) Passive Skin Penetration Enhancement and its Quantification *In Vivo*. K. Moser, K. Kriwet, A. Naik,

- Y.N. Kalia and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **52**: 103-112 (2001).
- (218) Stabilization of Supersaturated Solutions of a Lipophilic Drug for Dermal Delivery. K. Moser, K. Kriwet, Y.N. Kalia and R.H. Guy. *Int. J. Pharm.*, **224**: 169-176 (2001).
- (219) Piroxicam Delivery into Human Stratum Corneum *In Vivo*: Iontophoresis versus Passive Diffusion. C. Curdy, Y.N. Kalia, A. Naik and R.H. Guy. *J. Control. Release*, **76**: 73-79 (2001).
- (220) Contributions of Electromigration and Electroosmosis to Iontophoretic Drug Delivery. D. Marro, Y.N. Kalia, M.B. Delgado-Charro and R.H. Guy. *Pharm. Res.*, **18**: 1701-1708 (2001).
- (221) Optimizing Iontophoretic Drug Delivery: Identification and Distribution of the Charge-Carrying Species. D. Marro, Y.N. Kalia, M.B. Delgado-Charro and R.H. Guy. *Pharm. Res.*, **18**: 1709-1713 (2001).
- (222) Iontophoretic Transport across the Skin. R.H. Guy, M.B. Delgado-Charro and Y.N. Kalia. *Skin Pharmacol. Appl. Skin Physiol.*, **14 (suppl.1)**: 35-40 (2001).
- (223) Assessment of Topical Bioavailability *In Vivo*: The Importance of Stratum Corneum Thickness. Y.N. Kalia, I. Alberti, A. Naik and R.H. Guy. *Skin Pharmacol. Appl. Skin Physiol.*, **14 (suppl.1)**: 82-86 (2001).
- (224) Biodegradable Polymer Nanocapsules Containing a Sunscreen Agent: Preparation and Photoprotection. R. Alvarez-Román, G. Barré, R.H. Guy and H. Fessi. *Eur. J. Pharm. Biopharm.*, **52**: 191-195 (2001).
- (225) Permeation of a Myristoylated Dipeptide Across the Buccal Mucosa: Topological Distribution and Evaluation of Tissue Integrity. F. Veuillez, F. Falson-Rieg, R.H. Guy, J. Deshusses and P. Buri. *Int. J. Pharm.*, **231**: 1-9 (2002).
- (226) Transdermal Iontophoresis for Controlled Drug Delivery and Non-invasive Monitoring. M.B. Delgado-Charro and R.H. Guy. *STP Pharma*, **11**: 403-414 (2001).
- (227) Determining Dermal Absorption Parameters *In Vivo* from Tape Strip Data. M.B. Reddy, A.L. Stinchcomb, R.H. Guy and A.L. Bunge. *Pharm. Res.*, **19**: 292-298 (2002).
- (228) Post-Iontophoresis Recovery of Human Skin Impedance *In Vivo*. C. Curdy, Y.N. Kalia and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **53**: 15-21 (2002).
- (229) *In Vivo* Assessment of Skin Electroporation Using Square Wave Pulses. N. Dujardin, E. Staes, Y. Kalia, P. Clarys, R. Guy and V. Pr at. *J. Control. Release*, **79**: 219-227 (2002).
- (230) Reverse Iontophoretic Monitoring in Premature Neonates: Feasibility and Potential. N. Sekkat, A. Naik, Y.N. Kalia, P. Glikfeld and R.H. Guy. *J. Control. Release*, **81**: 83-89 (2002).
- (231) A Biophysical Study of Porcine Ear Skin *In Vitro* and its Comparison to Human Skin *In Vivo*. N. Sekkat, Y.N. Kalia and R.H. Guy. *J. Pharm. Sci.*, **91**: 2376-2381 (2002).
- (232) Quantitative Structure-Permeation Relationships for Solute Transport across Silicone Membranes. S. Geinoz, S. Rey, G. Boss, A.L. Bunge, R.H. Guy, P.-A. Carrupt, M. Reist and B. Testa. *Pharm. Res.*, **19**: 1622-1629 (2002).
- (233) Frequency and Thermal Effects on the Enhancement of Transdermal Transport by Sonophoresis. G. Merino, Y.N. Kalia, M.B. Delgado-Charro, R.O. Potts and R.H. Guy. *J. Control. Release*, **88**: 85-94

- (2003).
- (234) Ultrasound-Enhanced Transdermal Transport. G. Merino, Y.N. Kalia and R.H. Guy. *J. Pharm. Sci.*, **92**: 1125-1137 (2003).
- (235) Skin Permeability Enhancement by Low-Frequency Sonophoresis: Lipid Extraction and Transport Pathways. R. Alvarez-Román, G. Merino, Y.N. Kalia, A. Naik and R.H. Guy. *J. Pharm. Sci.*, **92**: 1138-1146 (2003).
- (236) Optimization of Aminolevulinic acid (ALA) Delivery by Iontophoresis. R.F.V. Lopez, M.V.L.B. Bentley, M.B. Delgado-Charro and R.H. Guy. *J. Control. Release*, **88**: 65-70 (2003).
- (237) Enhanced Delivery of 5-Aminolevulinic Acid Esters by Iontophoresis *In Vitro*. R.F.V. Lopez, M.V.L.B. Bentley, M.B. Delgado-Charro, D. Salomon, H. van den Bergh, N. Lange and R.H. Guy. *Photochem. Photobiol.*, **77**: 304-308 (2003).
- (238) Transdermal Reverse Iontophoresis of Valproate: A Non-invasive Method for Therapeutic Drug Monitoring. M.B. Delgado-Charro and R.H. Guy. *Pharm. Res.*, **20**: 1508-1513 (2003).
- (239) Reverse Iontophoresis for Noninvasive Glucose Monitoring: The Internal Standard Concept. A. Sieg, R.H. Guy and M.B. Delgado-Charro. *J. Pharm. Sci.*, **92**: 2295-2302 (2003).
- (240) Iontophoretic Drug Delivery. Y.N. Kalia, A. Naik, J. Garrison and R.H. Guy. *Adv. Drug Deliv. Rev.* **56**: 619-658 (2004).
- (241) Quantitative Structure-Permeation Relationships (QSPeRs) to Predict Skin Permeation: A Critical Evaluation. S. Geinoz, R.H. Guy, P.-A. Carrupt and B. Testa. *Pharm. Res.*, **21**: 83-92 (2004).
- (242) Noninvasive Assessment of the Effect of Formulation Excipients on Stratum Corneum Barrier Function *In Vivo*. C. Curdy, A. Naik, Y.N. Kalia, I. Alberti and R.H. Guy. *Int. J. Pharm.*, **271**: 251-256 (2004).
- (243) Photodynamic Therapy of Skin Cancer: Controlled Drug Delivery of 5-ALA and its Esters. R.F.V. Lopez, N. Lange, R.H. Guy and M.V.L.B. Bentley. *Adv. Drug Deliv. Rev.* **56**: 77-94 (2004).
- (244) Reverse Iontophoresis for Non-Invasive Transdermal Monitoring. B. Leboulanger, R.H. Guy and M.B. Delgado-Charro. *Physiol. Measure.* **25**: R35-R50 (2004).
- (245) Non-invasive Glucose Monitoring by Reverse Iontophoresis *In Vivo*: Application of the Internal Standard Concept. A. Sieg, R.H. Guy and M.B. Delgado-Charro. *Clin. Chem.*, **50**: 1383-1390 (2004).
- (246) Reverse Iontophoresis as a Non-Invasive Tool for Lithium Monitoring and Pharmacokinetic Profiling. B. Leboulanger, R.H. Guy and M.B. Delgado-Charro. *Pharm. Res.*, **21**: 1214-1222 (2004).
- (247) Visualization of Skin Penetration Using Confocal Laser Scanning Microscopy. R. Alvarez-Román, A. Naik, Y.N. Kalia, H. Fessi and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **58**: 301-316 (2004).
- (248) Non-Invasive Monitoring of Phenytoin by Reverse Iontophoresis. B. Leboulanger, R.H. Guy and M.B. Delgado-Charro. *Eur. J. Pharm. Sci.*, **22**: 427-433 (2004).
- (249) Enhancement of Topical Delivery of a Lipophilic Drug from Biodegradable Nanoparticles. R. Alvarez-Román, A. Naik, Y.N. Kalia, R.H. Guy and H. Fessi. *Pharm. Res.*, **21**: 1818-1825 (2004).

- (250) Skin Penetration and Distribution of Fluorescent Nanoparticles. R. Alvarez-Román, A. Naik, Y.N. Kalia, R.H. Guy and H. Fessi. *J. Control. Release*, **99**: 53-62 (2004).
- (251) Lithium Monitoring by Reverse Iontophoresis *In Vivo*. B. Leboulanger, J-M. Aubry, G. Bandolfi, R.H. Guy and M.B. Delgado-Charro. *Clin. Chem.*, **50**: 2091-2100 (2004).
- (252) Porcine Ear Skin as a Model for the Assessment of Transdermal Drug Delivery to Premature Neonates. N. Sekkat, Y.N. Kalia and R.H. Guy. *Pharm. Res.*, **21**: 1390-1397 (2004).
- (253) Development of an In Vitro Model for Premature Neonatal Skin: Biophysical Characterization Using Transepidermal Water Loss. N. Sekkat, Y.N. Kalia and R.H. Guy. *J. Pharm. Sci.*, **93**: 2936-2940 (2004).
- (254) Transdermal Delivery from a Lipid Sponge Phase - Iontophoretic and Passive Transport in vitro of 5-Aminolevulinic Acid and its Methyl Ester. N. Merclin, J. Bender, E. Sparr, R.H. Guy, H. Ehrsson and S. Engström. *J. Control. Release*, **100**: 191-198 (2004).
- (255) Electroosmosis in Transdermal Iontophoresis: Implications for Non-invasive and Calibration-free Glucose Monitoring. A. Sieg, R.H. Guy and M.B. Delgado-Charro. *Biophys. J.*, **87**: 3344-3350 (2004).
- (256) Simultaneous Extraction of Urea and Glucose by Reverse Iontophoresis In Vivo. A. Sieg, R.H. Guy and M.B. Delgado-Charro. *Pharm. Res.*, **21**: 1805-1810 (2004).
- (256a) Biotechnological Aspects of Transport Across Human Skin. J. Hadgraft and R.H. Guy. *Biotech. Genet. Eng. Rev.*, **21**: 183-193 (2004).
- (257) Reverse Iontophoresis of Lithium: Electrode Formulation Using a Thermoreversible Polymer. V. Wascotte, B. Leboulanger, R.H. Guy and M.B. Delgado-Charro. *Eur. J. Pharm. Biopharm.*, **59**: 237-240 (2005).
- (258) Noninvasive and Minimally Invasive Methods for Transdermal Glucose Monitoring. A. Sieg, R.H. Guy and M.B. Delgado-Charro. *Diabet. Tech. Therap.*, **7**: 174-197 (2005).
- (259) Percutaneous Absorption of 4-Cyanophenol from Freshly Contaminated Soil In Vitro: Effects of Soil Loading and Contaminant Concentration. G.D. Touraille, K.D. McCarley, A.L. Bunge, J.-P. Marty and R.H. Guy. *Environ. Sci Tech.*, **39**: 3723-3731 (2005).
- (260) Ultrasound-Mediated Gene Delivery: Kinetics of Plasmid Internalization and Gene Expression. S. Mehier-Humbert, T. Bettinger, F. Yan and R.H. Guy. *J. Control. Release*, **104**: 203-211 (2005).
- (261) Plasma Membrane Poration Induced by Ultrasound Exposure: Implication for Drug Delivery. S. Mehier-Humbert, T. Bettinger, F. Yan and R.H. Guy. *J. Control. Release*, **104**: 213-222 (2005).
- (262) Physical Methods for Gene Transfer: Improving the Kinetics of Gene Delivery into Cells. S. Mehier-Humbert and R.H. Guy. *Adv. Drug Delivery Rev.*, **57**: 733-753 (2005).
- (263) Emerging Strategies for the Transdermal Delivery of Peptide and Protein Drugs. Y.B. Schuetz, A. Naik, R.H. Guy, and Y.N. Kalia. *Expert Opin. Drug Delivery*, **2**: 533-548 (2005).
- (264) Transdermal Iontophoretic Delivery of Vapreotide Acetate across Porcine Skin In Vitro. Y.B. Schuetz, A. Naik, R.H. Guy, E. Vuaridel and Y.N. Kalia. *Pharm. Res.*, **22**: 1305-1312 (2005).
- (265) Transdermal Iontophoretic Delivery of Triptorelin (Decapeptyl®). Y.B. Schuetz, A. Naik, R.H. Guy, E.

- Vuaridel and Y.N. Kalia. *J. Pharm. Sci.*, **94**: 2175-2182 (2005).
- (266) Effect of Amino Acid Sequence on Transdermal Iontophoretic Peptide Delivery. Y.B. Schuetz, A. Naik, R.H. Guy, and Y.N. Kalia. *Eur. J. Pharm. Sci.*, **26**: 429-437 (2005).
- (267) Comparison of the Lipid Composition of Porcine Buccal and Esophageal Permeability Barriers. I. Diaz del Consuelo, G.-P. Pizzolato, Y. Jacques, R.H. Guy and F. Falson. *Arch. Oral Biol.*, **50**: 981-987 (2005).
- (268) Transport of Fentanyl through Pig Buccal and Esophageal Epithelia *In Vitro*. Influence of Concentration and Vehicle pH. I. Diaz del Consuelo, F. Falson, R.H. Guy and Y. Jacques. *Pharm. Res.*, **22**: 1525-1529 (2005).
- (269) Evaluation of Pig Esophageal Mucosa as a Permeability Barrier Model for Buccal Tissue. I. Diaz del Consuelo, G.-P. Pizzolato, F. Falson, R.H. Guy and Y. Jacques. *J. Pharm. Sci.*, **94**: 2677-2688 (2005).
- (270) Capillary Zone Electrophoresis for the Estimation of Transdermal Iontophoretic Mobility. N. Abla, L. Geiser, M. Mirgaldi, A. Naik, J.-L. Veuthey, R.H. Guy, Y.N. Kalia. *J. Pharm. Sci.*, **94**: 2667-2675 (2005).
- (271) Contributions of Electromigration and Electroosmosis to Peptide Iontophoresis across Intact and Impaired Skin. N. Abla, A. Naik, R.H. Guy and Y.N. Kalia. *J. Control. Release*, **108**: 319-330 (2005).
- (272) Effect of Charge and Molecular Weight on Transdermal Peptide Delivery by Iontophoresis. N. Abla, A. Naik, R.H. Guy and Y.N. Kalia. *Pharm. Res.*, **22**: 2069-2078 (2005).
- (273) Electromigration of Ions Across the Skin: Determination and Prediction of Transport Numbers. B. Mudry, R.H. Guy, M.B. Delgado-Charro. *J. Pharm. Sci.*, **95**: 561-569 (2006).
- (274) Prediction of Iontophoretic Transport Across the Skin. B. Mudry, R.H. Guy, M.B. Delgado-Charro. *J. Control. Release*, **111**: 362-367 (2006).
- (275) Transport Numbers in Transdermal Iontophoresis. B. Mudry, R.H. Guy, M.B. Delgado-Charro. *Biophys. J.*, **90**: 2822-2830 (2006).
- (276) Testosterone Hormone Replacement Therapy: State-of-the-Art and Emerging Technologies. M.-L. Leichtnam, H. Rolland, P. Wüthrich and R.H. Guy. *Pharm. Res.*, **23**: 1117-1132 (2006).
- (277) Formulation and Evaluation of a Testosterone Transdermal Spray. M.-L. Leichtnam, H. Rolland, P. Wüthrich and R.H. Guy. *J. Pharm. Sci.*, **95**: 1693-1702 (2006).
- (278) Identification of Penetration Enhancers for Testosterone Transdermal Delivery from Spray Formulations. M.-L. Leichtnam, H. Rolland, P. Wüthrich and R.H. Guy. *J. Control. Release*, **113**: 57-62 (2006).
- (279) Impact of Antinucleants on Transdermal Delivery of Testosterone from a Spray. M.-L. Leichtnam, H. Rolland, P. Wüthrich and R.H. Guy. *J. Pharm. Sci.*, **96**: 84-92 (2007).
- (280) Enhancement of Transdermal Testosterone Delivery by Supersaturation. M.-L. Leichtnam, H. Rolland, P. Wüthrich and R.H. Guy. *J. Pharm. Sci.*, **95**: 2373-2379 (2006).
- (281) Structure-Permeation Relationships for the Non-Invasive Transdermal Delivery of Cationic Peptides by Iontophoresis. Y.B. Schuetz, A. Naik, R.H. Guy, and Y.N. Kalia. *Eur. J. Pharm. Sci.*, **29**: 53-59 (2006).

- (282) Pig Ear Skin *ex vivo* as a Model for *in vivo* Dermatopharmacokinetic Studies in Man. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft and R.H. Guy. *Pharm. Res.*, **23**: 1850-1856 (2006).
- (283) Ibuprofen Transport into and through Skin from Topical Formulations: *in vitro* – *in vivo* Comparison. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft and R.H. Guy. *J. Invest. Dermatol.*, **127**: 135-142 (2007).
- (284) Topical Iontophoresis of Valaciclovir Hydrochloride Improves Cutaneous Aciclovir Delivery. N. Abla, A. Naik, R.H. Guy and Y.N. Kalia. *Pharm. Res.*, **23**: 1842-1849 (2006).
- (285) Dermatopharmacokinetic Prediction of Topical Drug Bioavailability *in vivo*. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft and R.H. Guy. *J. Invest. Dermatol.*, **127**: 887-894 (2007).
- (286) Monitoring of Urea and Potassium by Reverse Iontophoresis *in vitro*. V. Wascotte, M.B. Delgado-Charro, E. Rozet, P. Wallemacq, P. Hubert, R.H. Guy and V. Pr at. *Pharm. Res.*, **24**: 1131-1137 (2007).
- (287) Quantitative Structure-Permeation Relationship for Iontophoretic Transport across the Skin. B. Mudry, P.A. Carrupt, R.H. Guy, and M.B. Delgado-Charro. *J. Control. Release*, **122**: 165-167 (2007).
- (288) Ultrasound-mediated Gene Delivery: Influence of Contrast Agent on Transfection. S. Mehier-Humbert, F. Yan, P. Frinking, M. Schneider, R.H. Guy and T. Bettinger. *Bioconj. Chem.*, **18**: 652-662 (2007).
- (289) Transdermal Science and Technology - an Update. R.H. Guy. *Drug Delivery System*, **22**: 442-449 (2007).
- (290) Reverse Iontophoresis of L-Lactate: *in vitro* and *in vivo* Studies. S. Nixon, A. Sieg, M.B. Delgado-Charro and R.H. Guy. *J. Pharm. Sci.*, **96**: 3457-3465 (2007).
- (291) Assessment of the "Skin Reservoir" of Urea by Confocal Raman Microspectroscopy and Reverse iontophoresis *in vivo*. V. Wascotte, P. Caspers, J. de Sterke, M. Jadoul, R.H. Guy and V. Pr at. *Pharm. Res.*, **24**: 1897-1901 (2007).
- (292) *Ex vivo* Evaluation of Bioadhesive Films for Buccal Delivery of Fentanyl. I. Diaz del Consuelo, G.-P. Pizzolato, F. Falson, R.H. Guy and Y. Jacques. *J. Control. Release*, **122**: 135-140 (2007).
- (293) Application of the Threshold of Toxicological Concern (TTC) to the Safety Evaluation of Cosmetic Ingredients. R. Kroes, A.G. Renwick, V. Feron, C.L. Galli, M. Gibney, H. Greim, R.H. Guy, J.C. Lhuguenot, and J. van de Sandt. *Food Chem. Toxicol.*, **45**: 2533-2562 (2007).
- (294) Effect of Propylene Glycol on Ibuprofen Absorption into Human Skin *in vivo*. C. Herkenne, A. Naik, Y.N. Kalia, J. Hadgraft and R.H. Guy. *J. Pharm. Sci.*, **97**: 185-197 (2008).
- (295) Novel Beads Made of Alpha-Cyclodextrin and Oil for Topical Delivery of a Lipophilic Drug. L. Trichard, M.B. Delgado-Charro, R.H. Guy, E. Fattal, and A. Bochot. *Pharm Res.*, **25**: 435-440 (2008).
- (296) *In vivo* Methods for the Assessment of Topical Drug Bioavailability. C. Herkenne, I. Alberti, A. Naik, Y.N. Kalia, F.-X. Mathy, V. Pr at, and R.H. Guy. *Pharm. Res.*, **25**: 87-103 (2008).
- (297) Bioavailability and Bioequivalence of Topical Glucocorticoids. S. Wiedersberg, C.S. Leopold, and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **68**: 453-466 (2008).
- (298) Non-invasive Diagnosis and Monitoring of Chronic Kidney Disease by Reverse Iontophoresis of Urea

- in vivo*. V. Wascotte, E. Rozet, A. Salvaterra, O. Devuyt, R.H. Guy, P. Hubert, M. Jadoul and V. Pr at. *Eur. J. Pharm. Biopharm.*, **69**: 1077-1082 (2008).
- (299) *In Vivo* Infrared Spectroscopy Studies of Solvent Effects on Human Skin. M. Dias, A. Naik, R.H. Guy, J. Hadgraft and M.E. Lane. *Eur. J. Pharm. Biopharm.*, **69**: 1171-1175 (2008).
- (300) Optimizing Metrics for the Assessment of Bioequivalence between Topical Drug Products. B. N'Dri-Stempfer; W.C. Navidi; R.H. Guy; A.L. Bunge. *Pharm. Res.*, **25**: 1621-30 (2008).
- (301) *In Vitro* Optimization of Dexamethasone Phosphate Delivery by Iontophoresis. J.-P. Sylvestre, R.H. Guy and M.B. Delgado-Charro. *Phys. Ther.*, **88**: 1177-1185 (2008).
- (302) Iontophoresis of Dexamethasone Phosphate: Competition with Chloride Ions. J.-P. Sylvestre, C. D az-Mar n, M.B. Delgado-Charro and R.H. Guy. *J. Control. Release*, **131**: 41-46 (2008).
- (303) Extraction of Amino Acids by Reverse Iontophoresis: Simulation of Therapeutic Monitoring *in vitro*. A. Sieg, F. Jeanneret, M. Fathi, D. Hochstrasser, S. Rudaz, J.-L. Veuthey, R.H. Guy, M.B. Delgado-Charro. *Eur. J. Pharm. Biopharm.*, **70**: 908-913 (2008).
- (304) Influence of Ethanol on the Solubility, Ionisation and Permeation Characteristics of Ibuprofen in Silicone and Human Skin. R.M. Watkinson, C. Herkenne, R.H. Guy, J. Hadgraft, G. Oliveira and M.E. Lane. *Skin Physiol. Pharmacol.*, **22**: 15-21 (2009).
- (305) Prediction of Chemical Absorption into and through the Skin from Cosmetic and Dermatological Formulations. S. Gr goire, C. Ribaud, F. Benech, J.R. Meunier, A. Garrigues-Mazert and R.H. Guy. *Brit. J. Dermatol.*, **160**: 80-91 (2009).
- (306) Pharmacodynamics and Dermatopharmacokinetics of Betamethasone-17-Valerate: Assessment of Topical Bioavailability. S. Wiedersberg, A. Naik, C.S. Leopold, R.H. Guy. *Brit. J. Dermatol.*, **160**: 676-686 (2009).
- (307) Dermatopharmacokinetics of Betamethasone-17-valerate: Influence of Formulation Viscosity and Skin Surface Cleaning Procedure. S. Wiedersberg, C.S. Leopold and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **71**: 362-366 (2009).
- (308) Improved Bioequivalence Assessment of Topical Dermatological Drug Products Using Dermatopharmacokinetics. B. N'Dri-Stempfer, W.C. Navidi, R.H. Guy, and A.L. Bunge. *Pharm. Res.*, **26**: 316-328 (2009).
- (309) Dermatopharmacokinetics: Factors Influencing Drug Clearance from the Stratum Corneum. S. Nicoli, A.L. Bunge, M.B. Delgado-Charro and R.H. Guy. *Pharm. Res.*, **26**: 865-71 (2009).
- (310) Effects of Various Vehicles on Skin Hydration *in vivo*. S. Wiedersberg, C.S. Leopold and R.H. Guy. *Skin Physiol. Pharmacol.*, **22**: 128-130 (2009).
- (311) Dye Diffusion from Microcapsules with Different Shell Thickness into Mammalian Skin. H.N. Yow, X. Wu, A.F. Routh, and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **72**: 62-68 (2009).
- (312) Extraction of Amino Acids by Reverse Iontophoresis *in vivo*. A. Sieg, F. Jeanneret, M. Fathi, D. Hochstrasser, S. Rudaz, J.-L. Veuthey, R.H. Guy, M.B. Delgado-Charro. *Eur. J. Pharm. Biopharm.*, **72**: 226-231 (2009).
- (313) Influence of Polymer Adjuvants on the Ultrasound-Mediated Transfection of Cells in Culture. S.

- Mehier-Humbert, T. Bettinger, F. Yan, and R.H. Guy. *Eur. J. Pharm. Biopharm.*, **72**: 567-573 (2009).
- (314) Measurement and Prediction of the Rate and Extent of Drug Delivery into and through the Skin. L.M. Russell and R.H. Guy. *Expert Opin. Drug. Deliv.*, **6**: 355-369 (2009).
- (315) Epidermal Barrier Dysfunction in Atopic Dermatitis. M.J. Cork, S.G. Danby, Y. Vasilopoulos, J. Hadgraft, M.E. Lane, M. Moustafa, R.H. Guy, A. MacGowan, R. Tazi-Ahnini and S.J. Ward. *J. Invest. Dermatol.*, **129**: 1892-1908 (2009).
- (316) Drug Delivery to the Skin from Sub-micron Polymeric Particle Formulations: Influence of Particle Size and Polymer Hydrophobicity. X. Wu, B. Biatry, C. Cazeneuve and R.H. Guy. *Pharm. Res.*, **26**: 1995 - 2001 (2009).
- (317) Optimisation of Cosolvent Concentration for Topical Drug Delivery - II: Influence of Propylene Glycol on Ibuprofen Permeation. R.M. Watkinson, R.H. Guy, J. Hadgraft and M.E. Lane. *Skin Pharmacol Physiol.*, **22**: 225-230 (2009).
- (318) Disposition of Nanoparticles and an Associated Lipophilic Permeant Following Topical Application to the Skin. X.Wu, G.J. Price and R.H. Guy. *Molecular Pharmaceutics*, **6**: 1441-1448 (2009).
- (319) Preparation and in vitro Evaluation of Topical Formulations Based on Polystyrene-poly-2-hydroxyl Methacrylate Nanoparticles. X.Wu, P. Griffin, G.J. Price and R.H. Guy. *Molecular Pharmaceutics*, **6**: 1449-1456 (2009).
- (320) Reverse Iontophoresis of Amino Acids: Identification and Separation of Stratum Corneum and Subdermal Sources in vitro. C.C. Bouissou, J.-P. Sylvestre, R.H. Guy, and M.B. Delgado-Charro. *Pharm. Res.*, **26**: 2630-2638 (2009).
- (321) Applications of Nanoparticles in Topical Drug Delivery and in Cosmetics. X. Wu and R.H. Guy. *J. Drug Deliv. Sci. Tech.*, **19**: 371-384 (2009).
- (322) Disposition of Charged Nanoparticles Following Their Topical Application to the Skin. X. Wu, K. Landfester, A. Musyanovych and R.H. Guy. *Skin Pharmacol. Physiol.*, **23**: 117-123 (2010).
- (323) Microemulsion Formulations for the Transdermal Delivery of Testosterone. R.M. Hathout, T.J. Woodman, S. Mansour, N.D. Mortada, A.S. Geneidi and R.H. Guy. *Eur. J. Pharm. Sci.* **40**: 188-196 (2010).
- (324) Extraction and Quantification of Amino Acids in Human Stratum Corneum in vivo. J.-P. Sylvestre, C.C. Bouissou, R.H. Guy, and M.B. Delgado-Charro. *Brit. J. Dermatol.* **143**: 458-465 (2010).
- (325) Predicting the Rate and Extent of Fragrance Chemical Absorption Into and Through the Skin. R.H. Guy. *Chem. Res. Toxicol.* **23**: 864-870 (2010).
- (326) Optimisation of Cosolvent Concentration for Topical Drug Delivery - III: Influence of Lipophilic Vehicles on Ibuprofen Permeation. R.M. Watkinson, R.H. Guy, G. Oliveira, J. Hadgraft and M.E. Lane. *Skin Pharmacol Physiol.*, **24**: 22-26 (2011).
- (327) Uptake of Microemulsion Components into the Stratum Corneum and their Molecular Effects on Skin Barrier Function. R.M. Hathout, S. Mansour, N.D. Mortada, A.S. Geneidi and R.H. Guy. *Molecular Pharmaceutics*, **7**: 1266-1273 (2010).
- (328) Trans-scleral Iontophoretic Delivery of Low Molecular Weight Therapeutics. S. Güngör, M.B.



- Delgado-Charro, B. Ruiz-Perez, W. Schubert, P. Isom, P. Moslemy, M.A. Patane, and R.H. Guy. *J. Control. Release*, **147**: 225-231 (2010).
- (329) Effect of Aqueous Cream BP on Human Stratum Corneum *In Vivo*. M. Tsang and R.H. Guy. *Brit. J. Dermatol.*, **163**: 954-958 (2010).
- (330) Perturbation of Solute Transport at a Liquid-Liquid Interface by Polyethylene Glycol (PEG): Implications for PEG-Induced Biomembrane Fusion. R.H. Guy and F.C. Szoka, Jr. *Phys. Chem. Chem. Phys. (PCCP)*, **13**: 5346 - 5352 (2011).
- (331) Mathematical Models of Skin Permeability: An Overview. S. Mitragotri, Y.G. Anissimov, A.L. Bunge, H.F. Frasch, R.H. Guy, J. Hadgraft, G.B. Kasting, M.E. Lane and M.S. Roberts. *Internat. J. Pharmaceut.*, **418**: 115-129 (2011).
- (332) AFM Nanotools for Surgery of Biological Cells. J.D. Beard, S.N. Gordeev and R.H. Guy. *Journal of Physics: Conference Series*, 286, 012003 (2011).
- (333) Assessment of Dermal Exposure to Pesticide Residues during Re-entry. N.A. Belsey, S.F. Cordery, A.L. Bunge and R.H. Guy. *Environ. Sci. Tech.*, 45: 4609-4615 (2011).
- (334) Imaging Drug Delivery to Skin with Stimulated Raman Scattering Microscopy. B.G. Saar, L.R. Contreras-Rojas, X.S. Xie and R.H. Guy. *Molecular Pharmaceutics*, **8**: 969-975 (2011).
- (335) Passive and Iontophoretic Transdermal Delivery of Phenobarbital: Implications in Paediatric Therapy. A. Djabri, R.H. Guy and M.B. Delgado-Charro. *Int. J. Pharmaceut.*, **435**: 76-82 (2012).
- (336) Transdermal Iontophoresis of Ranitidine: an Opportunity in Paediatric Drug Therapy. A. Djabri, R.H. Guy and M.B. Delgado-Charro. *Int. J. Pharmaceut.*, **435**: 27-32 (2012).
- (337) Novel Imaging Method to Quantify Stratum Corneum in Dermatopharmacokinetic Studies. L.M. Russell and R.H. Guy. *Pharm. Res.* **29**: 2389-2397 (2012).
- (338) Comparison of Gravimetric and Spectroscopic Approaches to Quantify Stratum Corneum Removed by Tape-Stripping. D. Mohammed, Q. Yang, R.H. Guy, P.J. Matts, J. Hadgraft and M.E. Lane. *Eur. J. Pharm. Biopharm.* **82**: 171-174 (2012).
- (339) Objective Assessment of Nanoparticle Disposition in Mammalian Skin after Topical Exposure. C. Campbell, L.R. Contreras-Rojas, M.B. Delgado-Charro and R.H. Guy. *J. Control. Release*, **162**: 201-207 (2012).
- (340) Novel Imaging Method to Quantify Stratum Corneum in Dermatopharmacokinetic Studies: Validation and Proof-of-Concept with Acyclovir Formulations. L.M. Russell and R.H. Guy. *Pharm. Res.* **29**: 3362-3372 (2012).
- (341) Mechanical Tomography of Human Corneocytes with a Nanoneedle. J.D. Beard, R.H. Guy and S.N. Gordeev. *J. Invest. Dermatol.* **133**: 1565-1571 (2013).
- (342) Iontophoresis-targeted, Follicular Delivery of Minoxidil Sulphate for the Treatment of Alopecia. G.M. Gelfuso, T. Gratieri, M.B. Delgado-Charro, R.H. Guy and R.F.V. Lopez. *J. Pharm. Sci.* **102**: 1488-1494 (2013).
- (343) Effects of Iontophoresis, Hydration and Permeation Enhancers on Human Nail Plate: Infrared and Impedance Spectroscopy Assessment. I. Benzeval, C.R. Bowen, R.H. Guy and M.B. Delgado-Charro.

- Pharm. Res.* **30**: 1652-1662 (2013).
- (344) Skin – “That Unfakeable Young Surface”. R.H. Guy. *Skin Physiol. Pharmacol.* **26**: 181-189 (2013).
- (345) Products in “Bounty Bags” Potentially Harm Newborn Skin. M. Ridd, R. Guy, N. Ball and H. Williams. *British Medical Journal* **346**: f3859.
- (346) Transdermal Flux Predictions for Selected Selective Estrogen Receptor Modulators (SERMs): Comparison with Experimental Results. S. Güngör, M.B. Delgado-Charro, V. Masini-Etévé, R.O. Potts and R.H. Guy. *J. Control. Release* **172**: 601-606 (2013).
- (347) Evaluation of Drug Delivery to Intact and Porated Skin by Coherent Raman Scattering and Fluorescence Microscopies. N.A. Belsey, N.L. Garrett, L.R. Contreras-Rojas, A.J. Pickup-Gerlaugh, G.J. Price, J. Moger and R.H. Guy. *J. Control. Release* **174**: 37-42 (2014).
- (348) Effective Use of Transdermal Drug Delivery in Children. M.B. Delgado-Charro and R.H. Guy. *Adv. Drug Delivery Rev.* **73**: 63-82 (2014).
- (349) A Non-Rewarding, Non-Aversive Buprenorphine/Naltrexone Combination Attenuates Drug-Primed Reinstatement to Cocaine and Morphine in Rats in a Conditioned Place Preference paradigm. S. Cordery, A. Taverner, I. Ridzwan, R.H. Guy, M.B. Delgado-Charro, S.M. Husbands, and C.P. Bailey. *Addiction Biology.* **19**: 575-586 (2014).
- (350) Serious Photocontact Dermatitis Induced by Topical Ketoprofen Depends on the Formulation. R.H. Guy, H. Kuma and M. Nakanishi. *Eur. J. Dermatol.* **24**: 365-371 (2014).
- (351) Characterisation of Polyphenolic Compounds in *Clerodendrum petasites* S. Moore and Their Potential for Topical Delivery Through the Skin. P. Thitilertdecha, R.H. Guy and M.G. Rowan. *J. Ethnopharmacol.* **154**: 400-407 (2014).
- (352) Transdermal Drug Delivery: 30+ Years of War and Still Fighting! S. Wiedersberg and R.H. Guy. *J. Control. Release* **190**: 150-156 (2014).
- (353) Topical Formulation and Dermal Delivery of Active Phenolic Compounds in the Thai Medicinal Plant - *Clerodendrum petasites* S. Moore. P. Thitilertdecha, M.G. Rowan and R.H. Guy. *Internat. J. Pharmaceut.* **478**: 39-45 (2014).
- (354) Characterisation of Skin Barrier Function Using Bioengineering and Biophysical Techniques. Q. Yang and R.H. Guy. *Pharm. Res.* **32**: 445-457 (2015).
- (355) Iontophoretic Transdermal Sampling of Iohexol as a Non-invasive Tool to Assess Glomerular Filtration Rate. A. Djabri, W. van't Hoff, P. Brock, I.C.K. Wong, R.H. Guy, and M.B. Delgado-Charro. *Pharm. Res.* **32**: 590-603 (2015).
- (356) Formulation Considerations in the Design of Topical, Polymeric Film-forming Systems for Sustained Drug Delivery to the Skin. K. Frederiksen, R.H. Guy and K. Petersson. *Eur. J. Pharm. Biopharm.* **91**: 9-15 (2015).
- (357) Characterisation of Topical Film-forming Systems Using Atomic Force Microscopy and Raman Micro-spectroscopy. H. Garvie-Cook, K. Frederiksen, R.H. Guy, K. Petersson and S. Gordeev. *Mol. Pharmaceut.* **12**: 751-755 (2015).
- (358) An *in vitro* Method to Quantify Dermal Absorption of Pesticide Residues. J.F. Clarke, S.F. Cordery,

- N.A. Morgan, P.K. Knowles and R.H. Guy. *Chem. Res. Toxicol.* **28**: 166-168 (2015).
- (359) Molecular Diffusion in the Human Nail Measured by Stimulated Raman Scattering Microscopy. W.S. Chiu, N.A. Belsey, N.L. Garrett, J. Moger, M.B. Delgado-Charro and R.H. Guy. *Proc. Natl. Acad. Sci., USA* **112**:7725-7730 (2015).
- (360) Development of Lipid Nanoparticle-based Dressings for Topical Treatment of Chronic Wounds. G. Gainza, W.S. Chiu, R.H. Guy, J.L. Pedraz, R.M. Hernandez, M.B. Delgado-Charro and M. Iguarta. *Int. J. Pharmaceut.*, **409**: 404–411 (2015).
- (361) Iontophoresis of Minoxidil Sulphate Loaded Microparticles, a Strategy for Follicular Drug Targeting? G.M. Gelfuso, M.A. De Oliveira Barros, M.B. Delgado-Charro, R.H. Guy and R.F.V. Lopez. *Colloid & Surfaces B – Biointerfaces*, **134**: 408-412 (2015).
- (362) Biophysical Elucidation of the Mechanism of Enhanced Drug Release and Topical Delivery from Polymeric Film-forming Systems. H. Garvie-Cook, K. Frederiksen, R.H. Guy, K. Petersson and S. Gordeev. *J. Control. Release* **212**: 103-112 (2015).
- (363) Choice of Moisturiser for Eczema Treatment (COMET): Study Protocol for a Randomized Controlled Trial. M.J. Ridd, N. Redmond, S. Hollinghurst, N. Ball, L. Shaw, R. Guy, V. Wilson, C. Metcalfe and S. Purdy. *Trials*, **16**: 304 (2015).
- (364) *In situ* Detection of Salicylate in *Ocimum Basilicum* Plant Leaves via Reverse Iontophoresis. M.I. Gonzalez-Sanchez, P.T. Lee, R.H. Guy and R.G. Compton. *Chem. Commun.*, **51**: 16534-16536 (2015).
- (365) Drug Delivery into Microneedle-Porated Nails from Nanoparticle Reservoirs. W.S. Chiu, N.A. Belsey, N.L. Garrett, J. Moger, G.J. Price, M.B. Delgado-Charro and R.H. Guy. *J. Control. Release*, **220**: 98-106 (2015).
- (366) Femtosecond Pulsed Laser Ablation to Enhance Drug Delivery across the Skin. H. Garvie-Cook, J.M. Stone, F. Yu, R.H. Guy and S.N. Gordeev. *J. Biophotonics*, **9**: 144-154 (2016).
- (367) Assessing the Safety of Cosmetic Chemicals: Consideration of a Flux Decision Tree to Predict Dermal Systemic Dose for Comparison with Oral TTC (Threshold of Toxicological Concern). F.M. Williams, H. Rothe, G. Barrett, A. Chiodini, J. Whyte, M.T.D. Cronin, N.A. Monteiro-Riviere, J. Plautz, C. Roper, J. Westerhout, C. Yang and R.H. Guy. *Regulatory Toxicology & Pharmacology*, **76**: 174-186 (2016).
- (368) The Potential of Polymeric Film-Forming Systems as Sustained Delivery Platforms for Topical Drugs. K. Frederiksen, R.H. Guy and K. Petersson. *Exp. Opin. Drug Delivery*, **13**: 349-360 (2016).
- (369) Managing Diabetes through the Skin. [News & Views] R.H. Guy. *Nature Nanotech.*, **11**: 493–494 (2016).
- (370) Ibuprofen Delivery into and through the Skin from Novel Oxidized Cellulose-based Gels and Conventional Topical Formulations. D. Celebi, R.H. Guy, K.J. Edler, J.L. Scott. *Internat. J. Pharmaceut.* **514**: 238-243 (2016).
- (371) Choice of Moisturiser for Eczema Treatment (COMET): Feasibility Study of a Randomised Controlled Parallel Group Trial in Children Recruited from Primary Care. M.J. Ridd, K. Garfield, D.M. Gaunt, S. Hollinghurst, N.M. Redmond, K. Powell, V. Wilson, R.H. Guy, N. Ball, L. Shaw, S. Purdy, C. Metcalfe. *BMJ Open* **6**: e012021 (2016).

- (372) Modelling Drug Flux through Microporated Skin. A.S. Rzhavskiy, R.H. Guy and Y.G. Anissimov. *J. Control. Release*, **241**: 194-199 (2016).
- (373) Reverse Iontophoretic Extraction of Metabolites from Living Plants and Their Identification by Ion-Chromatography Coupled to High Resolution Mass Spectrometry. M.I. Gonzalez-Sanchez, J. McCullagh, R.H. Guy and R.G. Compton. *Phytochem. Analysis*, in press (2017).
- (374) Bioequivalence Methodologies for Topical Drug Products: *In Vitro* and *Ex Vivo* Studies with a Corticosteroid and an Anti-Fungal Drug. L. Bastos Leal, S.F. Cordery, M.B. Delgado-Charro, A.L. Bunge and R.H. Guy. *Pharm. Res.*, in press (2017).

### **Publication metrics**

**A citation analysis of Dr. Guy's career-to-date peer-reviewed outputs (>370 in total as of 11-2016) shows that they have been cited over 15,000 occasions (average citations per article ~35) and that his Scopus h-index is 67.**

**In an editorial in *Pharmaceutical Research*, which is the official journal of the American Association of Pharmaceutical Scientists, marking the occasion of its 25th Anniversary at the end of 2008. (Lee, *VHL. Shaping the transformation of pharmaceutical science. Pharm Res* 25, 2707-2712, 2009), it was noted that Dr. Guy had co-authored more papers (72) than anyone else in *Pharmaceutical Research*, and that one of these publications was the fourth most cited in the journal (390 citations at the end of 2008, currently 689).**

### **Books**

- (1) *Transdermal Delivery Systems: Developmental Issues and Research Initiatives*. Edited by J. Hadgraft and R.H. Guy. New York: Marcel Dekker, 1989; reprinted 1993.
- (2) *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling*. Edited by R.C. Scott, R.H. Guy, and J. Hadgraft. London: IBC Technical Services, 1990.
- (3) *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling*. Volume 2. Edited by R.C. Scott, R.H. Guy, J. Hadgraft and H.E. Boddé. London: IBC Technical Services, 1992.
- (4) *Advanced Drug Delivery Reviews. Iontophoresis*. Theme Editor, R.H. Guy. Volume 9, Issue 2/3, 1992.
- (5) *Mechanisms of Transdermal Drug Delivery*. Edited by R.O. Potts and R.H. Guy. New York: Marcel Dekker, 1997.
- (6) *Metals and the Skin - Topical Effects and Percutaneous Absorption*. R.H. Guy, J.J. Hostynek, R.S. Hinz and C.R. Lorence. New York: Marcel Dekker, 1999.
- (7) *Pharmacokinetic Optimization in Drug Research*. Edited by B. Testa, H. van de Waterbeemd, G. Folkers and R.H. Guy. Weinheim: Wiley-VCH, 2001.
- (8) *Transdermal Drug Delivery (2<sup>nd</sup> Edition, Revised and Expanded)*. Edited by R.H. Guy and J. Hadgraft. New York: Marcel Dekker, 2003.

## Articles and Chapters in Books

- (1) Noninvasive Techniques for Determining Skin Function. H.I. Maibach, R. Bronaugh, R.H. Guy, E. Tur, D. Wilson, S. Jacques, and D. Chaing. Chapter in *Cutaneous Toxicity*, pp. 63-97. Edited by V.A. Drill and P. Lazar. New York: Raven Press, 1984.
- (2) Mathematical Models in Percutaneous Absorption. R.H. Guy and J. Hadgraft. Chapter in *Models in Dermatology, Vol. 2*, pp. 170-177. Edited by H.I. Maibach and N.J. Lowe. Basel: S. Karger Publishers, 1985.
- (3) Percutaneous Absorption: Interpretation of *In Vitro* Data and Risk Assessment. C.G.T. Mathias, R.S. Hinz, R.H. Guy, and H.I. Maibach. Chapter in *Dermal Exposure Related to Pesticide Use*, ACS Symposium Series #273, pp. 3-17. Edited by R.C. Honeycutt, G. Zweig, and N.N. Ragsdale. Washington, DC: American Chemical Society, 1985.
- (4) Transdermal Absorption Kinetics: A Physicochemical Approach. R.H. Guy, J. Hadgraft, and H.I. Maibach. Chapter in *Dermal Exposure Related to Pesticide Use*, ACS Symposium Series #273, pp. 19-31. Edited by R.C. Honeycutt, G. Zweig, and N.N. Ragsdale. Washington, DC: American Chemical Society, 1985.
- (5) Approaches to the Prediction of Dermal Absorption and Potential Cutaneous Toxicity. B.A. Firestone and R.H. Guy. Chapter in *Alternative Methods in Toxicology, Vol. 3: In Vitro Toxicology*, pp. 517-535. Edited by A.M. Goldberg. New York: Mary Ann Liebert, Inc., 1985.
- (6) Mathematical Models of Percutaneous Absorption. R.H. Guy and J. Hadgraft. Chapter in *Percutaneous Absorption*, pp. 3-15. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (7) Skin Metabolism – Theoretical. R.H. Guy and J. Hadgraft. Chapter in *Percutaneous Absorption*, pp. 57-64. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (8) Radial Transport in the Dermis. R.H. Guy, J. Hadgraft, and H.I. Maibach. Chapter in *Percutaneous Absorption*, pp. 335-346. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (9) Blood Flow Studies and Percutaneous Absorption. R.H. Guy, E. Tur, R.C. Wester, and H.I. Maibach. Chapter in *Percutaneous Absorption*, pp. 393-407. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (10) Calculations of Body Exposure from Percutaneous Absorption Data. R.H. Guy and H.I. Maibach. Chapter in *Percutaneous Absorption*, pp. 461-466. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (11) Percutaneous Penetration as a Means of Delivery to Muscle and Other Tissues. J.-P. Marty, R.H. Guy, and H.I. Maibach. Chapter in *Percutaneous Absorption*, pp. 469-487. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (12) Percutaneous Absorption in the Aged. K.V. Roskos, R.H. Guy, and H.I. Maibach. Chapter in *Dermatologic Clinics, Vol. 6*, pp. 455-465. Edited by B.A. Gilchrest. Philadelphia: W.B. Saunders Co., 1986.
- (13) Laser Doppler and Photoplethysmographic Assessment of Cutaneous Microvasculature. J.M.

- Stevenson, H.I. Maibach, and R.H. Guy. Chapter in *Models in Dermatology, Vol. 3*, pp. 121-140. Edited by H.I. Maibach and N.J. Lowe. Basel: S. Karger Publishers, 1987.
- (14) The Modelling of Skin Absorption and Controlled Drug Delivery to the Skin. J. Hadgraft and R.H. Guy. Chapter in *Controlled Drug Delivery*, pp. 238-249. Edited by B.W. Müller. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1987.
- (15) Drug Parameters Important for Transdermal Delivery. R.H. Guy and J. Hadgraft. Chapter in *Transdermal Delivery of Drugs, Vol. III*, pp. 3-22. Edited by A.F. Kydonieus and B. Berner. Boca Raton: CRC Press, 1987.
- (16) Kinetics of Drug Absorption Across Human Skin *In Vivo*. R.H. Guy, D.A.W. Bucks, J.R. McMaster, D.A. Villaflor, K.V. Roskos, R.S. Hinz, and H.I. Maibach. Chapter in *Skin Pharmacokinetics*, pp. 70-76. Edited by B. Shroot and H. Schaefer. Basel: S. Karger, 1987.
- (17) Cutaneous Metabolism of Transdermally Delivered Nitroglycerin *In Vitro*. G. Santus, N. Watari, R.S. Hinz, L.Z. Benet, and R.H. Guy. Chapter in *Skin Pharmacokinetics*, pp. 240-244. Edited by B. Shroot and H. Schaefer. Basel: S. Karger, 1987.
- (18) *In Vivo* Evaluations of Transdermal Drug Delivery. R.H. Guy, J. Hadgraft, R.S. Hinz, K.V. Roskos, and D.A.W. Bucks. Chapter in *Transdermal Controlled Systemic Medication*, pp. 179-224. Edited by Y.W. Chien. New York: Marcel Dekker, 1986.
- (19) A New Liposomal Delivery System for Controlled Drug Release. V.M. Knepp, R.S. Hinz, F.C. Szoka, and R.H. Guy. Chapter in *Recent Advances in Controlled Release Technology, ACS Symposium Series*, pp. 267-272. Edited by P.I. Lee and W.R. Good. Washington, DC: American Chemical Society, 1987.
- (20) Physicochemical Models for Percutaneous Absorption. J. Hadgraft and R.H. Guy. Chapter in *Recent Advances in Controlled Release Technology, ACS Symposium Series*, pp. 84-97. Edited by P.I. Lee and W.R. Good. Washington, DC: American Chemical Society, 1987.
- (21) Chemical Structure-Transport Rate Relationships for Model Skin Lipid Membranes. J. Houk, C. Hansch, L.L. Hall, and R.H. Guy. Chapter in *Alternative Methods in Toxicology, Vol. 5: In Vitro Toxicology – Approaches to Validation*, pp. 341-352. Edited by A.M. Goldberg. New York: Mary Ann Liebert, Inc., 1987.
- (22) Release and Diffusion of Drugs from Polymers. J. Hadgraft and R.H. Guy. Chapter in *Controlled Release of Drugs from Polymeric Particles and Macromolecules*, pp. 99-116. Edited by S.S. Davis and L. Illum. Bristol: Adam Hilger, 1987.
- (23) Structure-Penetration Relationships in Percutaneous Absorption. G. Ridout and R.H. Guy. Chapter in *Pesticide Formulations: Innovations and Developments, ACS Symposium Series*, pp. 112-123. Edited by B. Cross and H.B. Scher. Washington, DC: American Chemical Society, 1988.
- (24) Selection of Drug Candidates for Transdermal Drug Delivery. R.H. Guy and J. Hadgraft. Chapter in *Transdermal Delivery Systems: Developmental Issues and Research Initiatives*, pp. 59-81. Edited by J. Hadgraft and R.H. Guy. New York: Marcel Dekker, 1989.
- (25) Occlusion Does Not Uniformly Enhance Penetration *In Vivo*. D.A.W. Bucks, H.I. Maibach, and R.H. Guy. Chapter in *Percutaneous Absorption, 2nd Edition*, pp. 77-93. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1989.

- (26) Calculations of Body Exposure from Percutaneous Absorption Data. R.H. Guy and H.I. Maibach. Chapter in *Percutaneous Absorption, 2nd Edition*, pp. 391-396. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1989.
- (27) Structure-Activity Correlations in Percutaneous Absorption. R.H. Guy and J. Hadgraft. Chapter in *Percutaneous Absorption, 2nd Edition*, pp. 95-109. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1989.
- (28) Mathematical Models of Percutaneous Absorption. R.H. Guy and J. Hadgraft. Chapter in *Percutaneous Absorption, 2nd Edition*, pp. 13-27. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1989.
- (29) Percutaneous Penetration as a Means of Delivery to Muscle and Other Tissues. J.-P. Marty, R.H. Guy, and H.I. Maibach. Chapter in *Percutaneous Absorption, 2nd Edition*, pp. 511-529. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1989.
- (30) *In Vivo* Percutaneous Absorption: Effect of Repeated Application. D.A.W. Bucks, H.I. Maibach, and R.H. Guy. Chapter in *Percutaneous Absorption, 2nd Edition*, pp. 633-651. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1989.
- (31) Pharmacodynamics and Percutaneous Absorption: Minoxidil Stimulates Cutaneous Blood Flow in Balding Human Scalps. R.C. Wester, H.I. Maibach, R.H. Guy, and Ervin Novak. Chapter in *Percutaneous Absorption*, pp. 547-560. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1985.
- (32) Model Membranes to Predict Percutaneous Absorption. G. Ridout, J. Hadgraft, and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling*, pp. 84-92. Edited by R.C. Scott, R.H. Guy, and J. Hadgraft. London: IBC Technical Services, 1990.
- (33) Percutaneous Penetration Enhancers: Mode of Action. R.H. Guy, V.H.W. Mak, T. Kai, D. Bommannan, and R.O. Potts. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling*, pp. 213-223. Edited by R.C. Scott, R.H. Guy, and J. Hadgraft. London: IBC Technical Services, 1990.
- (34) Cutaneous Pharmacology and Skin Disorders. A.J. Bircher, R.H. Guy, and H.I. Maibach. Chapter in *Laser-Doppler Blood Flowmetry*, pp. 141-174. Edited by A.P. Shepherd and P.A. Oberg. Norwell, Massachusetts: Kluwell Academic Publishers, 1990.
- (35) Oral and Transdermal Drug Delivery Systems: Design, Technology and Function. J.B. Dressman, G. Ridout, and R.H. Guy. Chapter in *Comprehensive Medicinal Chemistry. Vol. 5: Biopharmaceutics*, pp. 615-660. Edited by J.B. Taylor. Oxford: Pergamon Press, 1990.
- (36) Principles of Skin Permeability Relevant to Chemical Exposure. R.H. Guy and J. Hadgraft. Chapter in *Dermal and Ocular Toxicology: Fundamentals and Methods*. pp 217-242. Edited by D.W. Hobson. New York: Telford, 1991.
- (37) Percutaneous Absorption. D. Bommannan, R.O. Potts, and R.H. Guy. Chapter in *Skin Pharmacology*, pp. 13-27. Edited by H.A. Mukhtar. Boca Raton: CRC Press, 1992.
- (38) Percutaneous Penetration Enhancement: Physicochemical Considerations and Implications for Prodrug Design. R.H. Guy and J. Hadgraft. Chapter in *Prodrugs and Their Topical Use*, pp. 1-16. Edited by K.B. Sloan. New York: Marcel Dekker, 1992.

- (39) Laser-Doppler-Measured Cutaneous Blood Flow: Effects with Age. A.J. Bircher, K.V. Roskos, H.I. Maibach, and R.H. Guy. Chapter in *Aging Skin: Properties and Functional Changes*, pp. 105-116. Edited by J-L. Leveque and P. Agache. Basel: S. Karger, 1992.
- (40) Percutaneous Absorption of 4,4'-Methylenedianiline *In Vitro*. R.S. Hinz, C.R. Lorence, C.D. Hodson, G.M. Talley, and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 2*, pp. 499-507. Edited by R.C. Scott, R.H. Guy, J. Hadgraft, and H.E. Boddé. London: IBC Technical Services, 1992.
- (41) Mechanism and Enhancement of Skin Penetration *In Vivo*. R.H. Guy, N. Higo, A. Naik, D. Bommannan, V. Ramanathan, R. Griffin, W.J. Irwin, and R.O. Potts. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 2*, pp. 1-12. Edited by R.C. Scott, R.H. Guy, J. Hadgraft, and H.E. Boddé. London: IBC Technical Services, 1992.
- (42) Lipid Free-Volume Fluctuations, Permeant Size and Stratum Corneum Permeability. R.O. Potts, M.L. Francoeur, and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 2*, pp. 148-155. Edited by R.C. Scott, R.H. Guy, J. Hadgraft, and H.E. Boddé. London: IBC Technical Services, 1992.
- (43) Visualizing the Pathways of Iontophoretic Current Flow in Real Time with Laser Scanning Confocal Microscopy and the Vibrating Probe Electrode. C. Cullander and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 2*, pp. 229-237. Edited by R.C. Scott, R.H. Guy, J. Hadgraft, and H.E. Boddé, London: IBC Technical Services, 1992.
- (44) Synthetic Membranes as Biological Models. J. Hadgraft and R.H. Guy. Chapter in *Advances in Pharmaceutical Sciences, Volume 6*, pp. 43-64. Edited by D. Ganderton and T. Jones. London: Academic Press, 1992.
- (45) Effect of Occlusion. D.A.W. Bucks, R.H. Guy, and H.I. Maibach. Chapter in *In Vitro Percutaneous Absorption: Principles, Fundamentals, and Applications*, pp. 85-114. Edited by R.L. Bronaugh and H.I. Maibach. Boca Raton: CRC Press, 1992.
- (46) Iontophoretic Drug Delivery. P.G. Green, M. Flanagan, B. Shroot, and R.H. Guy. Chapter in *Pharmaceutical Skin Penetration Enhancement*, pp. 311-333. Edited by K.A. Walters and J. Hadgraft. New York: Marcel Dekker, 1993.
- (47) Mechanism of Skin Penetration Enhancement, *In Vivo*, in Man. A. Naik, L. Pechtold, R.O. Potts, and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 3*, pp. 161-165. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1993.
- (48) Why Silver/Silver Chloride Electrodes? Criteria for Iontophoresis Electrodes. C. Cullander, G.Rao, and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 3*, pp. 381-390. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1993.
- (49) Iontophoretic Transdermal Delivery of Nucleotides. F. Hueber, C. Cullander, F.C. Szoka, and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 3*, pp. 400-405. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1993.
- (50) A Predictive Model for Dermal Exposure Assessment. A.L. Bunge, G.L. Flynn and R.H. Guy. Chapter



- in *Drinking Water Contamination and Health: Integration of Exposure Assessment, Toxicology and Risk Assessment*, pp. 347-373. Edited by R. Wang. New York: Marcel Dekker, 1994.
- (51) Recent Progress in Percutaneous Absorption. R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 4*, pp. 1-4. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1996.
- (52) The Effects of the Permeant's Molecular Size and Hydrogen Bond Activity on Skin Transport. R.O. Potts and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 4*, pp.45-47. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1996.
- (53) Microemulsion Drug Delivery Systems for the Skin. M.B. Delgado Charro, G. Iglesias Vilas, J. Blanco Mendez, M.A. Lopez Quintela, J-P. Marty and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 4*, pp. 100-101. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1996.
- (54) Estimating Dermal Absorption from Chemically Contaminated Soils. A.L. Bunge, J.M. Parks and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 4*, pp. 186-189. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1996.
- (55) Correlation Between Impedance Spectroscopy and Transepidermal Water Loss: Non-Invasive Probes of Human Skin permeability *in Vivo*. Y.N. Kalia, L.B. Nonato and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 4*, pp. 38-41. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1996.
- (56) Topical Bioavailability: Formulation, Optimization and Quantitation. R.H. Guy. Chapter in *Absorption of Micellar Systems*. Bulletin Technique Gattefossé **88**: 37-42, 1995.
- (57) Drug Delivery to and through the Skin from Novel Microemulsions. M.B. Delgado-Charro, G. Iglesias-Vilas, L.M. Liz-Marzán, J. Blanco-Méndez, M.A. López-Quintela, J-P. Marty and R.H. Guy. Chapter in *Absorption of Micellar Systems*. Bulletin Technique Gattefossé **88**: 55-60, 1995.
- (58) Pénétration cutanée et biodisponibilité. J.-P. Marty and R. Guy. Chapter in *Formes Pharmaceutiques pour Application Locale*. Edited by M. Seiller and M.-C. Martini, Paris, France: Technique & Documentation, 1996.
- (59) Infrared Spectroscopic and Differential Scanning Calorimetric Investigations of the Stratum Corneum Barrier Function. A. Naik and R.H. Guy. Chapter in *Mechanisms of Transdermal Drug Delivery*, pp. 87-162. Edited by R.O. Potts and R.H. Guy, New York, NY: Marcel Dekker, 1997.
- (60) Iontophoresis of Peptides. M.B. Delgado-Charro and R.H. Guy. Chapter in *Electronically Controlled Drug Delivery*, pp. 129-157. Edited by B. Berner and S.M. Dinh, Boca Raton, FL: CRC Press, 1998.
- (61) Routes and Mechanisms of Macromolecular Delivery by Iontophoresis. N.G. Turner, C. Cullander and R.H. Guy. Chapter in *Transdermal Administration, a Case Study, Iontophoresis*, pp. 68-76. Edited by P. Couvreur, D. Duchêne, P. Green and H.E. Junginger, Paris: Editions de Santé, 1997.
- (62) Characterization of Electroosmosis During Iontophoresis: Effect of pH. M. Rodríguez-Fernández, M.B. Delgado-Charro, J. Blanco-Méndez and R.H. Guy. Chapter in *Transdermal Administration, a Case Study, Iontophoresis*, pp. 274-277. Edited by P. Couvreur, D. Duchêne, P. Green and H.E.

- Junginger, Paris: Editions de Santé, 1997.
- (63) Transdermal Iontophoresis of Poly-L-Lysines and Poly-L-Glutamic Acids. J. Hirvonen and R.H. Guy. Chapter in *Transdermal Administration, a Case Study, Iontophoresis*, pp. 383-387. Edited by P. Couvreur, D. Duchêne, P. Green and H.E. Junginger, Paris: Editions de Santé, 1997.
  - (64) Iontophoresis: Noninvasive Drug Delivery and Clinical Chemistry. *Progress in Drug Delivery Systems VII*, 101-111, 1998.
  - (64a) A Reconstructed Skin Model (Testskin™ LSE™) for Permeation Studies. C. Lotte, R.S. Hinz, A. Rougier and R.H. Guy. Chapter in *Prediction of Percutaneous Penetration: Methods, Measurements, Modelling. Volume 5b*, pp. 133-134. Edited by K.R. Brain, V.J. James, and K.W. Walters, Cardiff, Wales: STS Publishing Ltd., 1998.
  - (65) Human Skin Penetration by Metal Compounds. J.J. Hostynek, R.S. Hinz, C.R. Lorence and R.H. Guy. Chapter in *Dermal Absorption and Toxicity Assessment*, pp. 647-668. Edited by M.S. Roberts and K.A. Walters, New York: Marcel Dekker, 1999.
  - (66) The Development of Skin Barrier Function in the Neonate. L.B. Nonato, Y.N. Kalia, A. Naik, C.H. Lund and R.H. Guy. Chapter in *Percutaneous Absorption, 3rd Edition*, pp. 825-860. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1999.
  - (67) Characterization of Molecular Transport Across Human Stratum Corneum In Vivo. A. Naik, Y.N. Kalia, F. Pirot and R.H. Guy. Chapter in *Percutaneous Absorption, 3rd Edition*, pp. 149-175. Edited by R.L. Bronaugh and H.I. Maibach. New York: Marcel Dekker, 1999.
  - (68) Transdermal Drug Delivery. M.B. Delgado-Charro and R.H. Guy. Chapter in *Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists*, pp. 207-236. Edited by A.M. Hillery, A.W. Lloyd and J. Swarbrick. London: Harwood Academic Publishers, 2001.
  - (69) Biological Models to Study Skin Permeation. N. Sekkat and R.H. Guy. Chapter in *Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical and Computational Strategies*, pp. 155-172. Edited by B. Testa, H. van der Waterbeemd, G. Folkers and R.H. Guy. Lausanne: Wiley-VCH, 2001.
  - (70) Peptides and Proteins - Transdermal Absorption. D. Marro, M.B. Delgado-Charro and R.H. Guy. Chapter in *Encyclopedia of Pharmaceutical Technology, 2<sup>nd</sup> Edition*, pp. 2125-2140. Edited by J. Swarbrick and J.C. Boylan. New York: Marcel Dekker, 2001.
  - (71) Feasibility Assessment in Topical and Transdermal Delivery: Mathematical Models and *In Vitro* Studies. J. Hadgraft and R.H. Guy. Chapter in *Transdermal Drug Delivery (2<sup>nd</sup> Edition, Revised and Expanded)*, pp. 1-23. Edited by R.H. Guy and J. Hadgraft. New York: Marcel Dekker, 2003.
  - (72) Iontophoresis: Applications in Drug Delivery and Noninvasive Monitoring. M.B. Delgado-Charro and R.H. Guy. Chapter in *Transdermal Drug Delivery (2<sup>nd</sup> Edition, Revised and Expanded)*, pp. 199-225. Edited by R.H. Guy and J. Hadgraft. New York: Marcel Dekker, 2003.
  - (73) "Minimally Invasive" Technologies for Transdermal Delivery and Clinical Chemistry. R.H. Guy. Chapter in *Challenge in Drug Delivery for the New Millenium*. Bulletin Technique Gattefossé **96**: 47-61, 2003.
  - (74) Modeling Dermal Absorption from Soils and Powders Using Stratum Corneum Tape-Stripping *In*

- Vivo. A.L. Bunge, G.D. Touraille, J.-P. Marty, and R.H. Guy, Chapter in *Dermal Absorption Models in Toxicology and Pharmacology*, pp. 191-212. Edited by J.E. Riviere, CRC Press, Boca Raton, FL, 2005.
- (75) Iontophoresis: Clinical Applications and Future Challenges. N. Abla, A. Naik, R.H. Guy and Y.N. Kalia. Chapter in *Percutaneous Penetration Enhancers*, 2<sup>nd</sup> edition, pp. 177-219. Edited by E.W. Smith and H.I. Maibach, CRC Press, Boca Raton, FL, 2005.
- (76) Iontophoresis in Transdermal Delivery. B. Mudry, R.H. Guy and M.B. Delgado-Charro. Chapter in *Enhancement in Drug Delivery*, pp. 279-302. Edited by E. Touitou and B.W. Barry, Taylor & Francis, New York, NY, 2006.
- (77) Skin Barrier Dysfunction in Atopic Dermatitis. M.J. Cork, M. Moustafa, S. Danby, Y. Vasilopoulos, R. Tazi-Ahnini, S.J. Ward, J. Hadgraft, M.E. Lane, R. Guy and A. MacGowan. Chapter in *Skin Moisturisation*, 2<sup>nd</sup> edition, pp. 211-239. Edited by A.W. Rawlings and J.J. Leyden, Informa Healthcare, New York, NY, 2009.
- (78) Transdermal Drug Delivery. R.H. Guy. Chapter in *Handbook of Experimental Pharmacology, Vol. 197: Drug Delivery*, pp.399-410. ISBN: 978-3642004766. Edited by M. Schäfer-Korting, Springer, Heidelberg, Germany, 2010.
- (79) Imaging Drug Delivery to Skin with Coherent Raman Scattering Microscopy. N.A. Belsey, L.R. Contreras-Rojas and R.H. Guy. Chapter in *Noninvasive Diagnostic Techniques in Clinical Dermatology*, pp. 225-231. Edited by E. Berardesca, H.I. Maibach and K.P. Wilhelm, Springer, Berlin, Germany, 2014.
- (80) Pharmacology of the Skin: Principles of Topical Drug Delivery. R.H. Guy. Chapter 13 in *Rook's Textbook of Dermatology*, 9<sup>th</sup> Edition. ISBN: 978-1-118-44119-0. Edited by C.E.M. Griffiths, J. Barker, R.J.G. Chalmers, T.O. Bleiker and D. Creamer, Wiley-Blackwell, Ltd., Chichester, U.K., 2016.

## Research Awards, Fellowships and Extramural Grants (since 1994)

- 1994-96 U.S. Environmental Protection Agency, \$183,074 TDC: Estimating the Absorbed Dose from Dermal Exposure to Environmental Pollutants: Development of Guidelines for Acquisition, Interpretation and Use of *In Vivo* and *In Vitro* Data (Co-Investigator; A.L. Bunge, Principal Investigator)
- 1994-98 U.S. Air Force, 94NL023, \$433,293 TDC: Prediction and Assessment of Dermal Exposure
- 1994-98 National Institutes of Health, 1-R01-ES06825, \$1,029,303 TDC: Dermal Absorption from Soils: Evaluation and Prediction (Co-Investigator; A.L. Bunge, Principal Investigator)
- 1995-98 National Institutes of Health, 1-R01-DA-09292, \$95,658 TDC: Neonatal Skin: Barrier Function and Drug Delivery
- U.S. Environmental Protection Agency, \$245,268 TDC: Structure-Activity Relationships for Predicting Pesticide Dermal Absorption from Multimedia (Co-Investigator; A.L. Bunge, Principal Investigator)
- 1997-99 U.S. Air Force, 94NL023, \$647,814 TDC: Dermal Absorption of Chemicals from Evaporating Vehicle Mixtures (Co-Investigator; A.L. Bunge, Principal Investigator)
- 1998-01 Fonds national suisse de la recherche scientifique, SFr 180,000: Mechanisms of Iontophoretic Drug Delivery Across Skin
- 1999-02 Programme Commun de Recherche en Génie Biomédical 1999-2002, SFr 374,000: Bioengineering for Transdermal Therapy and Diagnosis
- 2000-02 Fonds national suisse de la recherche scientifique, SFr 126,000: Prevention of Intravascular Device-Related Infections: Electrically-Mediated Skin Antisepsis [A. Naik, principal investigator]
- 2000-03 Fonds national suisse de la recherche scientifique, SFr 260,000: Reverse Iontophoresis: Noninvasive Drug Monitoring via the Skin [M.B. Delgado-Charro, principal investigator]
- 2003-04 U.S. Army Medical Research Acquisition Activity, \$231,380: Skin Bioengineering – Noninvasive Transdermal Monitoring
- U.S. Food & Drug Administration, \$12,000: Dermatopharmacokinetics – Improvement of Methodology for Assessing Bioequivalence of Topical Dermatological Drug Products [A.L. Bunge, principal investigator; total budget \$100,000]
- 2003-08 U.S. National Institutes of Health, 1-R01-EB-001420, \$675,000 TDC: Skin Bioengineering – Noninvasive Transdermal Monitoring
- 2005-08 Parkinson's Disease Society, UK, £105,781 TDC: Optimizing the Pharmacological Treatment of Parkinson's Disease via Transdermal Iontophoresis [M.B. Delgado-Charro, principal investigator]
- 2005-09 European Commission 6<sup>th</sup> Framework, NMP3-CT-2005-011844, €244,952 TDC:

Nanostructured Waterborne Polymer Films with Outstanding Properties [J.M. Asua, Program Director]

- 2009-10 Department of the Environment, Food and Rural Affairs (Defra), PS2616, £91,800 FEC: Skin Uptake and Penetration of Pesticides
- 2009-11 Medical Research Council, G0802728, £242,172 FEC: Transdermal delivery of a Buprenorphine/Naltrexone Combination for the Treatment of Drug Abuse [S.M. Husbards, principal investigator]
- 2013-15 National Institute for Health Research (NIHR), £333,787 (Bath share £9,772): Choice of moisturiser in eczema treatment (COMET)
- 2013-18 U.S. Department of Health & Human Services; Food & Drug Administration, 1-U01-FD-004947-01, \$2,499,989 (Bath share £434,779): Bioequivalence of topical drug products: in vitro - in vivo correlations [A.L. Stinchcomb, U. of Maryland, principal investigator]
- 2015-16 MRC Confidence-in-Concepts Scheme: £67,057 (100% FEC): "The 'Glucose Pathfinder': Noninvasive, transdermal, path-selective and highly specific glucose monitoring on a graphene platform" [A. Ilie, principal investigator]
- 2015-18 Sir Halley Stewart Trust: £50,000: New method for glucose monitoring in diabetics [A. Ilie, principal investigator]
- 2016-19 The Leo Foundation: DKK 3,564,000 (£309,514): Development and validation of physiologically-based pharmacokinetic model for dermal absorption [M.B. Delgado-Charro, principal investigator]

#### **Participation in Other Sponsored Research Activity (since 1994)**

- 1994-95 Becton Dickinson Transdermal Systems (USA), \$35,000 TDC: Iontophoresis and the pH Profile of the Skin
- 1995-96 Becton Dickinson Transdermal Systems (USA), \$35,000 TDC: Peptide Iontophoresis: Electrorepulsion *Versus* Electroosmosis
- 1997-98 Tilderm Systems (France), SFr67,000: Electroosmosis and Skin Impedance
- Electricité de France, Institut Electricité Santé, FF300,000: Nouvelle Méthode non invasive de diagnostique et de suivi thérapeutique par ionophorèse inverse (ICI)
- Cygnus, Inc. (USA), \$55,482: Ultrasound-Enhanced Transport Across the Skin: Effect of Frequency?
- 1997-99 Novartis Pharma, Inc. (Switzerland), SFr215,250: Topical Drug Bioavailability: Evaluation and Optimisation
- 1998-2000 Novartis Pharma, Inc. (Switzerland), SFr 105,000: Supersaturation as a Method to Improve Topical Bioavailability of Lipophilic Drugs
- Becton Dickinson Transdermal Systems (USA), \$150,000 TDC: Peptide Iontophoresis:

Electrorepulsion *Versus* Electroosmosis

- 1999-2001 Galderma (France), SFr410,000: Topical Dermatological Drug Product Bioavailability and Bioequivalence *in vivo*
- 2001-2002 Hisamitsu Pharmaceutical Co. Ltd. (Japan), SFr 70,000: Mechanisms of Iontophoresis  
Pierre-Fabre, Institut de Recherche (France), FF 120,000: L'Eau dans la Peau  
L'Oréal (France), SFr 121,000: Skin Absorption Databases
- 2001-2005 Leo Pharmaceutical Products, Inc. (Denmark), SFr 375,015: The Rational Design of Dermatological Products
- 2002 Power Paper (Israel), € 42,500: Iontophoresis of Cosmeceuticals
- 2002-2003 DPC Products, Inc. (USA), € 26,955: Skin Penetration Enhancement with Naturally-Occuring Oils  
Abbott Laboratories (USA), € 57,504: Transdermal Development of Mavik - Options and Strategies
- 2002-2005 Servier, Institut des recherches internationales (France), SFr 105,000: Development of a Transdermal 'Spray Patch' for the Systemic Administration of Testosterone  
Bracco Research S.A. (Switzerland), SFr 172,269: Sonoporation
- 2003 L'Oréal (France), € 14,600: Iontophoresis of Vitamin C
- 2003-2004 Novozymes A/S (Denmark), € 68,170: Hyaluronic Acid: Skin Penetration and Hydration
- 2003-2005 L'Oréal (France), \$ 150,150: Skin Absorption Database Project  
Vyteris, Inc. (USA), SFr 463,000 "Vyteris Europe"
- 2003-2006 Vyteris, Inc. (USA), \$ 147,000: Iontophoretic Drug Delivery: Increasing the Odds
- 2004 L'Oréal (France), € 15,000: Iontophoresis of Vitamin C  
L'Oréal (France), € 15,000: Skin Uptake of Nanoparticles  
Proctor & Gamble (UK), € 9,000: Reverse Iontophoresis and Skin Health
- 2005-2006 Vyteris, Inc. (USA), £26,500: Iontophoretic Drug Delivery: Increasing the Odds  
Ascend Therapeutics (USA), £37,170: Feasibility study for transdermal delivery of a group of related compounds  
Galderma Research & Development (France), £27,000: Iontophoretic Delivery of Amorolfine across the Nail
- 2006-2010 York Pharma/BBSRC Case Award, £67,500: Bioavailability of Topically Applied Drugs for the Treatment of Atopic Eczema and Other Related Diseases
- 2007-2008 EyeGate Pharmaceuticals, Inc. (USA), £36,791: Ocular Iontophoresis

	GlaxoSmithKline (USA), £15,000: Dermatopharmacokinetics of Docosanol <i>ex vivo</i>
2009-2010	Zealand Pharma (Denmark), £33,691: In vitro Assessment of Transdermal Peptide Delivery
2010	LSC, Inc. (USA), £25,066 TDC: Dermal delivery of an “active” from hydroxysomes.
2010-2013	Leo Pharma A/S (Denmark), £73,577 TDC: Dermal Controlled Release. 3-year PhD studentship.
	Leo Pharma A/S (Denmark), £232,011 TDC: Imaging drug disposition and pharmacokinetics in skin by stimulated Raman scattering microscopy. 2-year postdoctoral fellowship.
2011	Exchange Supplies, Ltd. (U.K.), £23,051 TDC: Alternative buffers: Identifying suitable alternatives or additives to citric and ascorbic acid as a harm reduction tool to reduce the risks associated with illicit heroin and crack cocaine injections. [J. Scott, principal investigator]
	Grünenthal GmbH (Germany), £12,999 TDC: Iontophoresis of tapentadol hydrochloride.
	L’Oréal (France), £13,851 TDC: Iontophoresis and electrical enhancement in the cosmetic and skin-care fields: a review.
	L’Oréal (France), £8,015 TDC: Iontophoresis and cosmetics [UnivMed].
2011-12	Orexo AB (Sweden), £140,708 TDC: Orexo facilities and partial secondment agreement.
2012-13	Orexo AB (Sweden), £140,708 TDC: Orexo facilities and partial secondment agreement.
2012-15	GlaxoSmithKline Research & Development (USA), £192,573 TDC: Examining formulation effects on drug-vehicle skin penetration enhancement.
2013	Reckitt Benkiser (U.K.) £38,110: Ibuprofen delivery across the skin.
2013-17	Syngenta Ltd./BBSRC Case Award, £123,520 TDC: Quantification of dermal absorption from pesticide residues from treated plant surfaces.
2014	Unilever, £16,344: S12 Delivery into and through mammalian skin.
2015	Benanova, Inc., £10,503: Skin penetration and distribution of polymeric nanoparticle formulations.

## Other Creative Activities and Accomplishments

- 1992 U.S. Patent # 5,115,805, "Ultrasound-Enhanced Delivery of Materials Into and Through the Skin." D. Bommannan, H. Okuyama, R.H. Guy, P. Stauffer, and G.L. Flynn
- 1993 U.S. Patent # 5,231,975, "Ultrasound-Enhanced Delivery of Materials Into and Through the Skin." D. Bommannan, H. Okuyama, R.H. Guy, P. Stauffer, and G.L. Flynn
- 1994 *U.S. Patent # 5,279,543, "Device for Iontophoretic Non-Invasive Sampling or Delivery of Substances." P. Glikfeld, C. Cullander, R.S. Hinz, and R.H. Guy*
- 1994 U.S. Patent # 5,323,769, "Ultrasound-Enhanced Delivery of Materials Into and Through the Skin." D. Bommannan, H. Okuyama, R.H. Guy, P. Stauffer, and G.L. Flynn
- 1994 *U.S. Patent # 5,362,307, "Method for the Iontophoretic Non-Invasive Determination of the In Vivo Concentration Level of and Inorganic or Organic Substance." R.H. Guy, G. Rao, P. Glikfeld, C. Cullander and R.S. Hinz*
- 1997 U.S. Patent # 5,636,632, "Ultrasound-Enhanced Sampling of Materials Through the Skin". D. Bommannan, H. Okuyama, R.H. Guy, P. Stauffer, and G.L. Flynn
- 1998 *U.S. Patent # 5,730,714, "Method for the Iontophoretic Non-Invasive Determination of the In Vivo Concentration Level of Glucose." R.H. Guy, G. Rao, P. Glikfeld, C. Cullander and R.S. Hinz*
- 1999 U.S. Patent # 5,911,223, "Introduction of Modifying Agents into Skin by Electroporation". J.C. Weaver, T.E. Zewert, U. Pliquett, R. Vanbever, M.R. Prausnitz, T. Chen, C. Cullander, R. Guy and R.S. Langer.
- 2000 Spanish 'Patente de Invención' #009602541, "Procedimiento de control por iontoforesis del paso a través de membranas de sustancias incluidas en microemulsiones". G. Iglesias Vilas, M.B. Delgado Charro, J. Blanco Mendéz, M.A. López Quintela and R.H. Guy.
- 2001/2 Patent Application EP1401532 (WO03000340), "Method for Noninvasively Determining the Relative Levels of Two Substances Present in a Biological System". M.B. Delgado-Charro and R.H. Guy.
- 2003 *European Patent EP 673622B1, "Device for Iontophoretic Non-Invasive Sampling or Delivery of Substances." P. Glikfeld, C. Cullander, R.S. Hinz, and R.H. Guy*
- 2003 *U.S. Patent # 6,542,765 B1, "Method for the Iontophoretic Non-Invasive Determination of the In Vivo Concentration Level of and Inorganic or Organic Substance." R.H. Guy, G. Rao, P. Glikfeld, C. Cullander and R.S. Hinz*
- 2004 *U.S. Patent # 6,714,815 B2, "Method for the Iontophoretic Non-Invasive Determination of the In Vivo Concentration Level of and Inorganic or Organic Substance." R.H. Guy, G. Rao, P. Glikfeld, C. Cullander and R.S. Hinz*
- 2009 U.S. Patent # 7,555,337 B2, "Method for Non-Invasively Determining the Relative Levels of Two Biological Substances." R.H. Guy and M.B. Delgado-Charro
- 2009 Canadian Patent # CA 2450965, "Method for Non-Invasively Determining the Relative Levels of Two Biological Substances." R.H. Guy and M.B. Delgado-Charro



- 2009 Patent application WO/2009/065787, "Use of Amorolfine for Treating a Nail Disease by Iontophoresis." R.H. Guy and M.B. Delgado-Charro
- 2010 U.S. Patent # 7,693,573 B2, "Method for Non-Invasively Determining the Relative Levels of Two Biological Substances." R.H. Guy and M.B. Delgado-Charro
- 2012 European Patent 1401532, "Device for Non-Invasively Determining the Relative Levels of Two Substances Present in a Biological System." R.H. Guy and M.B. Delgado-Charro
- 2014 European Patent Application WO2014012652 (A1), "Electric-field Assisted Administration of Tapentadol." I. Friedrich, M. Mikyna, S. Gedat and R.H. Guy
- 2016 GB Patent Application 1607265.4, "Multiplexed Transdermal Extraction and Detection Devices for Non-Invasive Monitoring of Substances and Methods of Use." A. Ilie, F. Dougmene, B. Dupont, R.H. Guy, L.Lupani, F. Merken and R.M. Tyrrell

**Note:** Italicised patents were initially licensed to Cygnus, Inc. (and are now licensed to Johnson & Johnson), and comprise integral intellectual property associated with a U.S. Food & Drug Administration and CE-mark approved device (the GlucoWatch<sup>®</sup> Biographer) for noninvasive glucose monitoring.

## Graduated Ph.D. Students

- 1983-89 Daniel A.W. Bucks, Pharmaceutical Chemistry, University of California, San Francisco  
Thesis: "Prediction of Percutaneous Absorption"  
Current position: Dow Chemical, California, USA
- 1984-89 Victoria Knepp, Pharmaceutical Chemistry, University of California, San Francisco  
Thesis: "Controlled Drug Release from a Novel Liposomal Delivery System"  
Kathleen V. Roskos, Pharmaceutical Chemistry, University of California, San Francisco  
Thesis: "The Effect of Skin Aging on the Percutaneous Penetration of Chemicals Through Human Skin"  
Current position: Nektar, Inc., California, USA
- 1987-90 D. Bommaman, Bioengineering, University of California, San Francisco - University of California, Berkeley  
Thesis: "Enhancement of Transdermal Drug Delivery: Mechanisms and Methodologies"  
Current position: MaxVal California, USA
- 1991-96 Norris G. Turner, Pharmaceutical Chemistry, University of California, San Francisco  
Thesis: "Mechanisms of Iontophoretic Drug Delivery"  
Current position: Purdue Pharma, Connecticut, USA
- 1992-97 Lourdes Nonato, Bioengineering, University of California, San Francisco - University of California, Berkeley  
Thesis: "Evolution of Skin Barrier Function in Premature Neonates"
- 1994-96 Fabrice Pirot, Faculté de Médecine et de Pharmacie de Besançon, Université de Franche-Comté  
Thesis: "Analyse, Mesure et Prédiction de la Diffusion dans le Stratum Corneum Humain"  
Current position: Université Claude-Bernard Lyon 1
- 1996-2000 Ingo Alberti, Pharmaceutical Sciences, University of Geneva  
Thesis: "Local Bioavailability of Topical Dermatological Formulations *In Vivo* in Man"  
Current position: University of Geneva, Switzerland
- 1997-2000 Katrin Moser, Pharmaceutical Sciences, University of Geneva  
Thesis: "Supersaturation for the Enhanced Dermal Delivery of Lipophilic Drugs"  
Diego Marro, Pharmaceutical Sciences, University of Geneva  
Thesis: "Electromigration and Electroosmosis Contributions to iontophoretic Drug Delivery"  
Current position: Pharmacist-Manager, Huesca, Spain
- 1997-2001 Catherine Curdy, Pharmaceutical Sciences, University of Geneva  
Thesis: "Fonction Barrière du Stratum Corneum, chez l'Homme, *In Vivo*: Ionophorèse versus Diffusion Passive"  
Current position: Novartis Consumer Health, Nyon, Switzerland  
Gilles Touraille, Faculté de Pharmacie de Châtenay-Malabry, Université Paris XI  
Thesis: "Modalités d'Absorption Percutanée à Partir de Terre Contaminée par une Substance Chimique" [co-advisor: Prof. Jean-Paul Marty]  
Current position: EMEA, London, UK
- 1998-2001 Nabila Sekkat, Pharmaceutical Sciences, University of Geneva  
Thesis: "A Model for Neonatal Skin: Barrier Function and Drug Delivery"

- Current position: Novartis, Basel, Switzerland
- 1998-2002 Gustavo Merino, Pharmaceutical Sciences, University of Geneva  
Thesis: "Mechanisms of Ultrasound-Enhanced Skin Penetration"  
Current position: Carrefour Parapharmacie, Rennes, France
- 2000-2003 Rocio Alvarez-Román, Pharmaceutical Sciences, University of Geneva  
Thesis: "Evaluation of Nanoparticle-Based Vehicles for (Trans)dermal Drug Delivery"  
Current position: Universidad Nacional Autónoma de México, Mexico
- 2000-2004 Benoît Leboulanger, Pharmaceutical Sciences, University of Geneva  
Thesis: "Evaluation de l'Ionophorèse Inversée comme Méthode Non-invasive pour le Monitoring Thérapeutique"  
Current position: Novartis, Basel, Switzerland
- Anke Sieg, Pharmaceutical Sciences, University of Geneva  
Thesis: "The Internal Standard Concept for Non-Invasive Glucose Monitoring Using Reverse Iontophoresis"  
Current position: Dow Corning, Belgium
- 2000-2005 Yannic Schuetz, Pharmaceutical Sciences, University of Geneva  
Thesis: "Administration Transdermique des Peptides par Ionophorèse: Impact des Propriétés Moléculaires sur les Mécanismes de Transport et Applications Thérapeutiques"  
Current position: Triskel Integrated Services, Geneva, Switzerland
- Isabel Diaz del Consuelo, Pharmaceutical Sciences, University of Geneva  
Thesis: " Evaluation de la Muqueuse Oesophagienne de Porc comme Modèle pour l'Etude in vitro de la Perméabilité Buccale "  
Current position: Ipsen, SA, Barcelona, Spain
- Nada Abla, Pharmaceutical Sciences, University of Geneva  
Thesis: "Administration Transdermique par Ionophorèse: Effet de la Barrière Cutanée et Impact des Propriétés Physico-chimiques des Peptides sur leur Transport"  
Current position: Ferring SA, Lausanne, Switzerland
- Blaise Mudry, Pharmaceutical Sciences, University of Geneva  
Thesis: "Prediction and Optimization of Iontophoretic Transport Across the Skin"  
Current position: Ferring SA, Lausanne, Switzerland
- Christophe Herkenne, Pharmaceutical Sciences, University of Geneva  
Thesis: "Evaluation and Optimization of Topical Drug Bioavailability"  
Current position: DebioPharm, Martigny, Switzerland
- 2001-2005 Sophie Mehier-Humbert, Pharmaceutical Sciences, University of Geneva  
Thesis: "Mechanistic Investigation of Microbubble-Mediated Sonoporation for Intracellular Gene Delivery"  
Current position: CEO, Cerma SA, Archamps, France (biotech start-up)
- Marie-Laure Leichtnam, Pharmaceutical Sciences, University of Geneva  
Thesis: "Mise au Point d'un Spray pour l'Administration Transdermique de Testostérone à Visée Systémique"
- 2003-2006 Sandra Wiedersberg, Faculty of Science, University of Bath  
Thesis: "Dermatopharmacokinetics and Pharmacodynamics of Topical Glucocorticoids"  
Current position: Research Scientist, LTS Lohmann Therapie-Systeme AG

- 2003-2007 Valentine Wascotte, Faculté de Pharmacie, Université catholique de Louvain, Belgium  
Thesis:  
Current position: Research Scientist, GSK, Belgium
- 2004-2007 Jean-Philippe Sylvestre  
Thesis: "Applications of Iontophoresis in Sports Medicine"  
Current position: University of Montreal, Canada
- 2005-2008 Xiao Wu  
Thesis: "Characterisation and evaluation of novel nanoparticulate formulations for application to the skin"  
Current position: Eli Lilly & Co., Indianapolis, IN, U.S.A.
- 2005-2009 Lisa Russell  
Thesis: "Dermatopharmacokinetics: an approach to evaluate topical bioavailability"  
Current position: Consultant Pharmacist, Nottingham PCT
- Asma Djabri  
Thesis: "Iontophoresis in paediatric medicine: noninvasive drug delivery and monitoring applications"  
Current position: Pharmacist
- 2006-2010 Manda Tsang  
Thesis: "Formulation and delivery of topically applied drugs for the treatment of atopic eczema and other related diseases"  
Current position:
- 2008-2011 Quan Yang  
Thesis: "Application of Biophysics and Bioengineering to the Assessment of Skin Barrier Function"  
Current position: MHRA, London, UK
- 2008-2013 Premrutai Thitilertdecha  
Thesis: "Formulation optimization for the topical delivery of active agents in traditional medicines"  
Current position: Centre for Thai Traditional Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
- 2010-2014 Kit Frederiksen  
Thesis: "*In situ* polymeric film-forming systems for sustained topical delivery"  
Current position: Novo Nordisk, Denmark
- 2011-2014 Hazel Garvie-Cook  
Thesis: "Micro- and nano-scale assessment of novel (trans)dermal drug delivery strategies"  
Current position: Postdoctoral Research Associate, University of Bath
- Wing Chiu  
Thesis: "Mechanism and optimisation of drug delivery into and through the nail"  
Current position: Postdoctoral Research Associate, University of Bath

## Professional Research Personnel, Postgraduate Personnel, and Postdoctoral Fellows

### University of California, San Francisco

- 1982-83 Ethel Tur, M.D., Visiting Research Associate in Dermatology: Non-invasive monitoring of percutaneous absorption  
Current position: Ichilov Medical Center, Tel Aviv, Israel  
Michael Amantea, B.S., President's Undergraduate Fellow: The influence of alcohol at a model biomembrane interface  
Current position: UCSD School of Pharmacy, California, USA
- 1982–2001 Robert Hinz, Ph.D., Research Associate: Interfacial transport: Kinetics and perturbation
- 1983 Veronique Drouard, M.Pharm., Visiting Postgraduate Research Pharmacist: UV erythema  
Current position: Givaudan, Paris, France  
Charles Ryll, Pharm.D., M.S. Graduate Student: Pharmaceutical Chemistry
- 1983-84 Sharif Elamir, M.D., Visiting Research Associate in Dermatology: Quantification of irritation  
Larry Schall, M.D., Research Associate in Dermatology: Blood flow to the skin monitored by laser Doppler velocimetry
- 1983-89 Daniel A.W. Bucks, Graduate Student: Pharmaceutical Chemistry  
Current position: Dow Chemical, California, USA
- 1984 Eva M. Carlström, Postgraduate Research Chemist: *In vitro* skin penetration  
Current position: AstraZeneca, Sweden
- 1984-85 John M. Stevenson, B.S., Postgraduate Research Biologist: Skin irritancy studies  
Bruce A. Firestone, Graduate Student: Pharmaceutical Chemistry  
Current position: Allergan, California, USA
- 1984-88 Kathleen V. Roskos, Graduate Student: Pharmaceutical Chemistry  
Current position: Nektar, Inc., California, USA
- 1984-89 Victoria M. Knepp, Graduate Student: Pharmaceutical Chemistry  
Current position: Alza Corp., California, USA
- 1985 Kamaljit Ryatt, M.D., Visiting Lecturer in Dermatology: Skin blood flow  
Current position: Dermatologist, England
- 1985-86 GianCarlo Santus, Ph.D., Visiting Scientist (Sabbatical): Transdermal drug delivery and cutaneous metabolism  
Current position: NiCox, Sophia Antipolis, France  
Diana Villaflor, M.D., Visiting Postdoctoral Research Chemist: The influence of aging on the barrier function of skin
- 1985- Cynthia Lorence, B.S., Research Associate: Percutaneous absorption of organic compounds *in vitro*

- 1985-89 Joy Houk, M.S., Graduate Student: Pharmaceutical Chemistry
- 1986-88 Geoffrey Ridout, Ph.D., Postdoctoral Research Chemist: Models for percutaneous absorption  
 Katherine L. Kendrick, Ph.D., Postdoctoral Research Chemist: Interfacial transfer kinetics  
 Peretz Glikfeld, Dip. Chem. Eng., Postdoctoral Research Chemical Engineer: Transdermal drug delivery by iontophoresis  
 Current position: Israel Institute for Biological Research, Ness-Ziona, Israel
- 1987-88 C. Hodson, B.A., Research Associate: *In vitro* skin absorption
- 1987-90 D. Bommannan, M.S., Graduate Student: Bioengineering  
 Current position: CEO, Maxval Group, California, USA  
 Christopher Cullander, Ph.D., Postdoctoral Research Biophysicist: Electrical properties of skin  
 Current position: University of California – San Francisco, USA
- 1987-89 Takashi Kai, M.S., Postgraduate Research Chemist: Percutaneous penetration enhancement  
 Current position: Nippon Shokubai Co. Ltd., Japan  
 Vivien Mak, Ph.D., Postdoctoral Research Chemist: Spectroscopic investigations of skin barrier function  
 Current position: Independent consultant
- 1988-90 Naruhito Higo, B.S., Postgraduate Research Chemist: Transdermal drug delivery and cutaneous metabolism  
 Current position: Hisamitsu Pharmaceutical Co. Ltd, Tsukuba, Japan  
 Philip G. Green, Ph.D., Postdoctoral Research Chemist: Iontophoretic delivery of peptides across the skin  
 Current position: Merck Bioventures, New Jersey, USA
- 1989-90 Daniel A.W. Bucks, Ph.D.: Assistant Research Chemist: Percutaneous absorption  
 Current position: Dow Chemical, California, USA  
 Hirohito Okuyama, M.S.: Postgraduate Research Chemist: Effects of ultrasound on transdermal drug delivery  
 Current position: Boehringer Ingelheim, Narita, Japan
- 1990-92 Carol L. Gay, Ph.D.: Postdoctoral Research Chemist: Enhancement of Transdermal Delivery  
 Current position: GlaxoSmithKline Consumer Health, Weybridge, England
- 1990-93 Girish Rao, Ph.D.: Postdoctoral Research Chemist: Transdermal Sampling of Blood Glucose by Iontophoresis  
 Current position: Unilever, India
- 1990-94 Christopher Cullander, Ph.D.: Assistant Research Biophysicist: Electrophysiological and Microscopic Evaluations of Skin Barrier Function  
 Current position: Adjunct Associate Professor, University of California – San Francisco

- 1990-96 Jurij J. Hostynek, Ph.D.: Visiting Scientist: Prediction of Risk Following Dermal Exposure to Toxic Chemicals  
Current position: Research scientist, University of California, San Francisco
- 1991-92 Jens Brange, M.Sc.: Visiting Professor of Pharmacy: Iontophoretic Delivery of Insulin Analogs Across the Skin  
Liselotte Langkjaer, M.Sc.: Visiting Assistant Professor of Pharmacy: Iontophoretic Delivery of Insulin Analogs Across the Skin  
Current position: Novo Nordisk, Bagsværd, Denmark  
Ronald van der Geest, B.S.: Postgraduate Research Student: Transdermal Delivery of Oligonucleotides  
Current position: Tibotec-Virco Co., VA, Belgium
- 1991-93 Aeri Kim, Ph.D.: Postdoctoral Research Chemist: Iontophoretic Delivery of Insulin Analogs Across the Skin  
Current position: LG, Inc., Korea  
Rhonda Brand, Ph.D.: Postdoctoral Research Bioengineer: Biophysical Analysis of the Effect of Iontophoresis on Skin Barrier Function  
Current position: NorthWestern University, Illinois, USA  
M. Begoña Delgado Charro, Ph.D.: Visiting Assistant Professor: Iontophoretic Delivery of LHRH Analogs and Antagonists  
Current position: University of Bath, UK, Senior Lecturer in Pharmaceutical Sciences  
Seaung Oh, Ph.D.: Postdoctoral Research Chemist: Skin Impedance, Electroporation, and Transdermal Drug Delivery  
Current position: Sookmyung Women's University, Seoul, Korea
- 1991-94 Aarti Naik, Ph.D.: Postdoctoral Research Chemist: IR Spectroscopic Investigations of Skin Barrier Function  
Current position: Triskel SA, Geneva, Switzerland
- 1991-96 Norris Turner, Pharm.D.: Graduate Student: Pharmaceutical Chemistry  
Current position: Pfizer, Connecticut, USA
- 1992-93 Frédérique Hueber, Ph.D.: Postdoctoral Research Chemist: Iontophoresis of Oligonucleotides  
Current position: L'Oréal Research, Paris, France  
Amalia Rodriguez-Bayon, Ph.D.: Postdoctoral Research Chemist: Iontophoretic Delivery of LHRH Analogs and Antagonists.  
Current position: Associate Professor, Complutense University, Madrid, Spain  
Karine Buffard, B.S.: Postgraduate Research Student: Measurement of Skin Permeability *In Vivo*
- 1992-94 Elena Aspe-Carranza, M.S.: Postgraduate Research Student: Transdermal Delivery of an Antiviral Drug
- 1992-97 Lourdes Nonato, M.S.: Graduate Student: Bioengineering

- 1994 Patrizia Santi, Ph.D.: Visiting Assistant Professor of Pharmacy: Mechanisms of Iontophoretic Transport  
Current position: Professor, University of Parma, Italy
- 1994-96 Jouni Hirvonen, Ph.D.: Postdoctoral Research Chemist: Noninvasive Biological Monitoring via the Skin  
Current position: Professor and Dean, University of Helsinki, Finland
- 1994-96 Yogeshvar Kalia, Ph.D.: Postdoctoral Research Chemist: Theoretical and Experimental Modeling of Iontophoretic Drug Delivery  
Current position: Associate Professor, University of Geneva, Switzerland  
Fabrice Pirot, Pharm.D.: Postgraduate Research Pharmacist: Assessment of Dermal Exposure *in vivo*  
Current position: Associate Professor, Université Claude-Bernard Lyon 1
- 1995-96 Audra Stinchcomb, Ph.D.: Postgraduate Research Chemist: Chemical Absorption Across Human Skin *in vivo* - Effect of Vehicle  
Current position: Professor, University of Kentucky, USA
- 1995- Gilles Touraille, Pharm.D.: Postgraduate Research Pharmacist: Assessment of Dermal Exposure *in vivo* - Vehicle Effects  
Current position: EMEA, London, U.K.
- 1996 Monica Rodríguez-Fernandez: Postgraduate Research Student: Isoelectric Point of the Skin  
*University of Geneva - Centre Interuniversitaire de Recherche et d'Enseignement, Archamps*
- 1996 Virginia Merino-Sanjuan, Ph.D.: Visiting Professor: Reverse Iontophoresis  
Current position: Associate Professor, University of Valencia, Spain
- 1996, 1999 Alicia Lopéz, Ph.D. Visiting Postdoctoral Fellow: Reverse Iontophoresis; pl of Skin  
Current position: Associate Professor, University Cardenal Herrera, Valencia, Spain
- 1996-2000 Ingo Alberti, Dip. Pharm.: Doctorant: Evaluation and Optimisation of Topical Drug Bioavailability  
Current position: Swiss Medical Authority, Basel, Switzerland
- 1996-2001 Yogeshvar Kalia, Ph.D.: Maître Assistant: Theoretical and Experimental Modeling of Iontophoretic Drug Delivery  
Current position: Associate Professor, University of Geneva, Switzerland
- 1996-2003 M. Begoña Delgado-Charro, Ph.D.: Maître Assistante: Iontophoresis, Sonophoresis and Novel Topical Formulations  
Current position: Senior Lecturer in Pharmaceutical Sciences, University of Bath, UK
- 1996-2004 Aarti Naik, Ph.D. Visiting Postdoctoral Fellow, Maître Assistante: Mechanism and Enhancement of Transdermal Drug Delivery  
Current position: Triskel, SA, Geneva, Switzerland



- 1997 Asteria Luzardo-Alvarez, Dip. Pharm.: Visiting Graduate Student: Iontophoresis and Isoelectric Point of Skin  
Current position: University of Santiago de Compostela, Spain  
Antonella Casiraghi, Pharm.D.: Visiting Graduate Student: Infrared spectroscopy and Skin  
Current position: University of Milan, Italy
- 1997-2000 Diego Marro, Dip. Pharm.: Doctorant: Electropulsion and Electroosmosis in the Iontophoretic Delivery of Peptides  
Current position: Visiting Professor, University Cardenal Herrera, Valencia, Spain  
Katrin Moser, Dip. Pharm.: Doctorante: Supersaturation and Topical Drug Delivery  
Current position: MIT, Boston, USA
- 1997-2001 Catherine Curdy, Dipl. Pharm.: Doctorante: Skin Barrier Function  
Current position: Novartis Consumer Health, Nyon, Switzerland  
Gilles Touraille, Pharm. D.: Doctorant: Skin Penetration of Toxic Compounds Following Exposure to Contaminated Soil  
Current position: EMEA, London
- 1998-2000 Renata F.V. Lopez, Dipl. Pharm.: Visiting Graduate Student: Iontophoresis and Photodynamic Therapy  
Current position: Professor, University of São Paulo, Ribeirão Preto, Brazil
- 1998-2001 Nabila Sekkat, Dipl. Pharm.: Doctorante: A Model for Neonatal Skin Barrier Function  
Current position: Ferring, Lausanne, Switzerland
- 1998-2002 Gustavo Merino, Dipl. Pharm.: Doctorant: Ultrasound-Enhanced Transport Across the Skin  
Current position: Carrefour pharmacie, France
- 1999 Monica Dias, Ph.D.: Visiting Postdoctoral Scientist: Infrared spectroscopy and Skin  
Current position: EMEA, London, England
- 2000 Nathalie Dujardin, Pharm.D.: Visiting Graduate Student: Electroporation of the Skin  
Peretz Glikfeld, Dipl. Chem. Eng.: Visiting Scientist: Drug Delivery to the Nail  
Current position: Israel Institute for Biological Research, Ness-Ziona, Israel
- 2000-01 Hirotoshi Adachi, Ph.D.: Visiting Postdoctoral Scientist: Prevention of Intravascular Device-Related Infections - Electrically-Mediated Skin Antisepsis  
Current position: Hisamitsu Pharmaceutical Co. Ltd, San Diego, CA
- 2000-04 Rocio Alvarez-Román, Pharm.D.: Doctorante: Particulate Formulations for Topical Drug Delivery to the Skin  
Current position: Associate Professor, Universidad Autónoma de Nuevo León, Mexico  
Benoît Leboulanger, M.S.: Doctorant: Noninvasive Therapeutic Drug Monitoring by Reverse Iontophoresis  
Current position: Novartis, Basel, Switzerland  
Anke Sieg, Pharm.D.: Doctorante: Noninvasive Glucose Monitoring by Reverse Iontophoresis

- Current position: Dow-Corning, Brussels, Belgium
- 2000-05 Yannic Schütz, Dipl. Pharm.: Doctorante: Iontophoretic Delivery of peptides Across the Skin  
Current position: DebioPharm, Martigny, Switzerland  
Nada Abla, Dipl. Pharm.: Doctorante: Structure-Activity Relationships for peptide Iontophoresis  
Current position: Merck Serono, Geneva, Switzerland
- 2001-05 Christophe Herkenne, Dipl. Pharm.: Doctorant: Rational Design of Topical Formulations  
Current position: DebioPharm, Martigny, Switzerland  
Blaise Mudry, Dipl. Pharm.: Doctorant: Structure-Transport Relationships for Iontophoretic Drug Delivery Across the Skin  
Current position: Ferring, Lausanne, Switzerland  
Sophie Mehier, M.S.: Doctorante: Sonoporation – Ultrasound-Mediated Gene Delivery  
Current position: Managing Director, Cerma, SA, Archamps, France  
Isabel Diaz, Pharm.D.: Doctorante: Transmucosal Drug Delivery  
Current position: Ipsen SA, Barcelona, Spain  
Marie-Laure Leichtnam, M.S.: Doctorante: Development of a Transdermal ‘Spray Patch’ for the Systemic Administration of Testosterone
- 2002-04 Emmanuelle Sublet, M.S.: Staff Research Associate: Topical and Transdermal Drug Delivery  
Current position: Staff Research Associate, University of Geneva  
Danielle Masuelle, M.S.: Staff Research Associate: Topical and Transdermal Drug Delivery  
Current position: Staff Research Associate, University of Geneva  
Yves Jacques, Ph.D.: Senior Scientist: Transmucosal Drug Delivery  
Current position: Independent consultant
- 2002 Valentine Wascotte, B.S.: Visiting Erasmus Student: Novel Formulations for Application in Reverse Iontophoresis  
Current position: GSK, Belgium  
Nuria Uson, M.S.: Visiting Graduate Student: Microemulsions as Topical Vehicles  
Current position: CSIC, Barcelona, Spain
- 2003-04 M. Begoña Delgado-Charro, Ph.D.: Collaboratrice Scientifique: Reverse Iontophoresis and Prediction of Skin Permeability  
Current position: Senior Lecturer in Pharmaceutical Sciences, University of Bath, UK  
Susan Nixon, Pharm.D.: Doctorante: Noninvasive Monitoring of Lactate by Reverse Iontophoresis  
Current position: Novartis Consumer Health, Nyon, Switzerland
- 2004 Rocio Alvarez-Román, Ph.D.: Postdoctoral Scientist: Particulate Formulations for Topical Drug Delivery to the Skin  
Current position: Associate Professor, Universidad Autónoma de Nuevo León, Mexico

*University of Bath, Department of Pharmacy & Pharmacology*

- 2004-06 Sandra Weidersberg, Pharm.D.: Ph.D. student: Dermatopharmacokinetics of Topical Steroids  
Current position: Lohmann LTS, Neuwid, Germany  
Sara Nicoli, Ph.D.: Visiting Scientist: Evaluation of Topical Drug Bioavailability in the Skin  
Current position: Associate Professor, University of Parma, Italy
- 2004-07 Jean-Philippe Sylvestre, M.S.: Ph.D. student: Applications of Iontophoresis in Sports Medicine  
Current position: Postdoctoral scientist, University of Montreal, Canada
- 2005-08 Xiao Wu, M.Pharm.: Ph.D. student: Interactions of Nanoparticles with Skin  
Current position: Postdoctoral scientist, University of Kentucky, U.S.A.
- 2005-09 Lisa Russell, M.Pharm.: Ph.D. student: Dermatopharmacokinetics  
Current position: Pharmacist, Bristol PCT  
Asma Djabri, M.Pharm.: Ph.D. student: Applications of Iontophoresis in Pediatrics  
Current position: Pharmacist
- 2006-07 Camille Bouissou, Ph.D.: Postdoctoral Scientist: Reverse Iontophoresis as a Tool to Characterize "Skin Health".
- 2006-08 Sevgi Gungor, Ph.D.: Visiting Scientist: Transdermal Delivery of Anti-Cancer Drugs  
Current position: Associate Professor, Istanbul University, Turkey
- 2006-10 Manda Tsang, B.Sc.: Ph.D. student: Bioavailability of Topically Applied Drugs for Eczema
- 2006-16 Sarah Cordery, B.Sc.: Research Associate: Skin Research; Ph.D. student: Transdermal Treatment of Drug Abuse
- 2008-11 Quan Yang, M.Pharm.: Ph.D. student: Application of Biophysics and Bioengineering to the Assessment of Skin Barrier Function
- 2008-13 Premrutai Thitilertdecha, B.Sc.: Ph.D. student: Topical delivery of active agents in traditional medicines
- 2009-10 Christopher Campbell, Ph.D.: Postdoctoral Scientist: Disposition of nanoparticles on the skin  
Ian Benzeval, Ph.D.: Postdoctoral Scientist: Drug delivery to the nail  
Natalie Belsey, Ph.D.: Postdoctoral Scientist: Skin uptake and penetration of pesticides
- 2010-12 Natalie Belsey, Ph.D.: Postdoctoral Scientist: Imaging drug disposition and pharmacokinetics in skin by stimulated Raman scattering microscopy.
- 2009- Luis Rodrigo Contreras-Rojas, M.Pharm.: Ph.D. student: Disposition of nanoparticles on the skin

- 2010-14 Kit Frederiksen, M.Sc.: Ph.D. student: Controlled drug delivery to the skin.
- 2011-14 Hazel Garvie-Cook, M.Phys.: Ph.D. student: Atomic Force Microscopy Investigations of the Nanomechanical Properties of Skin and Nail  
Wing Sin Chiu, M.Pharm.: Ph.D. student: Drug Delivery to the Skin and Nail
- 2011-15 Bertrand Dupont, M.Eng.: Ph.D. student: Novel Applications of Graphene-Based Biosensors to the Skin  
Duygu Celebi, M.Chem.: Ph.D. student: Novel, sustainable gel materials for topical drug delivery
- 2013-14 Leila Leal, Ph.D.: Visiting Professor: *In vivo-in vitro* correlations for topical bioavailability
- 2013- James Clarke, B.Sc.: Ph.D. student: Quantification of dermal absorption from pesticide residues from treated plant surfaces  
Simon Vanstone, M.Phys.: Ph.D. student: Atomic Force Microscopy Investigations of the Nanomechanical Properties of Skin and Nail
- 2014-15 Hazel Garvie-Cook, Ph.D.: Postdoctoral Scientist: Imaging drug disposition and pharmacokinetics in skin.  
Wing Sin Chiu, Ph.D.: Postdoctoral Scientist: *In vivo-in vitro* correlations for topical bioavailability  
Mohammed Zaher Shehab, Ph.D.: Postdoctoral Scientist: *In vivo-in vitro* correlations for topical bioavailability
- 2014- M. Alice Naciel Tabosa, Pharm.D.: Ph.D. student: Development and validation of a pharmacokinetic model for dermal absorption
- 2015- Magdalena Hoppel, Pharm.D., Ph.D.: Postdoctoral Scientist: Development and validation of a pharmacokinetic model for dermal absorption  
Andrea Pensado-Lopez, Pharm.D., Ph.D.: Postdoctoral Scientist: *In vivo-in vitro* correlations for topical bioavailability  
Luca Lupani, Pharm.D.: Ph.D. student: Novel Applications of Graphene-Based Biosensors to the Skin  
Florian Doungmene, Ph.D.: Postdoctoral Scientists: Novel Applications of Graphene-Based Biosensors to the Skin

## Doctoral Dissertation Committees

- 1982-84 Ming-Zong Lai, Pharmaceutical Chemistry, University of California - San Francisco
- 1986-88 Kathleen V. Roskos, Pharmaceutical Chemistry, University of California - San Francisco
- 1986-89 Victoria M. Knepp, Pharmaceutical Chemistry, University of California - San Francisco  
Daniel A.W. Bucks, Pharmaceutical Chemistry, University of California - San Francisco
- 1988-90 Aeri Kim, Pharmaceutical Chemistry, University of California - San Francisco  
Seaung Oh, Pharmaceutical Chemistry, University of California - San Francisco  
D. Bommaman, Bioengineering, University of California - San Francisco - , University of California - Berkeley
- 1989-92 José M. Cornejo-Bravo, Pharmaceutical Sciences, University of California - San Francisco
- 1991-94 Marcello Gutierrez, Pharmaceutical Chemistry, University of California - San Francisco  
Murali Ramanathan, Bioengineering, University of California - San Francisco, University of California - Berkeley
- 1992 Tamie Minami, Pharmaceutical Sciences, University of Sydney, Australia
- 1993 Nagahiro Yoshida, Pharmaceutical Sciences, University of Queensland, Australia
- 1993-95 Sarah Noonberg, Bioengineering, University of California - San Francisco, University of California - Berkeley
- 1994 Uwe Rohr, Habilitationsschrift, Pharmaceutical Technology, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany  
Lucas Ferreira, Groupe de Formation Doctorale Biologie et Pharmacologie Cutanées, Université de Paris-Sud, Châtenay-Malabry, France
- 1995 Malua de Carvalho Bouton, Diplôme de Doctorat, L'Université Claude Bernard-Lyon 1, Lyon, France  
Fernando Guerra Domínguez, Facultad de Farmacia, Universidad de La Laguna, Tenerife, Spain
- 1996 Vikram K. Ramanathan, Pharmaceutical Chemistry, University of California - San Francisco  
Norris G. Turner, Pharmaceutical Chemistry, University of California - San Francisco  
Bernard Neau, Groupe de Formation Doctorale Biologie et Pharmacologie Cutanées, Université de Paris-Sud, Châtenay-Malabry, France  
Abdou E. Said, Faculté de Médecine et de Pharmacie de Besançon, Université de Franche-Comté  
Fabrice Pirot, Faculté de Médecine et de Pharmacie de Besançon, Université de Franche-Comté  
Christain Surber, Ph.D., Faculty of Medicine, University of Basel, Switzerland (Habilitation)

- 1997 Gabriela Marginean-Lazar, Groupe de Formation Doctorale Biologie et Pharmacologie Cutanées, Université de Paris-Sud, Châtenay-Malabry, France  
 Anne Jadoul, Université catholique de Louvain, Ecole de Pharmacie, Unité de Pharmacie Galénique, Industrielle et Officinale  
 Claudia Witschi, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Sophie Chesnoy, Groupe de Formation Doctorale Pharmacotechnie et Biopharmacie, Université de Paris-Sud, Châtenay-Malabry, France  
 Adriana Ganem-Quintanar, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Jacques Bailly, Groupe de Formation Doctorale Biologie et Pharmacologie Cutanées, Université de Paris-Sud, Châtenay-Malabry, France
- 1998 Peter Boderke, Swiss Federal Institute of Technology, Zürich (ETH-Z)  
 Ronald van der Geest, Leiden University, The Netherlands
- 1999 Laure Brinon, Groupe de Formation Doctorale Pharmacotechnie et Biopharmacie, Université de Paris-Sud, Châtenay-Malabry, France
- 2000 Gwénaëlle Potard, Groupe de Formation Doctorale Pharmacologie Expérimentale et Clinique, Université de Paris-Sud, Châtenay-Malabry, France  
 Nicole Wyttenbach, Swiss Federal Institute of Technology, Zürich (ETH-Z)  
 Ingo Alberti, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Katrin Moser, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Diego Marro, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Claudia Valenta, Ph.D., University of Vienna, Austria (Habilitation)  
 Alain Boucaud, Université de Tours, France
- 2001 Pascale Clement, Groupe de Formation Doctorale Pharmacologie Expérimentale et Clinique, Université de Paris-Sud, Châtenay-Malabry, France  
 Véronique Gobry, Swiss Federal Institute of Technology, Lausanne (EPFL)  
 Catherine Curdy, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Nabila Sekkat, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Gilles Touraille, Groupe de Formation Doctorale Pharmacologie Expérimentale et Clinique, Université de Paris-Sud, Châtenay-Malabry, France
- 2002 Nathalie Dujardin, Faculty of Medicine, Université catholique de Louvain, Belgium  
 Christain Tran, Faculty of Pharmacy, Université Claude-Bernard – Lyon 1, France  
 Ignacio de Miguel Clave, Université Paul Sabatier de Toulouse, France  
 Gustavo Merino, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Sandrine Geinoz, Université de Lausanne, Faculté des Sciences
- 2003 Rocio Alvarez-Román, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Anne-Rose Denet, Faculty of Medicine, Université catholique de Louvain, Belgium
- 2004 Benoît Leboulanger, Université de Genève, Faculté des Sciences, Section de Pharmacie

- Nuria Usón Sanchiz, Universitat de Barcelona, Spain  
 Anke Sieg, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Fabienne Jeanneret, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Brigitte Traversa, Victoria College of Pharmacy, Monash University, Australia
- 2005 Laïla Boulmedarat, Ecole doctorale 'Innovation thérapeutique: du fondamental a l'appliqué',  
 Université de Paris-Sud, Châtenay-Malabry, France  
 Yannic Schuetz, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Sophie Mehier-Humbert, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Nada Abla, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Marie-Laure Leichtnam, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Isabel Diaz de Consuelo, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Blaise Mudry, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Christophe Herkenne, Université de Genève, Faculté des Sciences, Section de Pharmacie  
 Yingxin Cui, London South Bank University  
 Rebecca Watkinson, University of Greenwich
- 2006 Paul Prentice, University of Dundee  
 Delphine Soury, Ecole doctorale 'Innovation thérapeutique: du fondamental a l'appliqué',  
 Université de Paris-Sud, Châtenay-Malabry, France  
 Giorgio Ottoviani, Faculté des sciences, Université de Genève, Switzerland
- 2007 Valentine Wascotte, Université catholique de Louvain, Brussels, Belgium  
 Andrés Femenía Font, Universidad CEU Cardenal Herrera, Valencia, Spain
- 2008 Corinne Eenschooten, Danish Technical University, Lyngby, Denmark  
 Virginie Vallet, Faculty of Pharmacy, Université Claude-Bernard – Lyon 1, France
- 2009 Yanjun Zhao, King's College, London
- 2010 Kent Wooi Ng, Cardiff University, Cardiff  
 Oliver Ackaert, Leiden University, Leiden, The Netherlands  
 Carine Jacques, Université Paul Sabatier – Toulouse III, Toulouse, France
- 2011 Harshal Kubavat, University of Bath  
 Marina Krämer, University of Bath  
 Marta Jorge Cabral Machado, University of London
- 2014 Xueqin Chen, Ecole Centrale, Marseille, France  
 Vikas Hegde, University of Dundee
- 2015 Martin Rowland, University of Bath  
 Clemence Chenevas-Paule, University of Sunderland

**Masters Examinations or Theses Committees**

- 1984 Chairman, Masters Degree Committee, Charles Ryll, Pharmaceutical Chemistry
- 1993 Masters Degree Committee, Karine Buffard, Pharmacy, Université de Paris-sud
- 1997 Docteur en Pharmacie Degree Committee, Gilles Touraille, Pharmacy, Université de Paris-sud



## UNIVERSITY AND PUBLIC SERVICE

### University Service

- 1998-2004 Faculty search committees, University of Geneva
- 2001-2003 Director, Ecole romande de pharmacie, Universities of Geneva and Lausanne
- 2004-2006 Executive Committee, Department of Pharmacy & Pharmacology, University of Bath  
Research Committee, Department of Pharmacy & Pharmacology, University of Bath
- 2004- Professorial promotion/appointment committees, University of Bath
- 2006-2008 Executive Committee, Faculty of Sciences, University of Bath  
Head of Department of Pharmacy & Pharmacology, University of Bath
- 2005-2009 External examiner, The Welsh School of Pharmacy, Cardiff University
- 2006-2008 Board of Studies, Faculty of Sciences, University of Bath  
Biosciences Services Management Committee, University of Bath  
Chair, Strategy Committee, Department of Pharmacy & Pharmacology, University of Bath  
Chair, Operating Committee, Department of Pharmacy & Pharmacology, University of Bath  
Chair, Safety Committee, Department of Pharmacy & Pharmacology, University of Bath  
Chair, ETG Committee, Department of Pharmacy & Pharmacology, University of Bath  
Chair, Board of Studies, M.Pharm. degree, Department of Pharmacy & Pharmacology, University of Bath  
Chair, Board of Studies, M.Pharmacol. and B.Pharmacol. degrees, Department of Pharmacy & Pharmacology, University of Bath
- 2008-11 University of Bath Research Committee
- 2008-10 University Research Students Committee, University of Bath  
Chair, University of Bath Research Information Group  
University Research Advisor, University of Bath
- 2009-10 Chair, Research Information Advisory Group, University of Bath
- 2009- University of Bath Senate
- 2010-12 Chair, Research Staff Working Group, University of Bath  
Impact Sub-Group, REF 2014, University of Bath
- 2010-13 Chair, Research Committee, Department of Pharmacy & Pharmacology, University of Bath  
Research Committee, Faculty of Science, University of Bath  
Unit of Assessment Leader, REF 2014, University of Bath
- 2011-12 Academic Staff Development Steering Committee, University of Bath
- 2013- Disciplinary Committee of Senate, University of Bath
- 2014 Academic Staff Appeal Committee, University of Bath

- 2015 Member, External Assessment Panel, B.Sc. programme in Cosmetic Science, University of Sunderland
- 2015-16 Member, "Partridge Group", responsible for new M.Pharm. curriculum development and GPhC reaccreditation, Department of Pharmacy & Pharmacology, University of Bath.
- 2016- Metrics in Research Assessment and Management Working Group, University of Bath

**Service to Educational, Governmental, and Other Agencies**

- 1998- Referee, Engineering and Physical Sciences Research Council, U.K.
- 2002 External Referee, Upjohn Research Award, University of Michigan, Ann Arbor, Michigan  
External Reviewer, Foundation for Research & Development, South Africa  
Reviewer, American Diabetes Association
- 2004- External Reviewer, Biotechnology and Biological Sciences Research Council, U.K.  
Referee, Medical Research Council, U.K.  
Referee, Science Foundation Ireland  
External Reviewer, U.S. National Institutes of Health  
Expert Reviewer, Cosmetics, Toiletries and Fragrance Association, New York, USA
- 2005-6 Member, Expert Group on the application of the Threshold of Toxicological Concern (TTC) to the safety evaluation of cosmetic ingredients and end products, COLIPA (The European Cosmetic, Toiletry and Perfumery Association), Brussels, Belgium  
Member, Scientific Committee on Consumer Products, Working Group on 'Nanotechnology', European Commission, Health & Consumer Protection Directorate-General, Brussels, Belgium.
- 2006 External Reviewer, Foundation for Research & Development, South Africa  
Referee, Israel Science Foundation
- 2007 Contributor to European Commission, Health & Consumer Protection Directorate-General, Scientific Committee on Consumer Products "Opinion on Safety of Nanomaterials in Cosmetic Products", adopted December 18, 2007.  
[http://ec.europa.eu/health/ph\\_risk/committees/04\\_sccp/docs/sccp\\_o\\_123.pdf](http://ec.europa.eu/health/ph_risk/committees/04_sccp/docs/sccp_o_123.pdf)
- 2009 Expert, European Medicines Evaluation Agency, London, U.K.  
Panel member, Research Councils for Health and Natural Sciences and Engineering of the Academy of Finland  
Expert, Federal Trade Commission, Washington, DC, USA  
Reviewer, Diabetes U.K.

- 2010 Expert witness on behalf of the Minister for Health & Ageing, Australia (Therapeutic Goods Administration), Administrative Appeals Tribunal, Sydney
- External Reviewer, National Research Foundation, South Africa
- External Assessor for the internal review of the University of Nottingham's School of Pharmacy
- 2010- Member, Expert Advisory Panel for Pharmaceutical Science, Royal Pharmaceutical Society of Great Britain
- 2011 Member, The Danish Council for Independent Research, Danish Agency for Science, Technology & Innovation, Medical Bio-Pharma grants review panel
- External Reviewer, British Skin Foundation
- External Reviewer, SPARKS
- External Reviewer, Wellcome Trust
- 2012 External Panel Member, Appointment committee for the Norbrook Chair in Pharmaceutical Sciences, University of Ulster
- External Assessor, Chair in Pharmaceutical Sciences, Welsh School of Pharmacy, Cardiff University
- External Member, Professors interview panel, University of the Arts London
- External Reviewer, ETH Zurich Research Commission
- 2013-14 Assessor for the REF Sub-panel 3: Allied Health Professions, Dentistry, Nursing and Pharmacy.
- 2013 External Reviewer, National Institute of Health Research
- 2014 External Reviewer, Czech Research Foundation
- External Reviewer (Stage 1 panel), Science Foundation Ireland
- Panel Member, International Life Sciences Research Announcement (ILSRA) Physiology, Monitoring and Pharmacology, NASA (Washington, D.C., USA)
- 2015 External Reviewer, Hadwen Trust
- External Reviewer, Queen's University, Belfast, MRC Confidence-in-Concepts grant applications
- External Reviewer, National Research, Development and Innovation Office, Hungary
- 2015-16 Panel Member, NC3Rs CRACK-IT Challenge Review Panel – Metaboderm, Wellcome Trust, U.K.

## PROFESSIONAL ACTIVITIES

### Service to Scholarly and Professional Societies (since 1994)

- 1994 Co-Director (with Professeur Jean-Paul Marty), "Administration Transdermique de Médicaments," a 3-day course covering all aspects of the transdermal administration of drugs. Marne la Vallée, France
- Co-Chairman (with Professeur Jean-Paul Marty), 21st International Symposium on Controlled Release of Bioactive Materials, Controlled Release Society. Nice, France
- 1994-95 Member, Organizing Committee, "Prediction of Percutaneous Penetration: Methods, Measurements, Modeling." International Conference. Montpellier, France
- 1994-97 Member, Electorate Nominating Committee, AAAS Section on Pharmaceutical Sciences. American Academy for the Advancement of Science. Washington, DC
- 1998-2001 Vice-President, President-Elect and President, Controlled Release Society, Deerfield, Illinois
- 2002-2006 Member, Høst-Madsen Award Committee, Fédération internationale de pharmacie (F.I.P.), The Hague, Netherlands
- 2003 Discussion Leader, Gordon Research Conference on 'Barrier function of mammalian skin', Roger Williams University, Rhode Island, USA
- 2003- Member, Executive Committee, Skin Forum
- 2005 Discussion Leader, Gordon Research Conference on 'Barrier function of mammalian skin', Mount Holyoke College, Massachusetts, USA
- 2008 Co-Chair, Lohmann LTS Academy Symposium on "Unmet Needs in Transdermal Drug Delivery", Königswinter, Germany
- 2009 Debate Leader, Gordon Research Conference on 'Barrier function of mammalian skin', Waterville Valley, New Hampshire, USA
- 2011 Discussion Leader, Gordon Research Conference on 'Barrier function of mammalian skin', Waterville Valley, New Hampshire, USA
- Conference Scientific Chair, Academy of Pharmaceutical Sciences, Great Britain, PharmSci 2011, Nottingham, UK
- 2011- Member of, now Advisor to, the Board of the Academy of Pharmaceutical Sciences, Great Britain
- Member, Expert Working Group on the 'evaluation of oral-to-dermal extrapolation', European Commission Project 'Integrated In Silico Models for the Prediction of Human repeated Dose Toxicity of COSMetics to Optimise Safety' (COSMOS).
- 2014 Co-author, "New Medicines, Better Medicines, Better Use of Medicines", a guide to the science underpinning pharmaceutical practice, Royal Pharmaceutical Society, London, May 2014.

### **Service to Scholarly and Professional Journals**

- 1981 – Referee, International Journal of Pharmaceutics  
Referee, Journal of Physical Chemistry  
Referee, Canadian Journal of Chemical Engineering
- 1982 – Referee, Journal of Pharmaceutical Sciences
- 1983 – Referee, Journal of Investigative Dermatology  
Referee, Pharmaceutical Research
- 1984 – Referee, Journal of Controlled Release  
Referee, Journal of Pharmacokinetics and Biopharmaceutics  
Referee, Chemical Reviews
- 1985 – Referee, Archives of Dermatology  
Referee, Microvascular Research  
Referee, Life Sciences
- 1986 – Referee, Science
- 1986 – Referee, Journal of the American Chemical Society  
Referee, Mathematical Biosciences
- 1987 – Referee, S. African Journal of Science  
Referee, Drug Design and Delivery  
Referee, Skin Pharmacology
- 1987-2008 Member, Editorial Advisory Board, Skin Pharmacology
- 1988 – Referee, Plastic and Reconstructive Surgery  
Referee, Toxicology and Applied Pharmacology  
Referee, Industrial and Chemical Engineering Research
- 1990 – Referee, Diabetes Care  
Referee, Chest
- 1992-2003 Member, Editorial Advisory Board, Advanced Drug Delivery Reviews  
Referee, American Institute of Chemical Engineers Journal  
Referee, Toxicology and Applied Pharmacology
- 1993–4 Member, Editorial Advisory Board, Pharmaceutical Research
- 1993 – Referee, European Journal of Pharmaceutical Sciences  
Referee, Journal of Pharmacology and Experimental Therapeutics  
Referee, European Journal of Pharmaceutics and Biopharmaceutics  
Referee, Journal of Drug Targeting  
Referee, Bioorganic & Medicinal Chemistry

1994 – Referee, Journal of Exposure Analysis and Environmental Epidemiology

1995 – Referee, S.T.P. Pharma Sciences (Editions de Santé)

1996 – Member, Editorial Advisory Board, European Journal of Pharmaceutics and Biopharmaceutics

1997-2000 Member, Editorial Advisory Board, Journal of Controlled Release

1997-2003 Member, Editorial Advisory Board, Journal of Pharmacy & Pharmacology

2000-16 Member, Editorial Advisory Board, Diabetes, Technology & Therapeutics  
Referee, Diabetes, Technology & Therapeutics

2001-02 Member, Editorial Advisory Board, Drug Discovery Today

2002-07 Associate Editor, Journal of Pharmaceutical Sciences  
Referee, Photochemistry & Photobiology

2003- Referee, Bioelectrochemistry  
Referee, Nature Reviews, Drug Discovery

2003- Member, Editorial Advisory Board, European Journal of Pharmaceutical Sciences

2004- Referee, Sensors and Actuators, B  
Referee, Environmental Science & Technology

2005- Referee, Journal of Drug Delivery Science & Technology  
Referee, Nature Reviews Immunology  
Referee, Skin Pharmacology & Physiology

2006- Referee, Pharm. Biochem. Behaviour  
Referee, Proceedings of the National Academy of Sciences, USA  
Referee, Journal of Medicinal Chemistry  
Referee, Expert Opinion in Drug Delivery  
Referee, American Journal of Drug Delivery

2008- Member, Editorial Advisory Board, Skin Pharmacology & Physiology  
Member, Editorial Advisory Board, Journal of Pharmaceutical Sciences  
Referee, Journal of Pharmacokinetics and Pharmacodynamics  
Referee, Biophysical Journal

2009- Referee, Nature Nanotechnology  
Referee, Journal of Drug Targeting

2010- Referee, Toxicology Letters  
Referee, ACS Nano

2011- Referee, Molecular Pharmaceutics  
 Referee, AAPS J.  
 Referee, Nanomedicine

2012- Referee, International Journal of Cosmetic Science

2014- Referee, Chemical Research in Toxicology  
 Referee, PLoS One

2015- Referee, Nature Protocols  
 Referee, Environmental Science & Technology  
 Referee, Lab on a Chip  
 Referee, Annals of Otology, Rhinology & Laryngology

2016- Referee, Clinical Pharmacokinetics  
 Referee, J. Appl. Toxicol.  
 Referee, J. Exposure Sci. Environ. Epidemiol.  
 Referee, Nature Nanotechnology

2017- Member, Editorial Advisory Board, International Journal of Pharmaceutics

**Consultant or Service as a Professional Expert (since 1994; active in green)**

1994-5 Co-Founder and Member, Board of Directors, De Novo, Inc., Menlo Park, California  
 Member, Scientific Advisory Board, De Novo, Inc., Menlo Park, California

1994-9 Consultant, Becton Dickinson Transdermal Systems, Franklin Lakes, New Jersey: Iontophoresis and Formulation  
 Member, Scientific Advisory Board, Advanced Polymer Systems, Redwood City, California

1994-2001 Consultant, Unilever Research, Port Sunlight, England: Skin/hair care

1995-6 Consultant, Tilderm Systems, Laboratoires Fournier, Chenôve, France: Iontophoresis  
 Member, Scientific Advisory Board, Advanced Therapies Inc., Novato, California

1996 Consultant, Searle, Skokie, Illinois: Transdermal drug delivery  
 Consultant, Zyma SA, Nyon, Switzerland: Topical and transdermal drug delivery

1996-9 Consultant, Novo Nordisk, Denmark: Iontophoresis and drug delivery  
 Consultant, Novartis, Basel, Switzerland: Optimization of topical drug delivery

1996-8 Member, Scientific Advisory Board, EKOS LLC, Seattle, Washington  
 Consultant, Cellegy, Inc., Foster City, California: Topical drug delivery

1997-8 Consultant, CIRD-Galderma, Sophia Antipolis, France: Topical drug delivery  
 Consultant, Institut de Recherche Pierre Fabre, Castanet Tolosan, France

1997-8 Member, Scientific Advisory Board, Biovector, Toulouse, France

1998-9 Member, Scientific Advisory Board, Cellegy, Inc., Foster City, California

1999-2000 Consultant, *éthymed*, Paris, France  
 Consultant, Innothera, Paris, France

1999-2002 Consultant, Pacific Corporation, Seoul, Korea

2001-2013 Consultant, L'Oréal, Paris, France

2001-2003 Member, Scientific Advisory Board, LSC, Inc., Burlingame, California

2001-2004 Consultant, OM Pharma, Geneva, Switzerland

2001-2006 Member, Scientific Advisory Board, Vyteris, Inc., Fair Lawn, New Jersey

2002-2007 Member, Scientific Advisory Board, TransPharma, Inc., Israel

2002-2004 Consultant, GSK Consumer Health, Weybridge, England  
 Consultant, Abbott Laboratories, Abbott Park, Illinois

2003 Consultant, Laboratoires Besins

2003-2004 Consultant, Galderma SA, Sophia Antipolis, France

2004-2005 Consultant, Shire Pharmaceuticals, PLC, Basingstoke, UK

2004-2006 Consultant; Member, Scientific Advisory Board, PowerPaper, Inc., Israel  
 Consultant, Firmenich, SA, Geneva, Switzerland

2005 Consultant, Amgen, Inc., Cambridge, UK

2005-2009 Consultant, York Pharma, Sheffield, UK

2005-2010 Member, Scientific Advisory Board, Acrux, Ltd., Melbourne, Australia

2006 Member, Scientific Advisory Board, Connetics, Inc., Palo Alto, CA, USA

2006-2008 Consultant, Shire Pharmaceuticals, PLC, Basingstoke, UK

2006-2010 Member, Scientific Advisory Board, DBV Technologies, Paris, France

2006-2013 Member, Scientific Advisory Board, EyeGate Pharmaceuticals, Inc., Waltham, MA, USA

2007 Consultant, GSK, Parsippany, NJ, USA  
 Consultant, Unilever, Trumbull, CT, USA

2007-2008 Consultant, Altea Therapeutics, Atlanta, GA, USA



Consultant, Pharmakodex, Chippenham, U.K.

2008-2011      Member, Scientific Advisory Board, Vyteris, Inc., Fair Lawn, New Jersey, USA  
 Chair, Scientific Advisory Board, Altea Therapeutics, Atlanta, GA, USA

2008            Consultant, Acclarent, Inc., Palo Alto, CA, USA  
 Consultant, Serentis, Ltd., Cambridge, U.K.  
 Consultant, TPG Partners, Fort Worth, TX, USA  
 Consultant, Rader, Fishman & Grauer PLLC, Bloomfield Hills, Michigan, USA

2008-09        Consultant, OBJ, Ltd., Leederville, WA, Australia

2009            Consultant, Bristol Myers Squibb, Moreton, Wirral, U.K.

2009-2010     Consultant, Therapeutic Goods Administration, Canberra, Australia

2009-            Consultant, PMIC, Anthony, France

2010-            Consultant, Grunenthal GmbH, Germany  
 Consultant, Leo Pharma A/S, Denmark

1997            Consultant, Novartis Pharma, Basel, Switzerland  
 Consultant, Isdin S.A., Spain

2011-            Consultant, Nemauro Pharma, Loughborough, U.K.

2012            Consultant, Genentech, South San Francisco, CA, USA  
 Consultant, GSK Consumer Health, Parsippany, NJ, USA  
 Consultant, Sanofi Recherche, Montpellier, France

2012-            Consultant, Delenex AG, Zurich, Switzerland

2013-            Consultant, Dermira, Inc., Redwood City, CA, USA  
 Consultant, Nitto Denko Technical Corporation, Oceanside, CA, USA

2013-14        Chair, Expert Panel Meeting on Topical Ketoprofen, Hisamitsu Pharmaceutical Co., Ltd.,  
 Japan

2014-            Consultant, GSK Consumer Health, Singapore  
 Consultant, Medivation, Inc., San Francisco, CA, USA  
 Consultant, Mundipharma Research Ltd., Cambridge, U.K.

2016-            Member, Scientific Advisory Board, Almirall S.A., Barcelona, Spain  
 Member, Scientific Advisory Board, Pierre-Fabre, Toulouse, France  
 Consultant, L'Oréal, Paris, France

## Invited Lectures and Seminars (since 2005)

- 2005      Mechanisms of Iontophoretic and Sonophoretic Drug Delivery Across the Skin. United Kingdom and Ireland Controlled Release Society, 11th Annual Symposium, Aston University, Birmingham, UK (January 6)
- Recent Advances in Transdermal Administration. Plenary Lecture. VII Congreso de la Sociedad Española de Farmacia Industrial y Galénica. Salamanca, Spain (February 8)
- Science Meets the Skin: Delivering Drugs Legally. Inaugural lecture. University of Bath, Bath, UK (February 23)
- Physical Delivery Methods: Iontophoresis and Beyond. Skin Science and Advances in Aesthetic Therapies Symposium, 39<sup>th</sup> Annual Conference of the Australian Society of Cosmetic Chemists. Brisbane, Australia (March 16)
- Following Substances Into (and Through) the Skin by Tape-Stripping. 39<sup>th</sup> Annual Conference of the Australian Society of Cosmetic Chemists. Brisbane, Australia (March 17)
- Biophysical Techniques in Skin Research: Infrared (IR) Spectroscopy. 39<sup>th</sup> Annual Conference of the Australian Society of Cosmetic Chemists. Brisbane, Australia (March 20)
- Following Substances Into (and Through) the Skin by Tape-Stripping. Acrux, Inc. Melbourne, Australia (March 22)
- (Trans)dermal Technologies. Hud och Läkemedel («Skin and Drugs»), University of Göteborg, Gothenburg, Sweden (May 18)
- Method Development and Modeling to Characterize Penetration, Absorption, Dose, and Local Effects Resulting from Dermal Exposures. Plenary lecture, Occupational and Environmental Exposures of the Skin to Chemicals, Karolinska Institute, Stockholm, Sweden (June 12)
- Closing the Loop: Noninvasive Drug Delivery and Clinical Monitoring via the Skin. Invited Lecture, 32<sup>nd</sup> Annual Meeting & Exposition of the Controlled Release Society, Miami Beach, Florida, USA (June 20)
- Novel Transdermal Technologies to Control, Manipulate and Optimize Drug Input Across the Skin. Sanofi-Aventis, Paris, France (June 28)
- Dermatopharmacokinetics: Opportunities and Limitations for Assessment of Topical Bioavailability. Invited speaker, 6<sup>th</sup> Annual Meeting of Skin Forum, University College, Winchester, UK (June 30)
- (Trans)Dermal Technologies for Delivery and Diagnosis. Proctor & Gamble, Egham, UK (July 10)
- Dermatopharmacokinetics: Opportunities and Limitations for Assessment of Topical Bioavailability. York Pharma, Sheffield, UK (July 12)
- Latest Developments in Iontophoresis. PowerPaper Scientific Advisory Board meeting, Paris, France (September 2)

Dermatopharmacokinetics: A Tool for Determining Bioequivalence between Topical Formulations. Invited speaker, "Biointernational 2005: Towards Resolution of Complex BE Issues", Royal Pharmaceutical Society, London, UK (October 24)

Measurement and Prediction of the Rate and Extent of Drug Delivery into and through the Skin. Invited speaker, 2<sup>nd</sup> EUFEPS Conference on "Optimizing Drug Delivery and Formulation", Versailles, France (November 23)

2006

Penetration of Molecules and Particles (?) into and through the Skin. Nanotoxicology Symposium: Toxicology and Technology of Nanoparticles. Centre for Xenobiotic and Environmental Risk Research, University of Zurich, Zurich, Switzerland (January 11)

Drug Delivery into and through the Skin: Quantification, Enhancement and Optimization. Connetics Visiting Lecture Series, Palo Alto, CA, USA (April 19)

Novel Transdermal Technologies to Control, Manipulate and Optimize Drug Input across the Skin. L'Oréal Research, Aulnay-sous-Bois, France (May 22)

Novel Transdermal Technologies to Control, Manipulate and Optimize Drug Input across the Skin. Galderma Research & Development, Sophia Antipolis, France (July 10)

Drug Delivery into and through the Skin: Quantification, Enhancement and Optimization. Galderma Research & Development, Sophia Antipolis, France (July 11)

Science Meets the Skin: Delivering Drugs Legally. USA, Warminster (July 19)

Transdermal Science and Technology in the New Millenium. Invited speaker, Teikoku Seiyaku Reception, 33<sup>rd</sup> Annual Meeting & Exposition of the Controlled Release Society, Vienna, Austria (July 23)

Closing the Loop: Noninvasive Drug Delivery and Clinical Chemistry via the Skin. Invited speaker, British Pharmaceutical Conference, Manchester, UK (September 6)

Estimating the Percutaneous Absorption of Fragrance Materials. Expert panel meeting of the Research Institute of Fragrance Materials, Berlin, Germany (September 11)

Topical Bioavailability: Stripping and Science. Invited speaker, 2<sup>nd</sup> APGI Symposium: Skin & Formulation. Versailles, France (October 10)

Chemical Enhancement of Transdermal Drug Delivery. Corium, Inc. Redwood City, CA, USA (October 23)

Novel Transdermal Technologies to Control, Manipulate and Optimize Drug Input across the Skin. Connetics, Inc., Palo Alto, CA, USA (October 24)

Topical Bioavailability: Quantification and Optimization. Invited speaker, 2<sup>nd</sup> International Meeting of the Society for Skin Pharmacology and Physiology: *Skin Physiology: Irritation and Penetration Pathways*. Rome, Italy (November 6)

Electrotransport Across the Skin: Physical Chemistry, Bioengineering and Clinical Application. Physical & Theoretical Chemistry Laboratory, Department of Chemistry, Oxford University, Oxford (November 13)

- 2007
- Closing the Loop: Noninvasive Drug Delivery and Clinical Monitoring via the Skin. The Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Galsgow, Scotland (January 30)
- Skin Barrier Function: Biophysics, Models and Measurements. Conopco, Inc., (Unilever), Trumbull, CT, USA (March 15)
- Iontophoresis: Basic Principles and Potential Applications. Eyegate Pharmaceuticals, Waltham, MA, USA (March 16)
- Topical Bioavailability: Stripping and Science. Invited speaker, 8<sup>th</sup> Skin Forum, London (April 4)
- Opportunities and Limitations for Assessment of Topical Bioavailability. Chulalongkorn University, Faculty of Pharmaceutical Sciences, Bangkok, Thailand (May 14)
- Electrotransport Across the Skin: Physical Chemistry, Bioengineering and Clinical Application. Chulalongkorn University, Faculty of Pharmaceutical Sciences, Bangkok, Thailand (May 14)
- Transdermal Science and Technology in the New Millenium. Altea Therapeutics, Atlanta, GA, USA (June 14)
- Drug Delivery: Hits, Hype and Hope for the 21<sup>st</sup> Century. Dept. of Pharmacy & Pharmacology, Centenary Science Day Celebration, University of Bath (July 5)
- Assessment of Topical Drug Delivery and Bioavailability. Invited speaker. Gordon Research Conference on "Barrier Function of Mammalian Skin", Newport, RI, USA (August 6)
- New Technologies in the Evolution of Transdermal Drug Delivery. Plenary speaker. 5<sup>th</sup> International Postgraduate Research Symposium on Pharmaceutics. Istanbul, Turkey (September 14)
- New Aspects of Cutaneous Drug Penetration. Invited speaker. World Congress of Dermatology, Buenos Aires, Argentina (October 4)
- Predicting the Rate and Extent of Chemical Absorption into and through the Skin. Invited speaker. American College of Toxicology, 28<sup>th</sup> Annual Meeting, Charlotte, NC, USA (November 13)
- Transdermal Drug Delivery: Principles, Practice and Promise. Hisamitsu Pharmaceutical Co., Ltd., 160<sup>th</sup> Anniversary Symposium. Plenary speaker. Tokyo, Japan (December 1)
- Assessment of Topical Drug Delivery and Bioavailability. Hisamitsu Pharmaceutical Co., Ltd., Tosu, Kyushu, Japan (December 3)
- 2008
- Iontophoresis, Electroporation and Other Techniques to Overcome the Skin's Barrier. L'Oréal (Cosmétique Active), Asnières, Paris, France (January 9)
- Electrotransport Across the Skin: Physical Chemistry, Bioengineering and Clinical Application. Plenary speaker, "Perspectives in Percutaneous Penetration", 11<sup>th</sup> International Conference, La Grande Motte, France (March 26)

Dermatopharmacokinetics. Invited speaker, "Perspectives in Percutaneous Penetration", 11<sup>th</sup> International Conference, La Grande Motte, France (March 27)

Topical Drug Bioavailability: Dermatopharmacokinetics. Invited speaker, "Topical and Transdermal Drugs – Challenges and Opportunities", Swedish Academy of Pharmaceutical Sciences, Stockholm, Sweden (April 23)

Dermatopharmacokinetics: Assessment of Topical Drug Bioavailability. Galderma S.A., Sophia Antipolis, France (June 16)

Topical Drug Bioavailability and Dermatopharmacokinetics. Invited speaker, 4<sup>th</sup> Skin Focus Meeting, Cardiff (June 18)

Topical Drug Bioavailability and Dermatopharmacokinetics. Invited speaker, L'Oréal Research, Aulnay-sous-Bois, France (October 13)

Iontophoretic Drug Delivery. Invited speaker. Lohmann LTS Academy Symposium on "Unmet Needs in Transdermal Drug Delivery", Königswinter, Germany (October 16)

Disposition of Nanoparticles Contacting the Skin. 1<sup>st</sup> International Conference on Dermatotoxicology, Vaals, The Netherlands (October 25)

Bioengineering and the Skin: Transdermal technologies for Drug Delivery and Clinical Monitoring. Department of Chemical Engineering, University of Cambridge, Cambridge (November 26)

2009 Bilateral Collaboration on Education and Research. UKIERI Awards Symposium. New Delhi, India (March 23)

Assessment of Topical Bioavailability. Invited speaker. Annual meeting of the British Society for Investigative Dermatology, Royal Agricultural College, Cirencester (March 30)

Transdermal Drug Delivery for Children. Invited speaker. Pharmaceutical Translational Research Conference. Medicines for Children Research Network. The School of Pharmacy, University of London, London (April 2)

Transdermal Drug Delivery. Invited speaker. 5<sup>th</sup> GPA/UKCPA Joint Annual National Conference. Leicester (May 16)

Transdermal Delivery Techniques. Invited speaker. Joint Conference in Medical Sciences 2009. Mahidol-Chulalongkorn Universities. Bangkok, Thailand (June 23)

Bioavailability of Actives Applied Topically to the Skin. Invited speaker. Joint Conference in Medical Sciences 2009. Mahidol-Chulalongkorn Universities. Bangkok, Thailand (June 23)

Non-Invasive Monitoring Across the Skin. Bath Biosensor Network, 1<sup>st</sup> Bath Interdisciplinary Meeting on Biosensors. Bath (September 23)

The Stratum Corneum as a Pharmacokinetic Compartment. Invited speaker. "StratumCorneum VI", International Society of Stratum Corneum Research. Boston, MA, USA (October 1)

Disposition of Nanoparticles Contacting the Skin: a Reality Check... Invited speaker.

Dermatopharmaceutics Focus Group Meeting, Annual Meeting of the American Association of Pharmaceutical Scientists. Los Angeles, CA, USA (November 11)

Microdialysis and Stratum Corneum Tape-Stripping for Dermatopharmacokinetics. Invited speaker. Annual Meeting of the American Association of Pharmaceutical Scientists. Los Angeles, CA, USA (November 11)

Fonction Barrière de la Peau. Les Matinees Scientifiques de Cosmétique Active. L'Oréal. Asnières-sur-Seine, France (December 4)

Research Study Options in the U.K. and at the University of Bath. Ph.D. Workshop China 2009. Beijing, China (December 12)

2010 Transdermal Drug Delivery. Department of Bioengineering & Therapeutic Sciences, University of California – San Francisco, San Francisco, CA, USA (January 25)

Optimising Topical Formulations for Drug Delivery into the Skin: Mechanisms and Methodologies. Leo Pharma A/S, Ballerup, Denmark (March 4)

Transdermal Drug Delivery Technologies. School of Pharmacy, Queen's University Belfast. Belfast, N. Ireland (March 10)

Topical Bioavailability and Formulation Optimisation. Invited speaker. 8<sup>th</sup> International Conference & Workshop on Biological Barriers. Saarland University, Saarbrücken, Germany (March 29)

Dermatopharmacokinetics: Assessment of Topical Drug Bioavailability. Leiden-Amsterdam Centre for Drug Research. Leiden University, Leiden, The Netherlands (April 28)

Dermatopharmacokinetics: Clinical Perspectives. University of Valencia. Valencia, Spain (June 1)

Predicting the Rate and Extent of Chemical Absorption Into and Through the Skin. Dermal Exposure Working Group, International Life Sciences Institute (ILSI) Research Foundation & U.S. Environmental Protection Agency, Washington, DC, USA (June 21)

Probing Drug Delivery to the Skin Using Stimulated Raman Scattering Microscopy. Invited speaker. 7th Annual Coherent Raman Microscopy Workshop, Harvard University, Cambridge, MA, USA (June 25)

Les Systèmes Iontophorétiques. L'Oréal. Asnières-sur-Seine, France (July 12)

Bioavailability Issues in Dermal Delivery – In Vivo Methods. Invited speaker. Academy of Pharmaceutical Sciences G.B., UK PharmSci 2010, University of Nottingham (September 1)

Optimising Topical Formulations to Deliver Actives into the Skin: Mechanisms and Methodologies. Unilever. Trumbull, CT, USA (December 14)

Skin – “That Unfakeable Young Surface”. Invited speaker. Festschrift for Prof. Jonathan Hadgraft. The School of Pharmacy, University of London (December 16)

2011 Optimising Topical Formulations to Deliver Actives into the Skin: Mechanisms and Methodologies. L'Oréal. Aulnay-sous-Bois, France (March 4)

Measuring Drug Permeation and Penetration into and through Skin Using Coherent Raman Microscopy. Invited speaker. Skin Forum 12<sup>th</sup> Annual Meeting (with APV). Frankfurt, Germany (March 29)

Imaging Drug Delivery to Skin with Stimulated Raman Scattering Microscopy. Invited speaker. 39<sup>th</sup> Interpharm Research Conference. Brockenhurst, UK (May 13)

Transdermal Technology for Drug Delivery. Invited speaker. 3<sup>rd</sup> PharmSciFair. Prague, Czech Republic (June 15)

Measuring Drug Permeation and Penetration into and through Skin Using Coherent Raman Microscopy. Invited speaker. CARS Explorer Symposium: Optical Solutions to Biomedical Problems. Marseille, France (June 20)

Imaging Drug Delivery to Skin with Stimulated Raman Scattering Microscopy. Leo Pharma A/S, Ballerup, Denmark (June 23)

Electrotransport Across the Skin – Delivery and Sampling. Invited speaker. Skin Trailblazer, 2<sup>nd</sup> Workshop. Boston, MA, USA (August 7)

Is There a Future for (Transdermal) Drug Delivery? Conference Scientific Chair's Address. PharmSci 2011, Academy of Pharmaceutical Sciences, Great Britain. Nottingham (August 31)

Imaging Drug Delivery to Skin Using Coherent Raman Scattering Microscopy. Invited speaker. PharmSci 2011, Academy of Pharmaceutical Sciences, Great Britain. Nottingham (August 31)

Predicting the Rate and Extent of Chemical Absorption through the Skin. International Life Sciences Institute (ILSI), COSMOS expert group 2, Brussels, Belgium (September 13)

Formulation Chemistry and (Trans)Dermal Drug Delivery. [in French] D.Young & Co., London (September 27)

Is There a Future for Transdermal Drug Delivery? Invited speaker. LTS Academy 8<sup>th</sup> Symposium "New Horizons in Drug Delivery: 35 years on". Bonn, Germany (September 29)

A Tiered Approach to Dermal Exposure Assessment for Anti-Microbial Pesticides. Speaker. Society for Risk Analysis 2011 Annual Meeting, Charleston, SC, USA (December 6)

A Tiered Approach to Dermal Exposure Assessment for Anti-Microbial Pesticides. U.S. Environmental Protection Agency, Crystal City, VA, USA (December 8)

1998 Predicting the Flux of Cosmetic Ingredients across the Skin. International Life Sciences Institute (ILSI), COSMOS expert group 2, Brussels, Belgium (March 19)

Transdermal Drug Delivery from Gels. Invited speaker, "Perspectives in Percutaneous Penetration", 13<sup>th</sup> International Conference, La Grande Motte, France (April 12)

Skin Biophysics and Transdermal Technologies for Drug Delivery and Clinical Monitoring. Department of Physics, University of Exeter, Exeter (April 23)

Imaging Drug Delivery to Skin Using Coherent Raman Scattering Microscopy. Invited speaker. Workshop on Applications of Coherent Raman Scattering Microscopy. University of Exeter, Exeter (April 23).

Disposition of Nanomaterials Applied to the Skin: Assessment and Imaging. Invited speaker. International Meeting: The Fundamental Pillars of Nanotechnology for the Cosmetic Industry. São Paulo, Brazil (May 18)

Delivering Actives into the Skin: Separating Fact from Fiction. Invited speaker. 5<sup>th</sup> Society of Cosmetic Scientists Annual Scientific Symposium, "Cosmetic Science: The Good, The Bad and The Beautiful", Trinity College, Dublin, Ireland (May 31)

Administration transdermique des médicaments: la technologie de pointe. [in French] Invited speaker. Académie galénique Michel Lanquetin: Sciences pharmaceutiques. Monte Carlo, Monaco (June 1)

Dermatopharmacokinetics: Assessing Bioavailability of Topically Applied "Actives". L'Oréal Research, Aulnay-sous-Bois, France (June 6)

Delivery of Ketoprofen from a Topical Patch Product: a Benefit/Risk Analysis. Invited speaker. 11<sup>th</sup> Congress of The European Society of Contact Dermatitis. Malmö, Sweden (June 13)

Improving the Bioavailability of Topically and Transdermally Administered Drugs. Invited speaker. 39<sup>th</sup> Annual Meeting of the Controlled Release Society. Quebec City, Canada (July 17)

Transdermal Drug Delivery - Past, Present and Future: Basic Science, Regulatory Challenges and New Technologies. GlaxoSmithKline Consumer Health. Parsippany, NJ, USA (July 19)

Technologies for Drug Delivery into and through the Skin. Reckitt Benkiser. Hull (July 27)

Noninvasive Sensing of Glucose and Other Analytes Across the Skin. Invited speaker. International Mini-Symposium on Sensing and Drug Delivery Systems. University of Bath (August 6)

Improving the Bioavailability of Topically and Transdermally Administered Drugs. Centre for Dermatology and Genetic Medicine, University of Dundee (October 9)

Transdermal Drug Delivery and Associated Pathology. Invited speaker. 27<sup>th</sup> Annual Scientific Meeting of the British Society of Toxicological Pathology. Astra Zeneca, Alderley Edge (November 16)

Predicting Chemical Uptake into Skin. Invited speaker. Society for Chemical Industry, Symposium: "Uptake across the leaf cuticle and skin", London (November 22)

Predicting and Measuring Drug Delivery into and through the Skin. Invited speaker. Sanofi-Aventis, Symposium: "Biopharmaceutical aspects of specific administration routes: Ocular, Otic and Cutaneous", Montpellier, France (November 29)

Imaging Drug Delivery to Skin Using Coherent Raman Scattering Microscopy. L'Oréal Research, Aulnay-sous-Bois, France (December 4)



- Transdermal Drug Delivery Technology. "Drug Delivery Strategies for Biologics", Knowledge Transfer Network – Healthtech and Medicines, BioCity – Nottingham, (December 13)
- 2013 Topical and Transdermal Drug Delivery: Rules, Tools and Nanoparticles. National Institute for Pharmaceutical Education & Research, Mohali (Punjab), India (January 21)
- Topical and Transdermal Drug Delivery: Rules, Tools and Nanoparticles. Invited speaker. Controlled Release Society Indian Chapter, 13<sup>th</sup> International Symposium. Mumbai, India (January 22)
- Transdermal Drug Delivery. Department of Bioengineering & Therapeutic Sciences, University of California – San Francisco, San Francisco, CA, USA (January 24)
- Topical Drug Delivery: Rules, Tools and Nanoparticles. Stiefel, a GSK company. Research Triangle Park, NC, USA (March 14)
- Modélisation de la Barrière et du Passage Transcutané. Invited speaker. 20<sup>ème</sup> Cours francophone de Biologie de la Peau (CoBiP 2013). Lyon, France (March 22)
- Predicting and Measuring Drug Delivery into and through the Skin. University of Maryland, School of Pharmacy, Baltimore, MD, USA (May 20)
- Dermatopharmacokinetics and Tape Stripping the Stratum Corneum: Origins and Problems. Invited speaker. Topical Drug Bioavailability/Bioequivalence Summit. University of Maryland, School of Pharmacy, Baltimore, MD, USA (May 21)
- Decision Framework for Data Needs to Estimate Dermal Exposure. Invited speaker. Webinar - Thresholds of Toxicological Concern: An Example of Integrated Approaches to Testing and Assessment. U.S. Environmental Protection Agency, Washington, DC, USA (June 11)
- Topical and Transdermal Drug Delivery: Rules, Tools and Nanoparticles. Invited speaker. Skin Forum 12<sup>th</sup> Annual Meeting, UCL School of Pharmacy, London (June 26)
- Skin – "The Finest Clothing Ever Made". Founders Award address, 40<sup>th</sup> Annual Meeting of the Controlled Release Society. Honolulu, HI, USA (July 22)
- Probing the Skin-Drug Delivery Platform Interface. Invited speaker. Gordon Conference on "Barrier Function of Mammalian Skin". Waterville Valley, NH, USA (August 21)
- Predicting and Measuring Drug Delivery into and through the Skin. Invited speaker. 28<sup>ème</sup> séminaire de 3<sup>ème</sup> cycle en sciences pharmaceutiques, "Innovation in Medicinal Chemistry". Zermatt, Switzerland (September 11)
- Drug Delivery and Targeting to Appendageal Structures in the Skin. Dermira, Inc. Redwood City, CA, USA (October 11)
- Predicting, Measuring and Optimising Drug Delivery to the Skin. Invited speaker. 4<sup>th</sup> Annual Symposium of the Pan Asian Pacific Skin Barrier Research Society. Seoul, Korea (October 15)
- Stratum Corneum et Imagerie. Invited speaker. Société Francophone d'Ingénierie et d'Imagerie Cutanée. Paris, France (October 24)

L'Absorption Cutanée – Théorie et Pratique. Invited short-course lecturer. L'Oréal Research. Chevilly-Larue, Paris, France (November 5-6)

Dermatopharmacokinetics (DPK): Potential and Limitations of Stratum Corneum Tape-Stripping. Invited speaker. Topical Bioequivalence Symposium. UCL School of Pharmacy. London (December 19)

2014 Optimisation and Quantification of Topical Drug Delivery to the Skin. National Skin Centre, Singapore (March 3)

Optimisation and Quantification of Topical Drug Delivery to the Skin. British High Commission Sponsored Lecturer, Singapore International Conference on Skin Research, Singapore (March 4)

Bioequivalence of Topical Drug Products: Development of *in vitro-in vivo* Correlations. Stiefel, a GSK company. Research Triangle Park, NC, USA (March 28)

Drug Delivery into and through the Skin. Invited speaker. 9<sup>th</sup> World Congress on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Lisbon, Portugal (April 3)

Nanoparticles and Skin: Unmoveable Objects and Irresistible Barrier. Invited speaker. 5<sup>th</sup> FIP Pharmaceutical Sciences World Congress. Melbourne, Australia (April 16)

Imaging Drug Delivery to Skin and Nail with Microspectroscopic Techniques. National Physical Laboratory. Teddington, U.K. (May 28)

Topical Bioavailability/Bioequivalence – Product Development and Regulatory Science. Stiefel, a GSK company. Webinar (June 2)

Transdermal Drug Delivery: Assessment and Evaluation of Feasibility. Tesa-Labtec GmbH, Langenfeld, Germany (July 3)

Technology is not Always Enough – a Lesson from Glucose Monitoring. PROSense (Marie-Curie ITN) Workshop on “Clinical perspectives and commercial forces on biosensor devices”. University of Bath (September 18)

Predicting, Measuring and Optimising Drug Delivery to the Skin. Pfizer, Inc., Cambridge, MA, USA (October 30)

Applying Advanced Spectroscopic and Imaging Techniques to Optimize Lipid-Based (Trans)dermal Drug Formulations. Invited speaker. American Association of Pharmaceutical Scientists, 2014 Annual Meeting & Exposition. San Diego, CA, USA (November 5)

Imaging the Disposition of Topical Drug Formulations Applied to the Skin. Invited speaker. Gattefossé Formulation Masterclass 2014. St. Priest, Lyon, France (November 24)

2015 Drug Delivery into and through the Skin. Almirall, S.A. Barcelona, Spain (February 9)

Application of Coherent Raman Scattering Microscopy to Topical Product Design and Development. Almirall, S.A. Barcelona, Spain (February 9)

Non-invasive, Reverse Iontophoretic Glucose Monitoring across the Skin. Physical &

Theoretical Chemistry Laboratory, Oxford University, Oxford (March 2)

Transdermal Drug Delivery: a Mature and Evolving Technology. Invited speaker. 1<sup>st</sup> European Conference on Pharmaceutics: Drug Delivery. Reims, France (April 13)

Imaging Drug Delivery to Skin and Nail with Microspectroscopic Techniques. Institut Fresnel, UMR 7249, Marseille, France (April 15)

Predicting, Measuring and Optimising the Delivery of Actives into the Skin. Unilever Research, Trumbull, CT, USA (April 27)

Imaging Drug Delivery to Skin and Nail with Micro(spectro)scopic Techniques. Oxford Institute of Biomedical Engineering, Oxford University, Oxford (June 2)

Predicting, Measuring and Optimising Drug Delivery to the Skin. Invited speaker. 6<sup>th</sup> Dermatological Product Development Workshop. Association for Applied Human Pharmacology. London (June 23)

In vivo Skin Stripping Studies to Evaluate Bioequivalence of Topical Drug Products. Invited speaker. FDA workshop: "Bioequivalence Testing of Topical Drug Products". Silver Spring, MD, USA (July 15)

Imaging Drug Delivery to Skin and Nail with Micro(spectro)scopic Techniques. Keynote speaker. Gordon Conference on "Barrier Function of Mammalian Skin". Waterville Valley, NH, USA (August 16)

Assessment and Optimisation of Drug Delivery to the Skin. Invited speaker. 39<sup>th</sup> Annual Meeting of the Spanish Society of Pharmacology. Valencia, Spain (September 16)

Imaging Drug Delivery to Skin and Nail with Micro(spectro)scopic Techniques. Hisamitsu Pharmaceutical Co. Ltd. Tsukuba, Japan (September 24)

Transdermal Drug Delivery: Scientific Ingenuity *versus* Skin Barrier Function. Keynote speaker. Transdermal Drug Delivery System World Symposium 2015. Tokyo, Japan (September 26)

2016 Imaging Drug Delivery to Skin and Nail with Micro(spectro)scopic Techniques. University of Bath, Department of Pharmacy & Pharmacology, Bath (March 9)

La pénétration des médicaments à travers l'ongle. Invited speaker. 11<sup>ème</sup> Colloque Francophone Thématique de Biologie Cutanée. Lyon, France (March 16).

Assessing Topical Bioavailability and Bioequivalence. Universidade Federal de Pernambuco, Department of Pharmaceutical Sciences, Recife, Brazil (March 29)

Transdermal Technologies for Drug Delivery and Clinical Monitoring. Universidade Federal de Pernambuco, Centre for Health Sciences, Recife, Brazil (March 30)

I've Got You Under My Skin. Maurice-Marie Janot Award Lecture, 10th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Glasgow (April 4)

Imaging Drug Delivery to Skin and Nail with Micro(spectro)scopic Techniques. Plenary speaker. International Society for Biophysics & Imaging of the Skin, Lisbon, Portugal (June

2)

Skin Pharmacokinetics: Modelling, Assessment and Manipulation. L'Oréal Research, Aulnay-sous-Bois, France (June 17).

Transdermal Technologies for Drug Delivery and Clinical Monitoring. University of Bath, Centre for Sustainable Chemical Technologies, Bath (July 12)

Drug Delivery to Targets in the Skin and Nail: Measurement and Optimisation. Plenary speaker. 4<sup>th</sup> Conference on Innovation in Drug Delivery, Antibes, France (September 26)

Optimisation and Evaluation of Topical Drug Bioavailability in the Skin. Pierre-Fabre, R&D Pharma, Toulouse, France (October 3)

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	29510807
<b>Application Number:</b>	13553972
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3635
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle
<b>Customer Number:</b>	22428
<b>Filer:</b>	Courtenay C. Brinckerhoff/Christine Arthur
<b>Filer Authorized By:</b>	Courtenay C. Brinckerhoff
<b>Attorney Docket Number:</b>	041457-0992
<b>Receipt Date:</b>	15-JUN-2017
<b>Filing Date:</b>	20-JUL-2012
<b>Time Stamp:</b>	15:39:54
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		responseids.pdf	316775 <small>b875e9534f867dd8965940d91e2479919aa03308</small>	yes	9

Multipart Description/PDF files in .zip description					
Document Description			Start	End	
Supplemental Response or Supplemental Amendment			1	6	
Transmittal Letter			7	8	
Information Disclosure Statement (IDS) Form (SB08)			9	9	
<b>Warnings:</b>					
<b>Information:</b>					
2	Affidavit-traversing rejectns or objectns rule 132	132decl.pdf	1432767	no	29
			a490c7b359349e78ce5cdcc7bab8af5c2bfaebc4		
<b>Warnings:</b>					
<b>Information:</b>					
3	Affidavit-traversing rejectns or objectns rule 132	cv.pdf	554175	no	78
			51cd3217c2559d0a15d2e03715bf62a99190c7ee		
<b>Warnings:</b>					
<b>Information:</b>					
4	Non Patent Literature	mantelle.pdf	1759342	no	3
			f9fd1666860cbf1d3ed3d9261a1e18ccf23ba4b7		
<b>Warnings:</b>					
<b>Information:</b>					
5	Non Patent Literature	a3.pdf	698742	no	17
			653b8bde58a14de9794057a9a1dc6bcd91794f7a		
<b>Warnings:</b>					
<b>Information:</b>					
6	Non Patent Literature	a2.pdf	401705	no	7
			67e021de357efcd55eabb2f3935453b9f0f2e55c		
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			5163506		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>PATENT APPLICATION FEE DETERMINATION RECORD</b> Substitute for Form PTO-875	Application or Docket Number <b>13/553,972</b>	Filing Date <b>07/20/2012</b>	<input type="checkbox"/> To be Mailed
---	---	----------------------------------	---------------------------------------

ENTITY:  LARGE  SMALL  MICRO

**APPLICATION AS FILED – PART I**

FOR	NUMBER FILED	NUMBER EXTRA	RATE (\$)	FEE (\$)
<input type="checkbox"/> BASIC FEE <small>(37 CFR 1.16(a), (b), or (c))</small>	N/A	N/A	N/A	
<input type="checkbox"/> SEARCH FEE <small>(37 CFR 1.16(k), (l), or (m))</small>	N/A	N/A	N/A	
<input type="checkbox"/> EXAMINATION FEE <small>(37 CFR 1.16(o), (p), or (q))</small>	N/A	N/A	N/A	
TOTAL CLAIMS <small>(37 CFR 1.16(i))</small>	minus 20 =	*	X \$ =	
INDEPENDENT CLAIMS <small>(37 CFR 1.16(h))</small>	minus 3 =	*	X \$ =	
<input type="checkbox"/> APPLICATION SIZE FEE <small>(37 CFR 1.16(s))</small>	If the specification and drawings exceed 100 sheets of paper, the application size fee due is \$310 (\$155 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).			
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIM PRESENT <small>(37 CFR 1.16(j))</small>				
* If the difference in column 1 is less than zero, enter "0" in column 2.			TOTAL	

**APPLICATION AS AMENDED – PART II**

	(Column 1)	(Column 2)	(Column 3)	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)
<b>AMENDMENT</b>	<b>06/15/2017</b>	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR			
		*	Minus	** 26	= 0	X \$80 = 0
		* 23		***5	= 0	X \$420 = 0
		* 2				
	<input type="checkbox"/> Application Size Fee <small>(37 CFR 1.16(s))</small>					
	<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <small>(37 CFR 1.16(j))</small>					
					TOTAL ADD'L FEE	<b>0</b>

	(Column 1)	(Column 2)	(Column 3)	PRESENT EXTRA	RATE (\$)	ADDITIONAL FEE (\$)
<b>AMENDMENT</b>		CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NUMBER PREVIOUSLY PAID FOR			
		*	Minus	**	=	X \$ =
		*		***	=	X \$ =
		*				
	<input type="checkbox"/> Application Size Fee <small>(37 CFR 1.16(s))</small>					
	<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM <small>(37 CFR 1.16(j))</small>					
					TOTAL ADD'L FEE	

\* If the entry in column 1 is less than the entry in column 2, write "0" in column 3.  
 \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, enter "20".  
 \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, enter "3".

LIE  
KIM WATSON

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found in the appropriate box in column 1.

This collection of information is required by 37 CFR 1.16. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





NOTICE OF ALLOWANCE AND FEE(S) DUE

22428 7590 06/27/2017
Foley & Lardner LLP
3000 K STREET N.W.
SUITE 600
WASHINGTON, DC 20007-5109

Table with 2 columns: EXAMINER (FISHER, MELISSA L), ART UNIT (1611), PAPER NUMBER

DATE MAILED: 06/27/2017

Table with 5 columns: APPLICATION NO. (13/553,972), FILING DATE (07/20/2012), FIRST NAMED INVENTOR (Juan Mantelle), ATTORNEY DOCKET NO. (041457-0992), CONFIRMATION NO. (3635)

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

Table with 7 columns: APPLN. TYPE (nonprovisional), ENTITY STATUS (UNDISCOUNTED), ISSUE FEE DUE (\$960), PUBLICATION FEE DUE (\$0), PREV. PAID ISSUE FEE (\$0), TOTAL FEE(S) DUE (\$960), DATE DUE (09/27/2017)

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.

HOW TO REPLY TO THIS NOTICE:

I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that entity status still applies. If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above. If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled "Change in Entity Status (from status indicated above)". For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity fees.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

**PART B - FEE(S) TRANSMITTAL**

**Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 or Fax (571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

22428                      7590                      06/27/2017  
**Foley & Lardner LLP**  
 3000 K STREET N.W.  
 SUITE 600  
 WASHINGTON, DC 20007-5109

**Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)
(Signature)
(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/553,972	07/20/2012	Juan Mantelle	041457-0992	3635

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	09/27/2017

EXAMINER	ART UNIT	CLASS-SUBCLASS
FISHER, MELISSA L	1611	424-487000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363). <input type="checkbox"/> Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached. <input type="checkbox"/> "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. <b>Use of a Customer Number is required.</b>	2. For printing on the patent front page, list (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, _____ 1 (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. _____ 2 _____ 3
--	--

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE \_\_\_\_\_ (B) RESIDENCE: (CITY and STATE OR COUNTRY) \_\_\_\_\_

Please check the appropriate assignee category or categories (will not be printed on the patent) :  Individual  Corporation or other private group entity  Government

4a. The following fee(s) are submitted: <input type="checkbox"/> Issue Fee <input type="checkbox"/> Publication Fee (No small entity discount permitted) <input type="checkbox"/> Advance Order - # of Copies _____	4b. Payment of Fee(s): ( <b>Please first reapply any previously paid issue fee shown above</b> ) <input type="checkbox"/> A check is enclosed. <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached. <input type="checkbox"/> The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number _____ (enclose an extra copy of this form).
--	---

5. **Change in Entity Status** (from status indicated above)

Applicant certifying micro entity status. See 37 CFR 1.29

Applicant asserting small entity status. See 37 CFR 1.27

Applicant changing to regular undiscounted fee status.

**NOTE:** Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

**NOTE:** If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

**NOTE:** Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

**NOTE:** This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature \_\_\_\_\_ Date \_\_\_\_\_

Typed or printed name \_\_\_\_\_ Registration No. \_\_\_\_\_



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Table with 5 columns: APPLICATION NO., FILING DATE, FIRST NAMED INVENTOR, ATTORNEY DOCKET NO., CONFIRMATION NO.
13/553,972 07/20/2012 Juan Mantelle 041457-0992 3635

22428 7590 06/27/2017
Foley & Lardner LLP
3000 K STREET N.W.
SUITE 600
WASHINGTON, DC 20007-5109

EXAMINER

FISHER, MELISSA L

ART UNIT PAPER NUMBER

1611

DATE MAILED: 06/27/2017

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(Applications filed on or after May 29, 2000)

The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.

Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the requirement that the Office provide a patent term adjustment determination with the notice of allowance. See Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term adjustment) should follow the process outlined in 37 CFR 1.705.

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

## OMB Clearance and PRA Burden Statement for PTOL-85 Part B

The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and Budget approval before requesting most types of information from the public. When OMB approves an agency request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration date for the agency to display on the instrument that will be used to collect the information and (ii) requires the agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR 1320.5(b).

The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450. Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

### Privacy Act Statement

**The Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

<b>Notice of Allowability</b>	<b>Application No.</b> 13/553,972	<b>Applicant(s)</b> MANTELLE, JUAN	
	<b>Examiner</b> Melissa Fisher	<b>Art Unit</b> 1611	<b>AIA (First Inventor to File) Status</b> No

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to 6/15/2017.  
 A declaration(s)/affidavit(s) under **37 CFR 1.130(b)** was/were filed on \_\_\_\_\_.
2.  An election was made by the applicant in response to a restriction requirement set forth during the interview on \_\_\_\_\_; the restriction requirement and election have been incorporated into this action.
3.  The allowed claim(s) is/are 14,16,17,21-26,28,29 and 31-42. As a result of the allowed claim(s), you may be eligible to benefit from the **Patent Prosecution Highway** program at a participating intellectual property office for the corresponding application. For more information, please see [http://www.uspto.gov/patents/init\\_events/pph/index.jsp](http://www.uspto.gov/patents/init_events/pph/index.jsp) or send an inquiry to [PPHfeedback@uspto.gov](mailto:PPHfeedback@uspto.gov).
4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

**Certified copies:**

- a)  All    b)  Some    \*c)  None of the:
1.  Certified copies of the priority documents have been received.
  2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  
 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.  
**Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).**
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

- |  |  |
|--|--|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892)   | 5. <input checked="" type="checkbox"/> Examiner's Amendment/Comment                  |
| 2. <input checked="" type="checkbox"/> Information Disclosure Statements (PTO/SB/08),<br>Paper No./Mail Date _____ | 6. <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| 3. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit<br>of Biological Material         | 7. <input type="checkbox"/> Other _____.   |
| 4. <input type="checkbox"/> Interview Summary (PTO-413),<br>Paper No./Mail Date _____.                             |  |

/Melissa Fisher/  
Primary Examiner, Art Unit 1611

### **DETAILED ACTION**

The present application is being examined under the pre-AIA first to invent provisions.

#### ***Continued Examination Under 37 CFR 1.114***

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after allowance or after an Office action under *Ex Parte Quayle*, 25 USPQ 74, 453 O.G. 213 (Comm'r Pat. 1935). Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, prosecution in this application has been reopened pursuant to 37 CFR 1.114. Applicant's submission filed on 6/6/2017 has been entered.

#### ***Information Disclosure Statement***

The Information Disclosure Statement (IDS) filed 6/15/2017 has been considered by the examiner.

The following is an examiner's statement of reasons for allowance:

The prior art does not teach nor reasonably suggest the claimed monolithic transdermal drug delivery system. Additionally, Applicant's arguments of unexpected results based on the coat weight of the polymer to achieve the claimed flux of drug

Art Unit: 1611

delivery are persuasive. Applicant has additionally filed a Declaration on 6/15/2017 providing further support of the unexpected results previously argued.

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Melissa Fisher whose telephone number is (571)270-7430. The examiner can normally be reached on Monday-Friday, 8am-5pm.

Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at <http://www.uspto.gov/interviewpractice>.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1611

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Melissa Fisher/  
Primary Examiner, Art Unit 1611



PTO/SB/08 (modified)

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number	13/553972
		Filing Date	7/20/2012
Date Submitted: June 15, 2017		First Named Inventor	Juan Mantelle
		Art Unit	1611
(use as many sheets as necessary)		Examiner Name	Melissa L. Javier
		Attorney Docket Number	041457-0992
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document	Filing Date of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>6</sup>
	A1	MANTELLE ET AL., "Effect of Silicone/Acrylic PSA Blends on Skin Permatation," Procced. Int'l. Symp. Control. Rel. Bioact. Mater., June 20-23, 1999				
	A2	Notice of Allowance issued on 04/26/2017 in application number 14/024,985 (US 2014/0200530)				
	A3	Office Action issued on 06/15/2017 in application number 14/870,574 (US 2016/0015655)				

Examiner Signature	/Melissa L Fisher/	Date Considered	06/22/2017
-----------------------	--------------------	--------------------	------------




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

BIB DATA SHEET

CONFIRMATION NO. 3635


<b>SERIAL NUMBER</b> 13/553,972	<b>FILING or 371(c) DATE</b> 07/20/2012 <b>RULE</b>	<b>CLASS</b> 424	<b>GROUP ART UNIT</b> 1611	<b>ATTORNEY DOCKET NO.</b> 041457-0992	
<b>APPLICANTS</b> <b>INVENTORS</b> Juan Mantelle, Miami, FL; <b>** CONTINUING DATA *****</b> This application is a CON of 12/216,811 07/10/2008 PAT 8231906 <b>** FOREIGN APPLICATIONS *****</b> <b>** IF REQUIRED, FOREIGN FILING LICENSE GRANTED **</b> 07/31/2012					
Foreign Priority claimed <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No 35 USC 119(a-d) conditions met <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No Verified and Acknowledged <u>/MELISSA L JAVIER/</u> Examiner's Signature	<input type="checkbox"/> Met after Allowance Initials _____	<b>STATE OR COUNTRY</b> FL	<b>SHEETS DRAWINGS</b> 1	<b>TOTAL CLAIMS</b> 16	<b>INDEPENDENT CLAIMS</b> 4
<b>ADDRESS</b> Foley & Lardner LLP 3000 K STREET N.W. SUITE 600 WASHINGTON, DC 20007-5109 UNITED STATES					
<b>TITLE</b> TRANSDERMAL ESTROGEN DEVICE AND DELIVERY					
<b>FILING FEE RECEIVED</b> 2540	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:		<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit		

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN	
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611	

CPC						
Symbol					Type	Version
A61K		9		7069	F	2013-01-01
A61K		9		7061	I	2013-01-01
A61K		31		565	I	2013-01-01
A61K		47		10	I	2013-01-01
A61K		47		32	I	2013-01-01
A61K		9		0014	I	2013-01-01


CPC Combination Sets				
Symbol	Type	Set	Ranking	Version

(Assistant Examiner) _____ (Date) _____		<b>Total Claims Allowed:</b> 23	
/MELISSA FISHER/ Primary Examiner.Art Unit 1611 (Primary Examiner) _____ (Date) _____		O.G. Print Claim(s) 1	O.G. Print Figure None

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611


US ORIGINAL CLASSIFICATION					INTERNATIONAL CLASSIFICATION											
CLASS		SUBCLASS			CLAIMED				NON-CLAIMED							
<b>CROSS REFERENCE(S)</b>					A	6	1	K	31 / 565 (2006.01.01)							
					A	6	1	K	9 / 70 (2006.01.01)							
CLASS	SUBCLASS (ONE SUBCLASS PER BLOCK)															

(Assistant Examiner) _____ (Date) _____		<b>Total Claims Allowed:</b> 23	
/MELISSA FISHER/ Primary Examiner. Art Unit 1611		O.G. Print Claim(s) 1	O.G. Print Figure None
(Primary Examiner) _____ (Date) _____			

<b>Issue Classification</b> 	<b>Application/Control No.</b> 13553972	<b>Applicant(s)/Patent Under Reexamination</b> MANTELLE, JUAN
	<b>Examiner</b> MELISSA JAVIER	<b>Art Unit</b> 1611

<input type="checkbox"/> Claims renumbered in the same order as presented by applicant		<input type="checkbox"/> CPA		<input checked="" type="checkbox"/> T.D.		<input type="checkbox"/> R.1.47									
Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original	Final	Original
	1	17	17	12	33										
	2		18	13	34										
	3		19	14	35										
	4		20	18	36										
	5	2	21	19	37										
	6	3	22	20	38										
	7	4	23	21	39										
	8	5	24	22	40										
	9	6	25	15	41										
	10	7	26	23	42										
	11		27												
	12	8	28												
	13	9	29												
1	14		30												
	15	10	31												
16	16	11	32												

		<b>Total Claims Allowed:</b>	
		23	
(Assistant Examiner)	(Date)	O.G. Print Claim(s)	O.G. Print Figure
/MELISSA FISHER/ Primary Examiner.Art Unit 1611	06/22/2017	1	None
(Primary Examiner)	(Date)		

<b>Search Notes</b>  	<b>Application/Control No.</b>  13553972	<b>Applicant(s)/Patent Under Reexamination</b>  MANTELLE, JUAN
	<b>Examiner</b>  MELISSA JAVIER	<b>Art Unit</b>  1611

CPC- SEARCHED		
Symbol	Date	Examiner

CPC COMBINATION SETS - SEARCHED		
Symbol	Date	Examiner

US CLASSIFICATION SEARCHED			
Class	Subclass	Date	Examiner

SEARCH NOTES		
Search Notes	Date	Examiner
EAST search (see attached history)	8/25/2013	MJ
Inventor search in EAST	8/25/2013	MJ
Google Scholar search (keywords used: transdermal monolithic estradiol)	8/25/2013	MJ
Updated EAST search	2/21/2014	MJ
Updated Google Scholar search	2/21/2014	MJ
Updated EAST search	4/29/2015	MJ
Updated Google Scholar search	4/29/2015	MJ
Updated EAST search	9/28/2015	MJ
Updated Google Scholar search	9/28/2015	MJ
Updated EAST search	4/22/2016	MJ
Updated Google Scholar search	4/22/2016	MJ
Updated EAST search	8/22/2016	MJ
Updated Google Scholar search	8/22/2016	MJ
(A61K31/565 A61K9/70).cpc. and estradiol	8/22/2016	MJ
Updated EAST search	12/2/2016	MJ
Updated Google Scholar search	12/2/2016	MJ
(A61K31/565 A61K9/70).cpc. and estradiol	12/2/2016	MJ
Updated EAST search	3/18/2017	MJ
Updated Google Scholar search	3/18/2017	MJ

	/M.F./ Primary Examiner.Art Unit 1611
--	--

## SEARCH NOTES

Search Notes	Date	Examiner
Updated EAST search	6/22/2017	MF
Updated Google Scholar search	6/22/2017	MF

## INTERFERENCE SEARCH

US Class/ CPC Symbol	US Subclass / CPC Group	Date	Examiner
	(monolith\$2 estradiol transdermal adhesive coat weight flux).clm.	9/28/2015	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	8/22/2016	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	12/2/2016	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	3/18/2017	MJ
	(monolith\$2 estradiol transdermal system adhesive coat weight flux).clm.	6/22/2017	MF

	/M.F./ Primary Examiner.Art Unit 1611
--	--

## EAST Search History

## EAST Search History (Prior Art)

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	16100	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:14
L2	5556	L1 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:14
L3	937	L2 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:14
L4	51	L3 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:14
L5	261	MANTELLE.in. and JUAN.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:15
L6	42	L5 and estradiol	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:15
L7	154	L5 and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:15
L8	188	Kanios.in. and David.in.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:15
L9	727	L1 and ("dipropylene glycol" oleyl)	USPAT; USOCR	OR	OFF	2017/06/22 18:15
L10	16100	estradiol and transdermal	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:15
L11	5556	L10 and ("surface area" flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:15
L12	937	L11 and acrylic and silicone and (PVP polyvinyl pyrrolidone)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:16
L13	51	L12 and (estradiol NEAR flux)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	OFF	2017/06/22 18:16

6/ 22/ 2017 6:17:06 PM

C:\Users\mjavier\Documents\EAST\Workspaces\13553972.wsp



**PART B - FEE(S) TRANSMITTAL**

Complete and send this form, together with applicable fee(s), to: **Mail** **Mail Stop ISSUE FEE**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, Virginia 22313-1450**  
 or **Fax** **(571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

**Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

22428                      7590                      06/27/2017  
**Foley & Lardner LLP**  
**3000 K STREET N.W.**  
**SUITE 600**  
**WASHINGTON, DC 20007-5109**

_____ (Depositor's name)
_____ (Signature)
_____ (Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/553,972	07/20/2012	Juan Mantelle	041457-0992	3635

TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY

APPLN. TYPE	ENTITY STATUS	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	UNDISCOUNTED	\$960	\$0	\$0	\$960	09/27/2017

EXAMINER	ART UNIT	CLASS-SUBCLASS
FISHER, MELISSA L	1611	424-487000

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  
 Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  
 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list  
 (1) The names of up to 3 registered patent attorneys or agents OR, alternatively, 1 Foley & Lardner LLP  
 (2) The name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed. 2 \_\_\_\_\_  
 3 \_\_\_\_\_

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON 'THE PATENT' (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE **Noven Pharmaceuticals, Inc.** (B) RESIDENCE: (CITY and STATE OR COUNTRY) **Miami, FLORIDA**

Please check the appropriate assignee category or categories (will not be printed on the patent):  Individual  Corporation or other private group entity  Government

4a. The following fee(s) are submitted:

- Issue Fee
- Publication Fee (No small entity discount permitted)
- Advance Order - # of Copies \_\_\_\_\_

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- A check is enclosed.
- Payment by credit card. Form PTO-2038 is attached.
- The director is hereby authorized to charge the required fee(s), any deficiency, or credits any overpayment, to Deposit Account Number 19-0741 (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- Applicant certifying micro entity status. See 37 CFR 1.29
- Applicant asserting small entity status. See 37 CFR 1.27
- Applicant changing to regular undiscounted fee status.

NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue fee payment in the micro entity amount will not be accepted at the risk of application abandonment.

NOTE: If the application was previously under micro entity status, checking this box will be taken to be a notification of loss of entitlement to micro entity status.

NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro entity status, as applicable.

NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.

Authorized Signature Courtenay C Brinckerhoff  
 Typed or printed name Courtenay C. Brinckerhoff

Date June 27, 2017  
 Registration No. 37,288

## Electronic Patent Application Fee Transmittal

<b>Application Number:</b>	13553972			
<b>Filing Date:</b>	20-Jul-2012			
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY			
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle			
<b>Filer:</b>	Courtenay C. Brinckerhoff			
<b>Attorney Docket Number:</b>	041457-0992			
Filed as Large Entity				
<b>Filing Fees for Utility under 35 USC 111(a)</b>				
<b>Description</b>	<b>Fee Code</b>	<b>Quantity</b>	<b>Amount</b>	<b>Sub-Total in USD(\$)</b>
<b>Basic Filing:</b>				
<b>Pages:</b>				
<b>Claims:</b>				
<b>Miscellaneous-Filing:</b>				
<b>Petition:</b>				
<b>Patent-Appeals-and-Interference:</b>				
<b>Post-Allowance-and-Post-Issuance:</b>				
UTILITY APPL ISSUE FEE	1501	1	960	960

Description	Fee Code	Quantity	Amount	Sub-Total in USD(\$)
<b>Extension-of-Time:</b>				
<b>Miscellaneous:</b>				
<b>Total in USD (\$)</b>				<b>960</b>

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	29621910
<b>Application Number:</b>	13553972
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	3635
<b>Title of Invention:</b>	TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
<b>First Named Inventor/Applicant Name:</b>	Juan Mantelle
<b>Customer Number:</b>	22428
<b>Filer:</b>	Courtenay C. Brinckerhoff/Katie Newcomb
<b>Filer Authorized By:</b>	Courtenay C. Brinckerhoff
<b>Attorney Docket Number:</b>	041457-0992
<b>Receipt Date:</b>	27-JUN-2017
<b>Filing Date:</b>	20-JUL-2012
<b>Time Stamp:</b>	16:03:26
<b>Application Type:</b>	Utility under 35 USC 111(a)

### Payment information:

Submitted with Payment	yes
Payment Type	CARD
Payment was successfully received in RAM	\$960
RAM confirmation Number	062817INTEFSW16055600
Deposit Account	190741
Authorized User	Katie Newcomb

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

37 CFR 1.16 (National application filing, search, and examination fees)

37 CFR 1.17 (Patent application and reexamination processing fees)

**File Listing:**

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Issue Fee Payment (PTO-85B)	0992_IF.pdf	72204  3f9c076ec59853bd4ea896d5e354a47e41f2bc2d	no	1

**Warnings:****Information:**

2	Fee Worksheet (SB06)	fee-info.pdf	30542  b431e5132351201fe6fa8bcac9b887c26ce16588	no	2
---	----------------------	--------------	---	----	---

**Warnings:****Information:**

<b>Total Files Size (in bytes):</b>	102746
-------------------------------------	--------

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Application Number</b>	13/553,972
Date Submitted: February 28, 2013		<b>Filing Date</b>	07/20/2012
(use as many sheets as necessary)		<b>First Named Inventor</b>	Juan Mantelle
Sheet 1 of 4		<b>Art Unit</b>	1615
		<b>Examiner Name</b>	Unassigned
		<b>Attorney Docket Number</b>	041457-0992

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2</sup> (if known)					
	A1	8,231,906		07/31/2012	MANTELLE		
Change(s) applied to document, N.G./ 10/20/2015	A2	8,343,538	01-01-2013	<del>04/13/2008</del>	KANIOS ET AL.		
	A3	5,446,070		08/29/1995	MANTELLE		
	A4	4,915,950		04/1990	MIRANDA ET AL.		
	A5	6,562,363		05/13/2003	MANTELLE ET AL.		
	A6	6,221,383		04/24/2001	MIRANDA ET AL.		
	A7	6,235,306		05/22/2001	MIRANDA ET AL.		
	A8	2005/0169977	A1		08/04/2005	KANIOS	
	A9	2005/0129749	A1		06/16/2005	STRAUSS	
	A10	2006/0240087	A1		10/26/2006	HOUZE ET AL.	
	A11	2006/0233870	A1		10/19/2006	HOUZE ET AL.	
Change(s) applied to document, N.G./ 10/16/2015	A12	4,994,278		02/19/1991	SABOLTSKY ET AL.		
	A13	<del>4,404,278</del>	4,994,278	2/19/1991	SABLOTSKY ET AL.		
	A14	5,300,291		4/5/1994	SABLOTSKY ET AL.		
	A15	5,958,446		9/28/1999	MIRANDA ET AL.		
	A16	5,474,783		12/12/1995	MIRANDA ET AL.		
	A17	4,814,168		3/21/1989	SABLOTSKY ET AL.		
	A18	4,994,267		2/19/1991	SABLOTSKY		
	A19	<del>5,665,286</del>	5,656,286	8/12/1997	MIRANDA ET AL.		
	A20	6,024,976		2/15/2000	MIRANDA ET AL.		
	A21	6,337,086		1/8/2002	KANIOS ET AL.		
20050202073	A22	6,638,528		10/2003	KANIOS		
	A23	RE 35,474		3/11/1997	WOODARD ET AL.	Reissue of USP 4,655,767	
	A24	4,655,767		4/7/1987	WOODARD ET AL.		
	A25	<del>2005/2022073</del>		09/15/2005	JACKSON ET AL.		
	A26	2003/099695		05/29/2003	MUELLER		
	A27	4,591,622		5/27/1986	BLIZZARD ET AL.		
	A28	<del>5,584,355</del>	4,584,355	4/22/1986	BLIZZARD ET AL.		
	A29	4,585,836		4/29/1986	HOMAN ET AL.		
	A30	4,390,520		6/28/1983	NAGAI ET AL.		
	A31	5,665,377		09/1997	GONELLA		
A32	2003/0228354		12/2003	MURAOKA ET AL.			
A33	5,730,999		03/24/1998	LEHMANN ET AL.			
A34	5,505,956		04/09/1996	KIM ET AL.			
A35	5,350,581		09/27/1994	KOCHINKE			
A36	4,983,395		01/08/1991	CHANG ET AL.			
A37	4,559,222		12/17/1985	ENSCORE ET AL.			
A38	5,762,952		06/09/1998	BARNHART ET AL.			
A39	4,591,622		05/27/1986	BLIZZARD ET AL.			

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



APPLICATION NO.	ISSUE DATE	PATENT NO.	ATTORNEY DOCKET NO.	CONFIRMATION NO.
13/553,972	08/15/2017	9730900	041457-0992	3635

22428                      7590                      07/26/2017  
 Foley & Lardner LLP  
 3000 K STREET N.W.  
 SUITE 600  
 WASHINGTON, DC 20007-5109

### ISSUE NOTIFICATION

The projected patent number and issue date are specified above.

**Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)**  
 (application filed on or after May 29, 2000)

The Patent Term Adjustment is 0 day(s). Any patent to issue from the above-identified application will include an indication of the adjustment on the front page.

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Application Assistance Unit (AAU) of the Office of Data Management (ODM) at (571)-272-4200.

APPLICANT(s) (Please see PAIR WEB site <http://pair.uspto.gov> for additional applicants):

Juan Mantelle, Miami, FL;

The United States represents the largest, most dynamic marketplace in the world and is an unparalleled location for business investment, innovation, and commercialization of new technologies. The USA offers tremendous resources and advantages for those who invest and manufacture goods here. Through SelectUSA, our nation works to encourage and facilitate business investment. To learn more about why the USA is the best country in the world to develop technology, manufacture products, and grow your business, visit [SelectUSA.gov](http://SelectUSA.gov).